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In people with Type 2 diabetes; chronic liver disease, particularly non-alcoholic fatty 
liver disease (NAFLD), is more common and has an increased risk of progression to 
cirrhosis and hepatocellular carcinoma. European guidelines (European Association 
for the Study of the Liver, European Association for the Study of Diabetes and 
European Association for the Study of Obesity) recommend screening for NAFLD in 
Type 2 diabetes yet both the natural history of liver disease in Type 2 diabetes and 
the factors associated with higher risk of progression to clinically significant disease 
are still incompletely understood. Further, it is thought that the recommended generic 
NAFLD risk prediction tools may perform sub-optimally in people with Type 2 
diabetes. 
Aims  
This study aimed to use a community cohort of over one thousand older people with 
Type 2 diabetes followed for 11 years to: 
1. Define the absolute and relative cohort incidence of liver disease to date. 
2. Determine whether current non-invasive fibrosis risk prediction tools reliably 
identified incident cirrhosis and hepatocellular carcinoma in people with Type 2 
diabetes. 
3. Determine whether the addition of baseline biomarkers to existing fibrosis risk 
prediction tools improved their ability to predict incident cirrhosis and 
hepatocellular carcinoma. 
4. Identify whether potential non-invasive tests for non-alcoholic fatty liver disease 
(those identifying steatosis, serum liver enzymes, markers of fibrosis) are 
associated with incident cirrhosis, hepatocellular carcinoma or all-cause mortality. 
Methods  
The Edinburgh Type 2 Diabetes Study recruited men and women with Type 2 diabetes 
(n=1,066, aged 60–75 at baseline) in 2006. Liver markers were measured at baseline 
and year 1; steatosis and fibrosis markers were calculated according to independently 
  vi 
published formulae. During follow-up, cases of cirrhosis and HCC were identified. 
Logistic regression (odds ratio) was used to determine associations between markers 
and outcomes, with competing risks regression used for sensitivity analyses. The 
predictive ability of tests was assessed using sensitivity, specificity, positive predictive 
value, negative predictive value, false positive and false negative rates. 
Results  
Over 11 years 43/1059 participants with no baseline cirrhosis or hepatocellular 
carcinoma developed incident liver disease. The 11-year incidence of liver cirrhosis 
was 3.92 per 1000 person years and of hepatocellular carcinoma 1.28 per 1000 
person years (whole population rates). 58% of those with cirrhosis had clinical 
complications of varices, ascites or hepatic encephalopathy. 
Existing non-invasive NAFLD fibrosis risk-stratification tools (AST:ALT ratio, AST: 
platelet ratio index (APRI), Enhanced Liver Fibrosis panel (ELF), Fibrosis 4 index 
(FIB-4), NAFLD Fibrosis Score (NFS)) were significantly associated (Odds Ratios, 
p<0.05) with incident cirrhosis and hepatocellular carcinoma but their ability to 
accurately identify those who developed incident disease was poor with low positive 
predictive values (5-46%) and high false negative and false positive rates (up to 60% 
and 77% respectively). When fibrosis risk scores were used in conjunction with the 
European algorithm, predictive performance was modestly improved. 
Among the risk-stratification scores tested, FIB-4 and APRI performed best. Of 
additional biomarkers assessed, hyaluronic acid, gamma-glutamyl transferase, 
glycated haemoglobin, C-reactive protein, interleukin-6, body mass index and 
deprivation index were each, individually, significantly associated with future cirrhosis 
or hepatocellular carcinoma after adjustment for age, sex and existing components of 
the base models. However, only the addition of hyaluronic acid (cut-point ≥50𝜇g/L) to 
FIB-4 (cut-point ≥1.3) reduced the number of people falsely identified as ‘high-risk’ by 
~50% whilst retaining a false negative rate of ≤25%. 
Serum liver enzymes, the Fatty Liver Index, hepatic steatosis on ultrasound, FIB-4 
and FIB-4 with hyaluronic acid all had false positive or false negative rates of >20% 
or >35% respectively for the identification of cirrhosis or HCC. A raised Fatty Liver 
Index was statistically associated with mortality (hazard ratio 1.45 (1.13-1.87)) but all 
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tests showed high false positive and false negative rates (>20% or >75% respectively) 
for mortality. 
Conclusions    
The increased incidence of cirrhosis and hepatocellular carcinoma in people with 
Type 2 diabetes were confirmed, with NAFLD the predominant aetiology. Markers of 
fibrosis were associated with incident cirrhosis and hepatocellular carcinoma but no 
non-invasive risk prediction tools reliably identified participants at increased risk of 
incident disease. The addition of hyaluronic acid to FIB-4 showed promise by reducing 
the proportion of people inappropriately identified as ‘high-risk’ but no combination of 
tests examined, provided a ‘good balance’ between false positive and negative rates 
in the identification of risk for cirrhosis, HCC or mortality.  
These results need to be validated in independent cohorts but suggest that the 
evidence does not exist for formal liver disease screening in people with Type 2 
diabetes and presently the only option for non-invasive liver disease surveillance is to 
use tests with a relatively low false positive rate in order to identify a proportion of 




Non-alcoholic liver disease is the leading cause of liver disease affecting 1 in 4 adults 
worldwide, and occurs more often in people with obesity or Type 2 diabetes. Build-up 
of fat in the liver often causes inflammation and damage that can get worse and lead 
to fibrosis (scarring), cirrhosis (severe scarring), liver failure and liver cancer. In 
advanced disease people have symptoms and may die without a liver transplant. 
Therefore, it is not surprising that screening for liver disease in people with Type 2 
diabetes has been recommended by international organisations even though there 
are big gaps in the detailed understanding needed to design reliable approaches.  
The Edinburgh Type 2 Diabetes Study is a unique resource for studying this issue. It 
included 1066 men and women with Type 2 diabetes and aged 60-75 at baseline who 
were followed for 11 years. Detailed clinical measurements at the start were linked 
with the development of new liver problems and death over the follow up period. 
This study found that the number of people who developed serious liver disease and 
its complications was higher than in the general population. But, unfortunately, the 
currently recommended screening pathways did not reliably identify the people who 
went on to develop advanced liver disease. These tests too often missed people at 
risk (false negatives) and wrongly identified others as being at high risk (false 
positives). We showed that adding a blood test measurement to one of the risk 
prediction tools (measurement of a chemical called hyaluronic acid to the Fibrosis-4 
index) reduced the false identification of people as ‘high-risk’ (for developing cirrhosis 
or liver cancer). However, no test provided a ‘good balance’ between accurately 
identifying those who developed severe liver disease and those who did not.  
Further research is needed if a reliable method of screening for risk of serious liver 
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Chapter 1 Introduction 
 
1.1 Non-alcoholic Fatty Liver Disease (NAFLD)- 
definition and diagnosis 
 
1.1.1 Definition 
NAFLD is defined as the presence of excessive fat (steatosis) in the liver when no 
secondary cause of hepatic steatosis can be found. NAFLD is the liver manifestation 
of the metabolic syndrome (a cluster of conditions including abdominal obesity, 
impaired glucose regulation or diabetes, hypertension, hypercholesterolaemia and 
hypertriglyceridaemia- all of which are associated with increased cardiovascular risk). 
The NAFLD spectrum encompasses: isolated steatosis (non-alcoholic fatty liver 
(NAFL)), steatosis with inflammation, ballooning or both (non-alcoholic steato-
hepatitis (NASH)), and NAFLD associated with fibrosis, cirrhosis (irreversible liver 
scarring) and/or hepatocellular carcinoma (HCC, a primary liver tumour that usually 
develops in the setting of chronic liver disease).  
1.1.2 Clinical presentation and implications 
Most people with NAFLD are asymptomatic and are diagnosed during investigation 
of raised serum liver enzymes or by incidental detection of hepatic steatosis on 
abdominal imaging. People with NAFLD, particularly NASH, may complain of fatigue 
or right upper abdominal discomfort. On examination, hepatomegaly may be found 
although this is highly variable at all stages, and indeed even if a person presents with 
late-stage disease and cirrhosis, the cirrhotic liver may indeed be small. People who 
have developed cirrhosis as a result of NAFLD may present with weight loss, fatigue, 
stigmata of chronic liver disease (for example spider naevi, palmar erythema, 
clubbing, gynaecomastia, splenomegaly, caput medusae) or with signs or symptoms 
of decompensated cirrhosis (for example variceal bleeding, ascites, hepatic 
encephalopathy). HCC is often asymptomatic but those affected may develop wide 
ranging symptoms from new decompensation of existing cirrhosis, jaundice, 
abdominal pain, weight loss, a palpable mass, bleeding from the tumour, fever, 
lymphadenopathy, symptoms from metastatic disease and paraneoplastic syndromes 
including hypoglycaemia, hypercalcemia due to PTHrP, diarrhoea and various non-
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specific cutaneous features. Without liver transplant, the life expectancy of someone 
with decompensated cirrhosis is around 6 months- 2 years while median 5-year 
survival for HCC is 15% (https://www.cancerresearchuk.org/). 
1.1.3 Diagnosis 
Diagnosis of NAFLD is made by detecting hepatic steatosis (defined as >5% liver fat, 
by ultrasound (USS), MRI or biopsy) where secondary causes of steatosis have been 
excluded from the medical history or liver screen tests (e.g. heavy alcohol intake 
(defined as alcohol intake >14 units/ week (female) or >21 units/ week (male) or a 
history of previous or current alcohol excess), hepatitis B or C infection; use of 
steatosis associated drugs (for example amiodarone, methotrexate, tamoxifen, 
valproate, anti-retroviral agents); parenteral nutrition; haemochromatosis; liver auto-
immune disease; Wilson’s disease; alpha1-antitrypsin deficiency; lipodystrophy or 
inborn errors of metabolism; and fatty liver associated with pregnancy). However, it is 
important to note that there is increasing awareness of a substantial population who 
have both NAFLD and alcoholic liver disease; they are thought to have a more 
aggressive disease course than people with either condition in isolation. 1  
NASH is a histological diagnosis that can be made only on liver biopsy. Fibrosis, 
cirrhosis and HCC are diagnosed by imaging and/or biopsy. Surrogate, non-invasive 
markers of fibrosis are also used and are discussed further below. If clinical, 
laboratory and radiological data strongly suggest the presence of cirrhosis, 
confirmatory biopsy is often not required. People with NAFLD may have elevated 
serum liver enzymes, though this is not a consistent finding. Laboratory abnormalities 
in people with advanced, fibrotic, disease include raised serum bilirubin or serum liver 
enzymes, prolonged prothrombin time, hypoalbuminaemia, hyponatraemia and 
thrombocytopaenia. Alpha-fetoprotein can be raised in the context of HCC but levels 
do not correlate well with clinical features and not all tumours secrete this protein. 
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1.2 The population importance of NAFLD 
Liver disease is now documented as the second most significant contributor to years 
of working life lost (the first being ischaemic heart disease). 2 Contrary to most 
diseases in the UK, mortality rates from liver disease have risen 400% since 1970. 3 
Whilst the majority of this impact is attributable to alcohol related liver disease, NAFLD 
and HCC are increasing contributors. 2 The future impact of NAFLD is concerning as 
it is clear that the numbers of people who are obese are rising, with a worrying rising 
trend in young people. 2,3 Despite the proportion of patients with NAFLD who progress 
to end stage liver disease being small, the vast population of patients with NAFLD 
means that a large proportion of liver related death is attributable to NAFLD, and 
NAFLD is now the second most common indication for liver transplant. 2-6 In addition, 
cardiovascular disease remains a significant cause of mortality in patients with 
NAFLD. 6 
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1.3 The prevalence and incidence of NAFLD  
NAFLD is thought to be the most common liver disease in the Western world. In the 
European population the median prevalence of NAFLD (any stage) is 25-26% (results 
calculated including paediatric populations, studies from 2000- present). 6,7 Another 
meta-analysis estimates a global adult prevalence (with imaging diagnostics) of 
25.24% (95% CI 22.10-28.65%) though in this analysis studies exclusively examining 
high risk groups were not included. 6-8 The prevalence of NAFLD is increased in ‘high 
risk’ groups including people with Type 2 diabetes (T2DM), dyslipidaemia and obesity. 
In people with T2DM population prevalence (by USS assessment) is reported 
between 40-70%.9-12 In the whole population among those with a body mass index 
(BMI) >30, a prevalence of >30% is seen on imaging studies whilst prevalence (biopsy 
diagnosis) in a morbidly obese bariatric surgery population can exceed 90%.13-16 It is 
important to note that precise prevalence of NAFLD in the general population has 
been difficult to define due to the use of many different diagnostic criteria (including 
USS, liver enzymes, magnetic resonance spectroscopy imaging (MRS) and non-
invasive tools developed using combinations of biomarkers (such as the fatty liver 
index (FLI) and liver biopsy). Of the non-invasive tools there is no gold-standard test 
increasing the difficulty of estimation. 17 
There is a paucity of data with regards to the incidence of NAFLD. One meta-analysis 
reports an incidence of 28/1000 person years (95% confidence interval 19.34-40.57) 
in the Western population and others report incidence rates of 52.34/1000 person 
years in the Asian population. 7,8,18,19 One English study reports an incidence of 
29/100,000 person years but this was based on ICD-10 diagnosis and as such is likely 
to be a significant underestimate. 7 Similarly, incidence is seen to be increased in high 
risk populations. El-Serag et al studied the incidence of NAFLD in a large cohort 
reporting significantly higher incidence of NAFLD in subjects with T2DM compared to 
those without (18.13 vs 9.55 per 10000 person years p<0.0001). 20 Similar results 
have been seen in a biobank study from China, with hazard ratio (HR) for developing 
NAFLD over 10 years being 1.76 (95% CI 1.47-2.16) in the context of T2DM 
compared to the general population. 21 
Data on the population prevalence of the non-alcoholic steatohepatitis (NASH) and 
fibrosis stages is sparse; mainly due to the gold standard diagnostic test for diagnosis 
being liver biopsy, and as an invasive test, unsuitable for use in population screening. 
For NASH, the only population data is in people who have had biopsies for a non-
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clinical reason (for example as a living donor) where the proportion of people with 
NASH was seen to be 6%.7 In the bariatric surgery population, NASH is found in 25-
70% people who agreed to liver biopsy at the time of surgery. 15,16,22 
Although there is no routine population registration of new diagnoses of cirrhosis in 
the UK, a comprehensive search of routinely collected electronic health care data 
from registries in England estimated the incidence of cirrhosis in England to be 0.37 
per 1000 person years, with approximately 25% of those thought to be related to 
NAFLD (giving a likely incidence rate of NAFLD cirrhosis as 0.07 per 1000 person 
years). 23 For HCC, one meta-analysis quotes an incidence in defined NAFLD cohorts 
of 0.44 per 1000 person years (95% CI 0.29-0.66). 8 On a population level, data on 
liver cancer as a whole tend to be presented rather than HCC alone, although HCC 
contributes around 90% of liver cancer cases (www.britishlivertrust.org.uk). In 
Scotland, the incidence of liver cancer is 0.12 per 1000 person years 
(www.isdscotland.org).  A recent USA paper looked at 296707 people with NAFLD 
(29.9% diabetes), followed for mean 9 years. They identified an incidence of HCC of 
0.21 per 1000 person years. Importantly, whilst incidence of HCC was greater in those 
with cirrhosis, 20% of  people with HCC did not have cirrhosis. 24 Rates of disease 
progression are discussed further in section 1.6. 
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1.4 The association between NAFLD and T2DM 
It is thought that there is a bidirectional relationship between NAFLD and T2DM. Both 
are associated with an increased prevalence of the other in epidemiological cohorts 
and the presence of both is associated with worse patient outcome that the presence 
of either alone. 
1.4.1 Evidence that the presence of NAFLD is associated with 
increasing prevalence, incidence and worsened 
outcomes of T2DM 
The prevalence of T2DM is consistently higher in cohorts with NAFLD than in matched 
cohorts without. In two studies, patients identified with NAFLD (MR SPECT diagnosis) 
had a much greater prevalence of diabetes, impaired glucose regulation and adipose 
tissue insulin resistance compared to obese controls without NAFLD (85% vs 30% in 
one study). 25,26 In addition, even in patients without T2DM, the presence of NAFLD 
is associated with increased HbA1c within the normal range, and the level of steatosis 
on biopsy has been seen to correlate with increasingly impaired glucose regulation. 
27,28  
In addition, rates of incident T2DM have been shown to be higher in people with 
NAFLD compared to those without. Several cohort studies have investigated the 
effect of NAFLD on the development of incident diabetes. Of these, the vast majority 
have found NAFLD to be a significant risk factor for the development of T2DM (Table 
1). The consistency of finding through these cohort studies suggests a true 
association. This is supported by a meta-analysis where a HR of 2.22 (95% CI 1.84-
2.6) for incident T2DM was found in the presence of imaging diagnosed NAFLD. 29 
However, it is important to note that there is significant inter-study variation in the 
quantification of the risk attributed to NAFLD. This is most likely attributable to the 
wide variation in study methodology including differing diagnostic assessment of 
NAFLD (though most studies use ultrasonography), the lack of differentiation in most 
studies between NAFLD severity, different lengths of follow up, variation in diagnostic 
criteria for T2DM and varying and frequently incomplete confounder adjustments. 30 
In addition, all except two studies were confined to Asian populations, so caution 
should be used when extrapolating to other populations. Nonetheless, evidence from 
these cohort studies supports the hypothesis that NAFLD may contribute to or be 
closely associated with the development of T2DM. Furthermore, 3 studies assessed 
incident diabetes in comparison to severity of liver disease. Two found increasing 
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incidence of T2DM in participants whose liver steatosis was more significant. 31,32 In 
the only study looking at participants with biopsy proven NAFLD, participants with 
NASH had a threefold increased risk of developing T2DM over mean 13 year follow 
up when compared with those with simple steatosis. 33 Interestingly, two studies 
looked at a subgroup of participants where liver steatosis had regressed during the 
period of follow-up. Importantly, in these subgroups, the rate of incident T2DM was 
lower than in the population where steatosis had persisted suggesting a potential 
causal association although this is unproven. 34,35  
Finally, there is epidemiological evidence to support an association between severity 
of NAFLD and worsening glycaemic control, macrovascular and microvascular 
complications of diabetes. 36 The Valpollicella Heart Diabetes Study looked at 2103 
patients with T2DM, free of cardiovascular disease or viral hepatitis. There was an 
association between USS diagnosed liver steatosis and renal disease (odds ratio 
(OR) 1.87 95% CI 1.3-4.1), and diabetic retinopathy (OR 1.75 95% CI 1.1-3.7) 
compared to those with T2DM and no NAFLD, even after correcting for age, sex, BMI, 
waist circumference, diabetes duration, glycated haemoglobin (HbA1c), lipids, 
hypertension, smoking status and medication use. 37 Macrovascular risk was also 
increased. 37 Two studies examined the link between liver steatosis and glycaemic 
control. One which examined inter-individual variation in insulin requirements of 
patients taking once daily insulin and metformin, showed that hepatic fat correlated 
with daily insulin dose and ability of intravenous insulin to suppress endogenous 
glucose production. 38 Another, examining a cohort of 300 patients with impaired 
glucose regulation, found the presence of liver fat on MRS imaging was a significant 
predictor for failure of lifestyle management for glycaemic control. 39 Additionally, one 
retrospective study of 337 people with diabetes showed increased mortality if there 
was a concurrent diagnosis of NAFLD (HR 2.2 95% CI 1.1-4.2). 40 
Putative pathogenic mechanisms to explain how hepatic steatosis can exacerbate 
T2DM have been put forward. The link between hepatic steatosis and insulin 
resistance is seen in its most pronounced form in lipodystrophy patients where lipids 
accumulate in ectopic tissue (including liver) due to the lack of adipose tissue. 
Interestingly, if adipose tissue is transplanted into lipodystrophic mice, permitting lipid 
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Table 1. Studies Investigating Incident Diabetes in the Context of NAFLD 
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Okamoto et al. 









0 Steatosis not associated with 
incident T2DM (HR 1.83 95% 
CI 0.95-3.51) 
age, alcohol intake, 
BMI, family history of 
T2DM, fasting 
glucose, HbA1c, sex 









8.5 Number with T2DM 
increased from 8.5% to 58%. 
Further 20% had developed 
impaired glucose tolerance. 
  















Steatosis associated with 
incident T2DM (OR 4.6 (95% 
CI 3.0-7.1)) 
age, BMI, sex 
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0 Steatosis associated with 
incident T2DM (HR 5.5 (95% 
CI 3.6-8.5)) 
age, BMI 
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Main Findings Adjustments for 
confounders 










0 Steatosis associated with 
incident T2DM (RR 1.51 
(95% CI 1.04-2.2))  
age, ALT, BMI, 
family history of 
T2DM, fasting 
glucose, lipids, sex, 
smoking, 
triglycerides 










0 Steatosis associated with 
incident impaired fasting 
glucose or T2DM in men (OR 
1.91 (95% CI 1.56-2.34)) and 






age, alcohol, BMI, 
bp, family history of 
T2DM, sex, smoking 










0 Steatosis associated with 
incident T2DM if pre-existing 
impaired fasting glucose (HR 
1.33 (95% CI 1.07-1.66))  
age, alcohol, BMI, 
bp, impaired fasting 
glucose, lipids, 
physical activity, sex, 
smoking 












0 Steatosis associated with 
incident T2DM (OR 2.42 
(95% CI 1.74-3.36)) 




activity, sex, smoking 
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Main Findings Adjustments for 
confounders 











0 Steatosis associated incident 
T2DM-  moderate/severe 
steatosis (HR 1.73 (95% CI 
1.0-3.0))  
age, bp, creatinine, 
CRP, family history 















0 Steatosis associated with 
incident T2DM (HR 1.64 
(95% CI 1.2-2.2)) 
age, ALT, BMI, bp, 
family history of 
T2DM, impaired 
fasting glucose, 
lipids, sex, waist 
circumference 










0 NFS associated with incident 
T2DM- high NFS (HR 4.74 
(95% CI 3.7-6.1)) 
age, alcohol, CRP, 
exercise, family 
history of T2DM, 
HOMA-IR, lipids, 
sex, smoking 














0 Steatosis and ALT 
associated with incident 
T2DM (HR 1.64 (95% CI 1.3-
2.1)) 
age, alcohol, BMI, 
bp, exercise, 
impaired fasting 
glucose, lipids, sex, 
smoking 










0 Steatosis associated with 
incident T2DM- new (OR 
2.49 (95% CI 1.5-4.1)), 
worsening (OR 6.13 (95% CI 
2.6-14.7)) 
age, alcohol, BMI, 
bp, exercise, 
glucose, insulin, 
lipids, liver function 
tests, sex, smoking 
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Main Findings Adjustments for 
confounders 












0 Steatosis associated with 
incident T2DM (HR 4.46 
(95% CI 1.9-10.7)) 
age, alcohol, BMI, 
bp, education, 
exercise, family 
history of T2DM, 
fasting glucose, 
lipids, oral glucose 
tolerance test, sex, 
smoking,  
Yamazaki et 










0 Steatosis associated with 
incident T2DM (OR 2.37 
(95% CI 1.6-3.5)) 
age, BMI, bp, 
exercise, family 
history of T2DM, 
impaired fasting 
glucose, lipids, sex 










0 Steatosis associated with 
incident T2DM (HR 3.37 
(95% CI 2.4-4.3)) 
age, ALT, bp,  
creatinine, lipids, 
sex, uric acid 










0 Steatosis associated with 
incident T2DM (HR 2.06 
(95% CI 1.5-2.8)) 
age, BMI, bp, CRP, 
ethnicity, exercise, 
family history of 
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Main Findings Adjustments for 
confounders 










0 Steatosis associated with 
incident T2DM – normal BMI 
(HR 3.59 95%CI 2.14-5.76), 




history of T2DM, 
HbA1c, sex, smoking 
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accumulation in transplanted adipocytes as opposed to liver, insulin resistance 
improves, suggesting a causal link. 54,55 Furthermore, in high fat diet rat 
models,hepatic steatosis can be seen at day three before the development of obesity, 
while insulin resistance post-dates hepatic steatosis but pre-dates obesity. 30,55,56 Of 
mechanisms postulated, the most consistent theme is a role for hepatic di-acylglycerol 
(DAG) and protein kinase C (PKC). It is thought that hepatic lipid leads to an increase 
in hepatic DAG which activates hepatic PKC. This is associated with decreased 
activation of the insulin receptor and subsequent insulin resistance. Supporting this 
are studies in rat and mouse models where if PKC expression is inhibited or knocked-
out, decreased hepatic insulin resistance is seen in the high fat diet model. 56,57 
Likewise, in a study that looked at reversal of insulin resistance, that reversal was 
associated with reduced DAG and PKC expression. 58 However, one study where 
DAG was overexpressed in mice lead to triglyceride accumulation but no increased 
insulin resistance, suggesting that the mechanism is multifactorial. 59 This can be 
extrapolated to humans where biopsy samples in obese participants show that 
hepatic DAG and PKC activation (as measured by mass spectrometry) were the 
strongest predictors of insulin resistance (as measured by HOMA-IR). 60,61 Other 
suggested mechanisms have included the possibility that liver inflammation and 
inflammatory pathways may inhibit phosphorylation of the insulin receptor leading to 
hepatic insulin resistance. Rat studies have shown that activation of nuclear factor 
kappa B (NF-B) can lead to insulin resistance and knocking-out inhibitor of nuclear 
factor kappa-B kinase subunit beta (IKK-) can lead to diminished insulin resistance. 
62,63 However, inconsistent results have been obtained in other studies. 30,64 
Alternatively, it has been proposed that fetuin-B, a hepatokine, may be implicated. 
Fetuin-B is differentially secreted in NAFLD compared to control individuals, and 
increased secretion is seen in patients with NAFLD and T2DM. Mechanistically, in 
vitro studies have shown that fetuin-B can impair insulin action, and in vivo mouse 
experiments have indicated that expression can lead to impaired glucose tolerance, 
with silencing of fetuin-B leading to improved glycaemic profile. 65 Lastly, it is known 
that ceramides can be increased in NAFLD and be deposited in hepatocyte cell 
membranes, interrupting the insulin receptor. Certainly, two rodent models have 
shown that inhibiting ceramide synthesis can improve glucose tolerance in obese 
models. 55,66,67  
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1.4.2 Evidence that the presence of T2DM is associated with 
increasing prevalence of and progression of disease in 
NAFLD 
It is widely acknowledged that the prevalence of NAFLD is increased in the T2DM 
population. Overall European population median prevalence is 25-26%, rising to 40-
70% in T2DM populations. 6,9-11,37,68 Furthermore, studies have shown increasing 
prevalence of not just steatosis but NASH, fibrosis, cirrhosis and NAFLD related HCC 
in people with T2DM compared to those without. In biopsy samples taken at the time 
of gastric bypass surgery the odds of finding NASH were 128 times greater (95% CI 
5.2-13137.0) and severe fibrosis 75 times greater (95% CI 4.5-123.7) if the patient 
had T2DM compared to no T2DM. 16 Similarly, biopsies undertaken in  an unselected 
NAFLD cohort found the prevalence of cirrhosis to be 25.5% in participants with 
diabetes, compared to 10.2% in those without (p=0.04) and another study has shown 
increased prevalence of cirrhosis in those with T2DM compared to people without 
diabetes. 69,70 
Many cohort studies have investigated potential risk factors for progression of NAFLD 
(Table 3). The influence of baseline factors on the speed of and risk of disease 
progression is discussed in section 1.7. From these studies, approximately 50% found 
diabetes at baseline to be associated with more frequent progression of disease. In 
addition, one large biobank study and one large community study have shown strong 
associations between progression of NAFLD to incident cirrhosis and HCC and the 
presence of diabetes at baseline. 21,71 One meta-analysis showed a statistically 
significant increased risk of HCC in those with diabetes compared to those without 
(RR 2.31, 95%CI 1.87-2.84), a finding replicated in a large community prospective 
cohort study where the presence of T2DM was associated with a HR or 2.96-7.52 of 
developing a diagnosis of HCC, interestingly with duration of diabetes being 
associated with increasing risk. 72,73 Furthermore, one recent multicentre international 
study of 200 individuals with Childs-Pugh A cirrhosis showed that those who also had 
T2DM had increased rates of decompensated liver disease (6.6/100 person years 
compared to 4.2/100 person years p<0.01) and HCC (3.1/100 person years compared 
to 1.2/100 person years p<0.01). 74  
Several epidemiological studies have investigated mortality in NAFLD cohorts. In 
these studies, diabetes has consistently been found to be a risk factor for mortality. 
One, looking at people with cirrhosis quoted a rate of 4.9/100 person years in those 
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with T2DM compared to 3.0 per 100 person years in those without (p<0.01) . 69,74-79 
Similarly, another study using population data has shown that T2DM is associated 
with an increased risk of both hospital admission for liver disease and death from liver 
disease. 80 
The pathogenic mechanisms which determine the link between T2DM and NAFLD 
are not fully understood. Possible pathways by which insulin resistance and diabetes 
contribute to the development of hepatic steatosis are discussed in the pathogenesis 
section of this thesis (section 1.5). Supporting evidence from mouse models suggests 
a causal rather than simply associative role. Importantly, Lo et al. showed that if mice 
fed a high fat diet were compared to those fed a high fat diet and rendered diabetic 
with streptozotocin, those with diabetes developed much more significant hepatic 
fibrosis. 81 In addition, Guimaraes et al. showed in 2010 in in-vitro experiments that 
hepatic stellate cells (HSC) express receptors for advanced glycosylation end 
products (AGEs) and that AGEs can stimulate HSC production of reactive oxygen 
species (ROS). 82 Another group, also using in-vitro methodology have shown that 
raised glucose can induce HSC proliferation and activation. 83 This suggests a 
mechanism by which patients with T2DM (in whom AGEs accumulate) may develop 
more severe liver inflammation and fibrosis than those without. 
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1.5 The pathogenesis of NAFLD 
The pathophysiology of NAFLD has not been fully elucidated. NAFLD was first 
identified when it was noted that there was a consistent association between the 
metabolic syndrome (defined as ≥3 of raised waist circumference, raised triglycerides, 
low HDL cholesterol, raised blood pressure and evidence of impaired glucose 
regulation or T2DM) and the development of ‘cryptogenic cirrhosis’. 84,85 NAFLD is 
now widely accepted as the ‘liver component’ of the metabolic syndrome.  
As previously mentioned, NAFLD comprises a spectrum of disease extending from 
isolated steatosis (NAFL) to end-stage cirrhosis. As a disease entity NAFL can 
progress to NASH, fibrosis and cirrhosis but this pathway is not always direct, for 
example it is thought that NASH can develop in the absence of NAFL. In addition, 
fibrosis, NASH and NAFL are all, to an extent, reversible, as evidenced in natural 
history studies (section 1.6). Lastly the precise mechanisms by which NAFL, NASH 
and fibrosis develop are not fully confirmed. Putative models of NAFLD pathogenesis 
have been suggested and will be discussed. It is likely that NAFLD is a multifactorial 
disease with many components contributing to progression or regression of disease 
(Figure 1).  
In 1998, Day and James proposed the ‘2 hit hypothesis’ for NAFLD pathogenesis. 86 
In this model, the accumulation of liver triglyceride was considered to be a ‘first hit’ 
that sensitised the liver to ‘second hits’ such as oxidative stress, lipid peroxidation, 
and mitochondrial dysfunction. It was postulated that is was to be the second hit that 
led to hepatocyte inflammation, damage and fibrosis. Subsequent studies have 
suggested that this hypothesis may not hold. 
Firstly, some studies have shown that triglyceride accumulation may not necessarily 
predispose to liver inflammation, damage and fibrosis. Triglyceride accumulation in 
itself could well be protective and it is probably the production of lipotoxins as part of 
dysfunctional hepatic lipid metabolism that leads to hepatic damage. 87,88 One study 
inhibited an enzyme in the final common pathway of liver triglyceride synthesis in mice 
fed a high fat diet. Although less steatosis was evident, these mice developed 
worsening hepatic inflammation and fibrosis in comparison to controls. 89 This 
phenomenon has not been consistently replicated. 90 Secondly, studies have shown 
an association between the level of steatosis and the chances of progression to NASH  
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Figure 1. Factors Associated with the Development of NAFLD and progression 
to Cirrhosis and HCC 
 
and liver fibrosis suggesting that liver steatosis, or a factor associated with it, is 
contributing to hepatocyte damage and it is not the innocent bystander suggested in 
the initial 2 hit hypothesis. 88,91 
NAFLD is now generally considered to be a multifactorial disease process whereby 
multiple parallel ‘hits’ including insulin resistance, disrupted lipid metabolism, 
lipotoxicity, oxidative stress, mitochondrial dysfunction, endoplasmic reticulum (ER) 
stress, autophagy, gastrointestinal endotoxins, alcohol, altered cytokine and 
adipokine signalling and genetic predisposition lead to hepatocyte inflammation, 
damage and progressive liver disease, hepatic fibrosis, cirrhosis and HCC  (Figure 
1). 92 
I will discuss in turn proposed contributory factors to the pathogenesis of NAFLD. 
1.5.1 The development of steatosis in NAFLD 
Hepatic steatosis is a key histopathological feature of NAFLD. 93 Its presence is a 
reflection of disordered hepatic lipid homeostasis. Hepatic fat is normally stored in the 
form of triglycerides. The liver derives lipid from 3 sources- triglyceride remnant from 
dietary lipid not absorbed into chylomicrons, circulating free fatty acids (FFA) derived 
from adipose tissue lipolysis and de novo lipogenesis which is primarily regulated by 
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insulin and glucose at a transcriptional level. One isotope study showed a contribution 
from all 3 sources in NAFLD with 59% hepatic triglyceride derived from serum, 26% 
from de novo lipogenesis and 15% from dietary sources. 94 This is especially notable 
with the increased proportion derived from de novo lipogenesis, thought to contribute 
to only 5% hepatic fat in people without NAFLD. 93  
Lipids can be processed by hepatocytes via several pathways. They can be used in 
phospholipid synthesis or re-esterified to create triglycerides and then very low 
density lipoprotein (VLDL) which can then be secreted from hepatocytes. 
Alternatively, they can undergo β-oxidation in mitochondria, oxidation in peroxisomes 
or microsomal oxidation in the ER (via p450) leading to adenosine triphosphate 
production, but at the expense of the production of reactive oxygen species (ROS). It 
is postulated that hepatic steatosis develops when VLDL secretion and oxidation of 
FFA are unable to keep up with the hepatic lipid overload and it is excessive FFA that 
are esterified into triglycerides and stored in lipid droplets. 93 Fitting with this, 
increased rather than decreased VLDL secretion is seen in NAFLD. 87 Interestingly, 
one study showed increased VLDL secretion in NAFL, but decreased in NASH 
suggesting that failure of VLDL secretion may contribute to the progression of disease 
from NAFL to NASH. 95  
Influences on the development of hepatic steatosis- insulin resistance 
Insulin resistance is seen in most patients with NAFLD. 96,97 In euglycaemic clamp 
studies, insulin resistance correlates with intrahepatic triglyceride concentration. 
26,98,99 It is thought to contribute to the development of hepatic steatosis via three 
mechanisms. Firstly, in health insulin acts on the liver to inhibit hepatic glucose 
production, stimulate hepatic glucose uptake and promote hepatic de novo 
lipogenesis. 93 In the context of insulin resistance, although the inhibitory effects are 
diminished, the stimulatory effect on de novo lipogenesis seems to be retained due to 
postulated differential enzymatic pathways. 100 In addition, hyperinsulinaemia and 
hyperglycaemia are thought to stimulate further hepatic de novo lipogenesis via 
stimulation of the carbohydrate and sterol response element binding protein 
transcription factors. 87,101,102  Secondly, in the context of insulin resistance, FFA 
uptake, metabolism and lipolysis in adipose tissue is altered, leading to increased 
FFA release and delivery to the liver. 103-106 Thirdly, insulin resistance in skeletal 
muscle leads to decreased muscle glucose uptake, leading to the increased delivery 
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of glucose to the liver. 93,98,99 The likely significant contribution of the above three 
mechanisms to the development of hepatic steatosis has led to the consensus that 
insulin resistance may be a primary pathological determinant of NAFLD.  
Influences on the development of hepatic steatosis- dysfunctional adipose 
tissue 
It is accepted that there is a correlation between increased visceral fat and NAFLD. It 
has been shown that rising visceral fat measurements correlate with the extent of 
hepatic inflammation and fibrosis, even when corrected for insulin resistance. 107 
Excessive lipid storage in adipose tissue leads to adipose tissue hypertrophy and 
hyperplasia. Whilst thought to be initially protective as it stores excess FFA, it is also 
thought to impair normal adipose tissue function and stimulates altered gene 
expression, promoting the production of cytokines akin to those produced by 
macrophages. 87 FFA and lipid by-products (such as diacylglycerol and ceramide) 
stimulate the induction of multiple inflammatory pathways, including Iκκ-β and 
subsequently NF- κβ and c-jun N terminal protein kinase 1 (JNK1) signalling which 
lead to the production of multiple inflammatory mediators including TNFα, interleukin-
6 (IL-6) and interleukin-1beta. These inflammatory mediators can interrupt insulin 
signalling, contributing to insulin resistance and then hepatic steatosis. 87,92 
Additionally, they likely exert a direct effect on the hepatocyte in NAFLD; this will be 
discussed later in this review. Supporting this mechanism is the knowledge that IL-6 
and TNFα are known to be increased in fat cells, increase in obesity and decrease 
with weight loss. 92,108,109 In addition, in murine models, JNK knockout mice fed with a 
high fat diet do not develop hepatic insulin resistance. 110-112  
The secretion of adipokines from adipocytes is known to be altered in obesity and 
may play a role in the development of steatosis. Adiponectin is normally secreted by 
adipose tissue and acts in the hepatocyte to stimulate FFA oxidation. 101 Systemic 
levels of adiponectin are reduced in obesity and NAFLD. 113 Studies have shown that 
adiponectin levels inversely correlate with liver steatosis, and in some studies hepatic 
inflammation and fibrosis. 113,114 Interestingly, in the ob/ob mouse model, the 
administration of adiponectin can alleviate NAFLD. 115 Leptin is also thought to play a 
role. Leptin deficient ob/ob mice are known to develop hepatic steatosis and it has 
been shown that leptin administration can reduce triglyceride levels. 93,116 However, 
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most people with NAFLD have increased systemic levels of leptin so its exact role is 
unclear, although it is postulated that leptin resistance may contribute to the picture.93 
Influences on the development of hepatic steatosis- dietary intake of fructose, 
gastrointestinal microbiota and gastrointestinal tract permeability 
Dietary intake of fructose has been shown in many studies to be associated with the 
development of NAFLD steatosis in humans.117 Fructose seems to be associated with 
a tendency towards the development of liver steatosis and inflammation above and 
beyond what would be expected from its calorific content. Animal studies have also 
shown increased liver steatosis when given a fructose rich diet compared to those 
without, despite equal total energy intake.118 Similarly, mice who have no fructokinase 
enzyme are more resistant to the development of liver steatosis.119 This is thought to 
be mediated firstly by liver metabolism of fructose which can lead to decreased ATP 
and increased uric acid, both of which are thought to be related to the development 
of hepatic steatosis and inflammation.117 Secondly, the metabolism of fructose in the 
small intestine can lead to increased gut permeability, the effects of which will be 
discussed in the following paragraph.117 
Obesity is associated with increased intestinal mucosal permeability, and NAFLD is 
associated with an altered composition of gut microbiota, most consistently with the 
decreased presence of bacteroides. 101,120-122 The role of the gut microbiome in the 
metabolic syndrome has been illustrated in mouse studies where it has been 
demonstrated that germ free mice develop less total body fat on the same diet; and 
when exposed to a gut microbiota from obese mice, normal mice develop a 60% 
increase in body fat and insulin resistance. 123 In addition mice fed with a high fat diet 
and treated with antibiotics show reduced hepatic triglyceride accumulation. 124 The 
mechanism by which altered microbiota and gastrointestinal tract permeability can 
impact on the development of steatosis is not fully defined. It is postulated that these 
changes can lead to increased serum ethanol levels (with increased abundance of 
ethanol producing bacteria in NAFLD microbiomes) and decreased choline (as it is 
known that specific microbial enzymes are required for choline conversion to 
trimethylamine and subsequent absorption). 93,125 Ethanol is well known to contribute 
to hepatic steatosis and hepatocyte damage in alcoholic liver disease, and choline 
deficient diets are commonly used to generate NAFLD models in rodents. 93 Adding 
weight to this argument are studies that show raised serum ethanol levels in NASH 
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compared to healthy control and obese participants without NASH, and increased 
expression of ethanol metabolism genes in NASH patients compared with 
controls.125,126 
Influences on the development of hepatic steatosis- genetics 
NAFLD prevalence varies by ethnicity, suggesting a potential genetic influence in 
NAFLD development. 127 Supporting this, twin studies have shown correlation 
between the development of NAFLD in monozygotic but not dizygotic twins. 128-130 
Furthermore, genome wide association studies have identified several candidate 
gene associations with NAFLD. 131 It is beyond the remit of this review to discuss all 
candidate genes, but the best defined, the rs738409 minor allele variant of PNPLA3 
and rs58542926 minor allele variant of the TM6SF2 gene, merit mention. These gene 
variants are the only two to be identified as to be associated with NAFLD in two or 
more studies. 132  
Genome wide association studies of participants with MRS, biopsy or CT diagnosed 
NAFLD have all identified an association with the rs738409 SNP of the PNPLA3 gene. 
131,133,134 Further studies have also found the rs738409 SNP to be associated with the 
histological severity of NAFLD, even after adjustment for metabolic risk factors. 135-137 
In addition, studies including a meta-analysis have shown rs738409 to be 
independently associated in multivariate analysis as an independent predictor of HCC 
occurrence in both NAFLD and ALD. 132,138,139   
The rs58542926 polymorphism in the TM6SF2 gene has been shown to be 
significantly associated with NAFLD, and additionally has been identified to be 
independently associated with increased fibrosis in studies comparing studies with 
biopsy proven NASH and fibrosis to healthy control participants. 132,135,140-142  
PNPLA3 codes for adiponutrin which is expressed in hepatocytes, adipocytes and 
hepatic stellate cells. It is thought to play a role in lipid droplet remodelling and VLDL 
secretion and in vitro affects phospholipase and triglyceride lipase. 93 Although mice 
studies with PNPLA3 knock-out have not been consistent, in vitro studies have 
suggested that presence of the RS738409 is associated with lipid accumulation. 
93,137,143,144 Similarly, TM6SF2 is thought to play a role in VLDL secretion, thus adding 
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to evidence that impaired VLDL secretion may be a key factor in the development of 
NAFLD. 93,137 
Lastly, one recent large population wide genetics study looking at 46544 people has 
shown an association with a splice variant of the HSD17B13 gene, which encodes for 
a lipid droplet protein, is associated with decreased prevalence of NAFLD (as 
diagnosed by evidence of electronic hospital patient record), suggesting that genetic 
factors may confer protection from as well as predisposition to NAFLD. 145 
Influences on the development of hepatic steatosis- autophagy 
Autophagy is the process by which lysosomes degrade intracellular proteins, 
organelles and lipids. In health it is thought to function to recycle cellular constituents, 
maintain cellular homeostasis and to provide energy in the context of starvation. 93 
Mouse studies have shown that the inhibition of autophagy can lead to increase 
triglyceride storage in hepatocytes, and induction of autophagy can decrease lipid 
storage. 111 In addition, a pilot immunohistochemical study has shown a reduction in 
autophagy marker LC3 with increased steatosis. 146 Thus defective autophagy is 
postulated to contribute to the development of hepatic steatosis, although its exact 
function in the development of NAFLD is not fully understood. 
1.5.2 The development of liver inflammation 
NASH is a histological diagnosis characterised by lobular inflammation and 
hepatocellular ballooning. The progression of NAFL to NASH, fibrosis and cirrhosis is 
thought to be secondary to hepatocellular damage caused by a combination of factors 
resulting in oxidative stress and inflammation. 147  
Liver inflammation- the role of oxidative stress and mitochondrial dysfunction 
Whether the presence of NAFL contributes to the development of NASH or NAFLD 
fibrosis has been controversial. However, it is increasingly thought that, whilst 
triglyceride accumulation in itself may not be hepatotoxic, and in fact may be a 
compensatory protective mechanism in response to triglyceride overload, that the 
presence of excess fat in hepatocytes can lead to the accumulation of fatty acid 
metabolites that act as lipotoxins, resulting in liver injury. 88,148 It is thought that, in the 
presence of excessive FFAs, increased mitochondrial oxidation leads to the increased 
production of ROS. In addition, in FFA excess, peroxisomes and microsomes are 
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recruited to oxidise FFA, a process with leads to proportionally greater ROS 
production than mitochondrial oxidation. 93 When ROS production exceeds the 
hepatocyte’s antioxidant capacity this leads to intracellular oxidative stress, nuclear 
and mitochondrial DNA damage, phospholipid membrane disruption, release of pro-
inflammatory cytokines and upregulation of apoptosis. 104 Immunochemical studies 
show evidence of oxidative stress and DNA damage and it is known anti-oxidant 
genes are upregulated in NAFLD, presumably as a compensatory mechanism. 93,149 
Furthermore, there is well documented evidence of mitochondrial disruption in NASH 
and NAFLD fibrosis but not in NAFL suggesting that this contributes to the progression 
of disease. 85,96,150  
Liver inflammation- the role of ER stress 
ER stress is thought to contribute to hepatocyte inflammation and stress in the context 
of NAFLD. ER stress, putatively caused by hyperlipidaemia and hyperinsulinaemia, 
affects normal translation leading to an ‘unfolded protein response’ whereby there is 
halting of normal translation, increased protein degradation and activation of 
inflammatory cascades including those that can aggravate insulin resistance. 
92,93,101,151 Human histological studies have shown markers of the unfolded protein 
response in NASH and correlation of damage with histological severity of disease. 152 
Liver inflammation- the creation of an inflammatory milieu 
In addition to intra-hepatocyte inflammation, distant inflammatory cascades are 
thought to contribute. Adipokines and the inflammatory cytokines produced by 
dysfunctional adipocytes are through to play a role, with adiponectin known to have 
an systemic anti-inflammatory effect and leptin has been shown to stimulate the 
release of pro-inflammatory cytokines from hepatocytes. 92,153 Secondly, changes in 
the gut microbiome may affect inflammation- with one study showing that the 
administration of a pro-biotic was associated with decreased inflammation and fibrosis 
compared to controls in a high fat diet rat model. 154,155  
Overall, increased expression of IKK-β, NF-κβ, TNFα and IL-6 are seen in mouse 
models. 63 In human studies increased serum IL-6 and TNFα are seen, and increased 
cytokine gene expression is seen in patients with NASH compared to obese control, 
with TNFα correlating with disease severity. 63,156-158 Conversely, inhibiting cytokine 
production in high fat diet and methionine-choline deficient mouse models attenuates 
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hepatic inflammation and insulin resistance. 153,159 Both intra-hepatic inflammation, 
increased hepatic FFA and systemic inflammation are thought to promote the pro-
inflammmatory phenotype of the Kuppfer cell (resident liver macrophage) in NASH. 
Kuppfer cells in health act to remove pathogens (normally gut derived) and injured 
hepatocytes, but if overactivated can result in harmful inflammation. 87,93 
1.5.3 Progression to fibrosis, cirrhosis and hepatocellular 
carcinoma 
Hepatic fibrosis (of which cirrhosis is the most advanced stage) is the final common 
pathway of pathogenesis for most chronic liver disease; and presence of fibrosis in 
the context of NAFLD or NASH confers a worse prognosis. 93,103 It is defined as a 
wound healing response which is characterised by the excessive deposition of 
collagen and extracellular matrix which leads to the formation of scar tissue. 93 
In health, the liver repairs damage through the duplication of mature hepatocytes. In 
chronic oxidative stress and injury, this is not seen and instead recruitment of hepatic 
progenitor cells is seen. 103 Additionally, HSCs are activated. These normally play a 
role in extracellular matrix homeostasis but are activated by free fatty acids, ROS and 
inflammatory cytokines, injured hepatocytes, hepatic progenitor cells and gut derived 
peptides to a myofibroblast-like phenotype. 93 It is important to note that in brief 
hepatic injury these mechanisms work to repair hepatic tissue, however in the context 
of persistent insult they seem to fail, and activation of HSCs leads to acquisition of 
fibrogenic potential. 93,103 Immunohistochemical and immunofluorescence studies 
have shown increased hepatic progenitor cells in human and murine models of 
NAFLD, and correlate with the extent of NASH and fibrosis. 160,161 Hepatic stellate cell 
activation has additionally been documented in humans in correlation with hepatic 
inflammation. 162 In murine models, inhibiting transforming growth factor beta cytokine 
expression can arrest fibrosis. 163,164 
In addition, the sustained inflammation and aberrant regeneration that are seen in 
NASH, fibrosis and cirrhosis lead to genetic and epigenetic events in the hepatocytes, 
the development of dysplastic nodules, preneoplastic lesions and hepatocellular 
carcinoma. 165 
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1.6 The natural history of NAFLD 
Better understanding of the natural history of NAFLD is needed to interpret the clinical 
relevance of specific findings and to develop potential interventional strategies. 
Presently the natural history of NAFLD is poorly understood and it is difficult to 
determine an individual’s risk of developing cirrhosis when diagnosed with NAFLD. 
However, it is becoming increasingly clear that the longstanding viewpoint that 
NAFLD simple steatosis was a benign condition that did not progress to clinically 
significant disease is incorrect; simple steatosis, as well as NASH and NAFLD fibrosis 
can all progress to cirrhosis and HCC. 3-5,166-168 In addition, the presence of NAFLD is 
associated with an increased mortality from cardiovascular disease and all cause 
malignancy, in fact non-liver-related mortality is significantly more common that liver-
related mortality for people with NAFLD. 17 
When examining the specific progression of NAFLD, the best available human data 
is found in studies looking at patients who have undergone sequential liver biopsies. 
Many studies have examined such data, discussed in more detail in further sections 
(Table 3). They report progression of NAFLD to increasing fibrosis, inflammation and 
cirrhosis in 25-53% subjects with meta-analyses reporting progression in 36%.33,48,169-
180 Importantly those people with steatosis only on initial biopsy were also susceptible 
to disease progression, though meta-analysis suggests that rate of disease 
progression on meta-analysis is more rapid in those with NASH on initial biopsy. 180 
However in addition these studies also indicate the potential of disease regression 
with 15-30% participants seeing improved disease on repeat biopsy (20-22% on 
systematic review and meta-analysis). 33,169,171,173,174,177-180 It is important to note the 
limitations of these studies. The numbers of patients studied in all these studies is 
small, with a maximum number of patients in any one study being 132, and only a 
total of 411 patients in meta-analysis. Duration of follow-up, likely to be a key factor 
in disease progression, is very variable ranging from one to twenty two years. 
Additionally in most studies patients were recruited after at least the first, if not the 
repeat, biopsy. Thus, there will be a significant selection bias within these cohorts for 
those patients whose condition merited specialty review and assessment at the start 
of analysis and may well not reflect the natural history of a community population with 
undiagnosed NAFLD. Contributory to this, as participants were reviewed at specialist 
clinics they are likely to have been provided with undocumented lifestyle modification 
therapy, as would be routine clinical practice, which may impact on the natural history 
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progression seen. Lastly, as with any biopsy study, the potential sampling error for 
liver biopsy must be acknowledged. 
Additionally, some cohort studies have examined clinical outcomes in NAFLD cohorts. 
Four studies document progression to cirrhosis. Adams et al. reported 9/103 of their 
cohort developing cirrhosis over the study period (range 0.7-21 years), Ekstedt et al 
reported 5.4% progression to cirrhosis with complications over mean 13 year follow-
up, Dam-Larsen et al. reported a 1.2% period prevalence of cirrhosis over 20 year 
follow-up and Sebastiani et al. reported the incidence of varices in 10 and ascites in 
13 of their 148 participants over a median 5 year follow-up. 33,171,181,182 Of note, only 
one study specifically identified NASH at baseline, all others were NAFLD at any pre-
cirrhotic stage. Four studies also report on the development of HCC. Hashimoto et al. 
report an incidence of HCC in 11/359 over 5 years in their NASH cohort while Ascha 
et al. noted a yearly cumulative incidence of 2.6% in people with NAFLD cirrhosis. 
183,184 Ekstedt et al. and Sebastiani et al. document progression to HCC in 3/129 and 
1/148 of their unselected NAFLD cohorts. 33,185 Importantly, HCC can develop in pre-
cirrhotic livers in the context of NAFLD, with one study identifying 50% people 
developing HCC in the context of NAFLD developing it in a non-cirrhotic liver. 186 
Importantly, a population study using routinely collected data has shown that those 
who develop HCC in the context of NAFLD have a shorter survival time and more 
advanced tumour stage than those who develop HCC secondary to alternative 
pathology. 187 Interestingly, a similar study comparing outcome to those with HCC 
secondary to hepatitis C found no mortality difference when patients were matched 
but acknowledged that HCC in the context of NAFLD is often identified at a late 
stage.186 
It has also been shown that NAFLD is associated with an increased risk of 
cardiovascular disease and malignancy. In one large cohort of people with T2DM 
(134,368 of whom 1,452 had NAFLD), the presence of NAFLD was linked to 
increased cardiovascular disease (HR 1.7 (95% CI 1.52-1.9), malignancy (HCC and 
other) and mortality (HR 1.6 (95%CI 1.4-1.83). 188 Seven cohort studies have looked 
at mortality in NAFLD populations. 33,76,181,189-192 Of these, 5 took an initial cohort of 
biopsy proven NAFLD, while 2 followed forward cohorts of patients with liver steatosis 
on USS imaging. There are obvious dichotomies between the diagnostic certainty of 
the biopsy cohort versus the more community-relevant nature of the USS cohorts. 
These studies showed that the main causes of mortality in this population were from 
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cardiovascular disease and malignancy, with Rafiq et al. documenting additionally an 
increase in liver related mortality, but only in their NASH cohort. Ekstedt et al. also 
demonstrated an increase in mortality in a NASH population compared to a reference 
population. 33 Additionally, supporting this Chang et al. showed an association 
between the presence of NAFLD on USS and increased coronary artery calcification 
score on CT  (OR 1.1 (95% CI 1.05-1.16)). 193  
Thus, there is increasing evidence for NAFLD being a progressive condition that has 
an impact on population morbidity and mortality. However, the natural history is also 
dynamic and complex with varying rates of progression and evidence that regression 
can also occur. The precise timescale and nature of progression, and the reasons for 
the inter-study discrepancies in findings remaining unclear. 
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1.7 Risk factors that determine the rate of disease 
progression in NAFLD 
A key interest in the NAFLD literature is the identification of factors that may be 
associated with disease progression. Identification of risk factors that accurately 
predict disease progression could enable targeted screening and surveillance of ‘at 
risk’ populations, in addition to forming potential therapeutic targets.  
Both cross-sectional studies and cohort studies have been undertaken to try to identify 
risk factors for disease progression. Firstly, we will discuss the data findings from 
cohort studies. 
1.7.1 Evidence from cohort studies 
The literature search for cohort studies looking at disease progression was 
undertaken using a systematic search protocol. The Medline and Embase databases 
were searched. The search strategy involved a MeSH terms search for (‘fatty liver OR 
non-alcoholic fatty liver disease’) AND (‘cohort studies OR follow-up studies OR 
longitudinal studies OR prospective studies OR retrospective studies’) AND (‘disease 
progression’ OR ‘prognosis’ OR ‘risk factors’). Results were confined to ‘English’ and 
‘Human’ and studies from 1998-2020. After results were combined and deduplicated 
the search returned 1302 papers. Abstracts and full articles were reviewed. To be 
included the studies had to fulfil the following criteria that they were a cohort study, 
examining progression of NAFLD, examined risk factors for progression, participants 
were not on disease modifying treatment, participants were followed up for at least 1 
year and participants had not undergone liver transplant. After abstract review, 39 
papers were selected that fulfilled these criteria, and 32 of those were selected for 
analysis following full text review. In addition, two systematic reviews/ meta-analyses 
and their associated references were reviewed. 179,180 From these, two additional 
relevant cohort studies were identified and included in analysis. 174,194 
As described above, a total of 34 cohort studies were identified and have been 
included in this assessment of the literature (Table 3). Diagnosis was mostly defined 
by biopsy showing NAFLD. Four used a baseline USS diagnosis of NAFLD. 189,195-197 
Two used ISD clinical diagnosis and one used a positive SteatoTest or 
FibroTest.71,176,198 Other liver pathology was excluded. 
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Participants were followed up for a wide variety of durations, with range 1-41 years. 
Outcomes assessed in most studies were primarily either change in histology on 
repeat biopsy or mortality. Eleven studies each looked at the development of clinical 
cirrhosis or HCC. 33,71,171,181-184,198-201 Diabetes prevalence within the cohorts varied 
significantly.  
The results of these studies have been highly variable, both with regards to rate of 
progression (section 1.6) and additionally in factors found to be associated with 
disease progression (Table 2).  Importantly, time to follow-up varied significantly 
within and between studies, but only three reported on the effect of time with regards 
to disease progression, and two of these reported a link between follow-up time and 
progression of disease, so this must be taken into account. Although studies excluded 
participants based on internationally agreed alcohol excess cut-offs, only one study 
looked into the relationship between disease progression and any lifetime alcohol 
intake, finding an association between any lifetime alcohol intake and risk of 
progression. 184 
There are benefits and limitations of these cohort studies. These are the only studies 
that have looked at disease progression over time in humans. In addition, some 
studies have followed up patients for >20 years, a substantial follow-up period. 
However, all but five studies examine populations who were referred to secondary 
care for concerns regarding liver disease. Thus, in many studies there is a selection 
bias towards patients who are likely to have more severe disease. This is introduced 
again in retrospective biopsy studies where the repeat biopsy was undertaken for 
clinical concern, thus again selecting for patients with a potentially clinically more 
severe disease. There are also limitations with diagnostic techniques used. Whilst 
biopsy is the gold standard diagnostic test for NAFLD, NAFLD histopathology is 
known not to be consistent throughout the liver and so sampling error can be 
significant. In those studies not using biopsy but instead using non-invasive imaging 
or markers, there is concern that they may not reliably diagnose all patients, and it is 
not possible to distinguish between simple steatosis and NASH with non-invasive 
diagnostics. Lastly, follow up between studies is variable with regard to follow up time, 
routine care (including potentially disease modifying lifestyle advice), and end points 
assessed. All these may affect end points and the ability to compare predictive factors. 
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Table 2. Factors identified in cohort studies associated with disease 
progression in NAFLD 
Baseline Factor Number studies - 
factor associated  
Number studies-  factor 
not associated  
Age 11 9 
Gender 1 13 
Race 1 4 
BMI 3 14 
Increasing Weight 1 0 
Smoking 2 5 
Diagnosed Diabetes 10 10 
Hypertension 1 11 
Hyperlipidaemia 2 12 
Metabolic syndrome 1 3 
Histology ↑fibrosis 10 2 
Steatosis 1 9 




Fibrotest/ steatotest 1 0 
FIB-4 5 2 
NFS 3 2 
APRI/ BARD 2 2 
Liver 
Biochemistry 
AST 2 high 1 low 7 
ALT 3 10 
AST:ALT 3 3 
ALP 2 4 
Bilirubin 2 4 
GGT 0 6 
Albumin 5 4 
PT/ INR 2 3 
Platelets 5 3 
Ferritin 1 5 
Diabetes 
Biochemistry 
HbA1c 1 4 




Other: TNFα, adiponectin, IL-6, 
CRP, leptin, CK-18, IgA, IgG, uric 
acid 
0 2 for all 
FIB-4 Fibrosis-4 score, NFS NAFLD fibrosis score, APRI AST to platelet ratio index, BARD 
BARD fibrosis score, PT prothrombin time, INR international normalised ratio, TNFα tumour 
necrosis factor alpha, IL-6 interleukin 6, CRP C reactive protein, CK-18 cytokeratin 18 
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There is one systematic review and one meta-analysis in the literature, both of which 
analyse a subsection of these cohort studies. 179,180 Argo et al. primarily analysed older 
studies, not included in this analysis. They identified inflammation on biopsy and age 
to be the only factors significantly associated with disease progression. Singh et al. 
looked at 11 studies, totalling 2145.5 person-year follow-up. They noted an increased 
proportion of their cohort developing progressive disease if NASH was present at 
baseline compared to NAFL, though there was evidence of progressive disease in 
both cohorts. On meta-analysis they identified hypertension and a low AST:ALT ratio 
to be the only features associated with progressive disease. Note was made of the 
limitations of the cohort studies, discussed above, and in addition concern was noted 
that most studies included were at least moderate risk of bias. 180  
The Edinburgh Type 2 Diabetes cohort study (ET2DS) examined development of 
clinically significant liver disease in a T2DM population. 202 Although it is not included 
above because it investigated all-cause liver disease, 14/15 incident cases of clinically 
significant liver disease were at least partially attributed to NAFLD. Baseline factors 
assessed were age, gender, index of multiple deprivation, duration of diabetes, fasting 
Glucose, HbA1c, antihyperglycaemic treatment, BMI, cholesterol, triglycerides, IL-6, 
TNFalpha, CRP, ALT, AST, AST:ALT, GGT, CK-18, % steatosis on USS, APRI, ELF, 
FIB-4, HA, NFS and platelets. Of these, SIMD, insulin use, BMI, IL-6, TNFalpha, CRP, 
ALT, AST, AST:ALT, GGT, CK-18, APRI, ELF, FIB4, HA, NFS were associated with 
development of clinically significant liver disease over 4-6 year follow up. 
1.7.2 Evidence from cross-sectional studies 
In addition to the cohort studies discussed above, several cross-sectional studies 
have been undertaken to identify factors that are associated with cohorts with more 
significant disease at a single point in time. 14,16,190,203-211 As with the cohort studies, 
the numbers of participants in each study was small, and there is wide ranging 
discrepancy with regards to which factors, if any, associate with more advanced 
disease. Four studies did examine findings when patients had liver biopsy at the time 
of bariatric surgery. 14-16,210 Whilst this population is not necessarily representative of 
the general population, it is interesting to examine the results in an asymptomatic 
population. Even in this small subsection of studies there was no inter-study 
correlation between examined baseline factors and disease severity, although three 
out of four studies found T2DM to be associated with more severe disease. However, 
an appreciable concern with cross-sectional data in this context is the fact that factors 
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that may be associated with the presence of more advanced disease at a single time 
point may well not be those which determine or predict the rate or significance of 
progression of the disease. 
1.7.3 Genetic association with disease progression 
Although none of the cohort or cross-sectional studies mentioned above examined 
genetic factors linked to disease progression, there is increasing interest in the role of 
genetic factors in the progression of NAFLD. As discussed in the pathogenesis 
section (section 1.5), there is evidence to suggest that two genes in particular, namely 
the RS738409 SNP of the PNPLA3 gene and RS 58542926 of the TM6SF2 gene, 
may play a role in the development of NAFLD and are associated with a more 
advanced disease phenotype. 132,134-137,140 One systematic review has shown an 
association between the RS738409 SNP of the PNPLA3 gene and progressive 
fibrosis. 138 In addition, in one study looking exclusively at patients with T2DM, 
evidence of fibrosis on fibrotest in a non-selected population of people with T2DM was 
associated with increasing prevalence of SNP RS 738409 PNPLA3. 212 
1.7.4 Summary 
Thus, in summary, although many potential associations with NAFLD disease 
progression in humans have been identified no clear cut, dominant baseline factors 
have yet emerged.
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Table 3. Cohort Studies Assessing Risk Factors for Progressive NAFLD. (note not all factors assessed in every study, only 
those reported documented 
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1.8 Risk prediction in NAFLD 
 
1.8.1 The need for risk prediction tools in NAFLD 
As NAFLD progresses from NAFL/ NASH and fibrosis to cirrhosis, decompensated 
cirrhosis and HCC; there is a prolonged often asymptomatic course with symptoms 
often not developing until cirrhosis or HCC is established. However, pre-cirrhotic 
disease is potentially reversible, and it is additionally helpful to identify those with pre-
cirrhotic NAFLD to enable optimal management of metabolic disease and 
cardiovascular risk; and consider screening for HCC in high risk groups. As discussed, 
T2DM is associated with an increased prevalence of NAFLD, and increased risk of 
progression to cirrhosis and HCC. People with T2DM are thus considered a high risk 
group for the development of NAFLD and proactive screening for pre-cirrhotic NAFLD 
is advised in joint European guidelines (European Association for the Study of the 
Liver, European Association for the Study of Diabetes, European Association for the 
Study of Obesity, EASL-EASD-EASO). 217 
The gold standard tool for identifying NASH and fibrosis is liver biopsy. However, liver 
biopsy is an invasive procedure and so inappropriate for use when considering 
population screening. Transient elastography (Fibroscan®), a non-invasive USS-
based imaging method to assess liver fibrosis, has been shown to perform reasonably 
well in identifying those with NAFLD related fibrosis but when considering population 
screening approaches, would be difficult to scale up on a population screening basis. 
211,218 Current interest thus lies in the identification of blood biomarker based risk 
prediction tools to identify those who would benefit from further investigation and 
appropriate treatment.  
1.8.2 Existing NAFLD fibrosis prediction tools/ models. 
A risk prediction tool is designed to combine factors at baseline which are associated 
with a future outcome. These factors may be causal or simply associated and 
predictive. Liver enzyme (AST, ALT, ALP, GGT) levels are commonly used in models. 
The enzymes AST and ALT are found in liver cells (though AST is not truly liver 
specific) and play a role in amino acid catabolism; in the context of liver injury they 
are released from liver cells leading to a rise in serum levels.219 ALP and GGT are 
involved in bile production and amino acid metabolism respectively; a rise in serum 
levels of these enzymes is generally considered a marker of cholestasis but can also 
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be associated with more general liver injury.219 Bilirubin is metabolised in the liver and 
so raised levels are indicative of impaired liver function. The liver is key to the 
synthesis of albumin and platelets so levels of both can decrease due to liver 
dysfunction, and splenomegaly secondary to portal hypertension in cirrhosis can 
further reduce platelet levels through increased destruction. None of these blood tests 
is truly liver specific because levels can be altered by other systemic diseases and 
treatments (for example cardiac and skeletal muscle damage, haemolysis and the 
use of statins)). Many prediction scores also use non-hepatic factors associated with 
likelihood of disease such as age, obesity and the presence of diabetes each of which 
is known to be associated with the metabolic syndrome and, in turn, NAFLD. As 
already discussed, however, few individual factors have been shown in isolation 
consistently to predict progressive disease in NAFLD and so there is much interest in 
developing models using multiple factors that can identify those at risk. Existing tools 
were initially designed to identify fibrosis at a point in time, rather than being designed 
to predict incident cirrhosis, HCC or death. However, as fibrosis is known to predict 
outcome, they have subsequently been used as risk-prediction surrogates with 
variable success. There are many existing potential tools. Those used more 
frequently, and those used within this thesis, will be discussed individually.  
AST to platelet ratio index (APRI) 
The APRI is derived from the AST level and platelet count. Initially described by Wai 
et al. in a Hepatitis C cohort, APRI was reported as having an area under the ROC 
curve (AUROC) of 0.8 for significant fibrosis compared to biopsy, accurately predicting 
fibrosis in 51% participants using their defined cut-points of ≤0.5 for no fibrosis and 
>1.5 for definite fibrosis. 220 Similar results have been shown in a NAFLD population. 
221 Other cohorts have used different APRI cut-offs, such as a single cut-off of 1, but 
without significant improvement in performance. 221  
AST to ALT ratio (AST:ALT) 
The AST: ALT was initially developed to distinguish NAFLD from ALD. This is 
because, in alcohol vitamin B6 is often decreased. B6 is required for synthesis of AST 
and ALT, but mostly for ALT leading to a disproportionate effect on ALT. However, it 
has since been seen as a marker for liver injury and a level of >0.8 or >1 is seen as 
an indicator of fibrosis, with one study quoting a negative predictive value (NPV) of 
>90% with a cut-point of 0.8 in a NAFLD cohort. 221,222 
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Enhanced Liver Fibrosis (ELF) test 
The ELF test comprises measurement of hyaluronic acid, amino terminal type III 
procollagen peptide and tissue inhibitor of metalloproteinase 1. These are 
constituents of the matrix and mediators of matrix remodelling seen in liver fibrosis. 
Levels have been shown to correlate with liver fibrosis on liver biopsy. 223 Validated 
by Guha et al. it has reported ability to distinguish severe fibrosis (compared with 
biopsy) with an AUROC of 0.9 for severe fibrosis and 0.82 for moderate fibrosis in a 
secondary care population with NAFLD and elevated liver enzymes. 224 Furthermore, 
in a hospital clinic population with mixed aetiology liver disease, at 6 year follow up 
14/16 of those who developed decompensated cirrhosis or HCC had a baseline ELF 
>9.8 (though 73 participants had high baseline ELF). 225 The proportion of participants 
with diabetes mellitus is not described. Various cut-points for the score have been 
used in studies; UK National Institute of Clinical Excellence guidelines recommend a 
cut-point of ≥10.51 to identify those at high risk of fibrosis. 226 
Fibrosis-4 (FIB-4) score 
The FIB-4 score comprises age, AST, ALT and platelets. Initially developed in a cohort 
with Hepatitis C and HIV co-infection, it was reported to have an AUROC of 0.77 for 
differentiating significant fibrosis compared to biopsy. 227 In a cohort with Hepatitis C 
mono-infection, similarly severe fibrosis was identified with an AUROC of 0.85. 228 It 
has subsequently been validated in NAFLD cohorts, although cut-points vary between 
studies in Hepatitis C and NAFLD. NAFLD studies suggest a FIB4 <1.3 would suggest 
low risk of fibrosis and FIB4 >2.67 high risk, with studies suggesting a NPV of 90% 
for FIB 4 <1.3 in comparison to biopsy. 221,229 
NAFLD Fibrosis Score (NFS) 
The NFS was developed in a hospital cohort of participants with biopsy diagnosed 
NAFLD. Comprising age, hyperglycaemia, BMI, platelets, albumin and AST:ALT, it 
reported an AUROC 0.82-0.88 for identification of fibrosis (compared to biopsy), with 
high positive predictive value (PPV) and NPV with cut-points of <-1.45 to identify those 
at low risk and >0.676 to identify those at high risk of fibrosis. 230 1/3 of this initial 
population had diabetes. Subsequently, one study has looked at 12-year mortality and 
liver outcomes against baseline NFS in a hospital population with NAFLD, 16% of 
whom had diabetes. In those with NFS >-1.5, there was increased incidence of 
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decompensated cirrhosis, HCC and increased mortality during follow-up (though total 
numbers who developed liver events were low with only 6/302 experiencing an 
event).231  
Comparison of non-invasive biomarker performance 
Several studies have compared the performances of these tools. Some have 
compared performance for the identification of fibrosis at the time of a simultaneous 
biopsy. In one secondary care NAFLD population NFS and APRI were compared 
suggesting respective AUROCs 0.88 and 0.87, and misclassification rates 14% and 
16%. 24% of the population had diabetes. 232 Other studies have similarly shown that 
tools often perform similarly though correlation with outcome in differing populations 
is very variable, as is best performing model. One (20-30% participants with diabetes) 
showed FIB-4 as having the highest AUROC 0.8 (NFS 0.77, AST:ALT 0.72, APRI 
0.72); another (50% participants with diabetes) also found FIB-4 to have the highest 
AUROC of 0.86 (AST:ALT 0.83, NFS 0.81, APRI 0.67). 221,229 However, even with the 
AUROCs in these studies, sensitivity was calculated at 50% and whilst NPV was 
>90% PPV was mostly <50%. A further study compared ELF, NFS and FIB-4 
undertaken at the time of biopsy (30% with diabetes). The AUROC for ELF was 
superior to that of FIB-4 or NFS but all were >0/8 for F≥3 fibrosis. 233 
Other studies have looked at the use of non-invasive fibrosis tools in their association 
with incident cirrhosis, decompensated cirrhosis, HCC or progressive disease. One 
320 participant cohort with NAFLD (at any stage), found an increase in incident 
decompensated cirrhosis, HCC and liver transplant in people with NFS ≥-1.455, APRI 
>0.5 or FIB4 ≥1.3 over 9-year follow-up. 234 Another study found an increased HR for 
decompensated cirrhosis, HCC or death at 5-year follow up in NASH participants with 
high risk APRI, FIB4 or NFS scores. 182 However, another study looking at 300 
participants with mixed liver disease reported that, at 6-year follow up, of the 16 who 
developed cirrhosis or HCC, 14/16 had an ELF ≥9.8 at baseline but only 6/16 had an 
APRI >1.5 and only 4/16 had a FIB-4 >3.25. 225 One study has looked at a large 
community population with NAFLD (any stage). In it, FIB-4 ≥1.3 was associated with 
an increased incidence of cirrhosis and HCC over mean 3.3-year follow-up. 71 Two 
studies have examined paired biopsy results, identifying rising markers (APRI, 
AST:ALT, FIB-4, NFS – not all used in both studies) to be associated with worsening 
fibrosis on interval biopsy. 177,235 
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Lastly, studies have assessed association with mortality. In the NHANES study, 
participants with an USS diagnosis of NAFLD steatosis were followed up for 14.5 
years. High risk scores for NFS and APRI, but not FIB-4, were associated with an 
increased HR for mortality, with almost all dying from cardiovascular disease. 189 A 
further two cohorts with USS diagnosis of NAFLD steatosis with around 6-year follow-
up showed an association with raised NFS but not other scores (APRI, AST:ALT, FIB-
4, not all assessed in both) and mortality. 191,231 However, a 320 participant cohort with 
NAFLD (any stage) found increased mortality rates in those with NFS ≥-1.455, APRI 
>0.5 or FIB-4 ≥1.3 over 9-year follow-up with another 18.8-year cohort finding high 
APRI, FIB-4 and NFS associated with mortality. 201,234 
Therefore, whereas there is consistent evidence of an association between existing 
risk prediction tools and outcomes, it is inconsistent and variable in strength of 
association depending on the cohort to which it is applied. Additionally, there are 
acknowledged concerns about the application of existing tools to use as screening 
tools in the general population. Most models have been developed in populations who 
are under secondary care services for NAFLD, thus testing on a limited population 
with likely symptomatic and higher-risk disease more likely to progress and so results 
may not extrapolate to the general population. It is acknowledged that in community 
populations with or without diabetes, that fibrosis scores perform less well with a large 
diagnostic grey zone, and possibly the inability to classify up to 1/3 population. 236 In 
addition, many of the biomarkers used in the tools can be influenced by non-liver 
disease (for example hyaluronic acid can be raised in joint disease, platelets can be 
affected by haematological disease).  
People with T2DM are thought to be at high risk for progressive disease in NAFLD, 
and guidelines advise screening this population for NAFLD.217 However few tools 
have been specifically validated in cohorts of people with diabetes, and there is 
increasing evidence that these tools perform less well in people with diabetes. A 
recent study of 284 hepatology clinic patients of whom 53% had T2DM looked at 
median 51 month outcomes. 237 Whilst it showed that T2DM conferred an increased 
risk of death/transplantation (HR 3.4(1.2-9.1)), decompensated cirrhosis (HR 4.7 (2-
11.3)) and HCC (HR 2.9 (1.2-7.3)); it showed that the accuracy of FIB-4 and APRI in 
predicting outcome was reduced in those with T2DM (p<0.005). Additionally, whilst 
no participant without diabetes and with a low score developed decompensated 
disease, 21% those with T2DM and low score developed decompensated cirrhosis 
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and 27% developed HCC. A recent study has shown poorer correlation between FIB-
4 scores and elastography values (a validated imaging method of identifying hepatic 
fibrosis) in people with diabetes than those without. 238 Furthermore, other studies 
have shown, that in populations with T2DM, the estimation of the percentage of the 
population to have fibrosis based on risk prediction model classification is extremely 
variable, and the agreement of the top 5% of the risk prediction model scores is 
poor.239,240 The reasons for these discrepancies are not fully elucidated. It has been 
shown that the measurement of AST and ALT may correlate less well with liver 
pathology in people with diabetes and this may affect the performance of scores 
based on these biomarkers. 241 Specifically, AST and ALT have been shown to be 
associated with increased insulin resistance in humans, and higher levels of AST and 
ALT are seen in mice models of diabetes although whether this is related to worsening 
NAFLD and metabolic syndrome, or is related to insulin dependent metabolism aside 
from NAFLD is unclear. 242,243 
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1.9 Potential treatment of NAFLD 
Ultimately, the aim of better understanding the natural history of NAFLD is to help 
identify targets for treatment to prevent disease progression, or even encourage 
disease regression. The identification of a reliably effective treatment is eagerly 
anticipated given the dramatically increasing prevalence of both NAFLD steatosis and 
progressive NAFLD with complicated liver disease. However, although multiple 
targets for treatment have been identified, definition of a specific candidate has proved 
elusive. 244 Within the limits of this section the broad areas of research interest and 
potentially positive candidates will be discussed, and ongoing difficulties in the search 
for treatments will be outlined. 
European guidelines recommend that every person with NAFLD should have full 
assessment for other components of the metabolic syndrome, optimisation of 
cardiovascular risk prevention (for example statin treatment, management of 
hypertension, management of co-existing diabetes), lifestyle advice regarding weight 
loss, and non-invasive monitoring for the development of fibrosis. 217 People with 
NAFLD are recommended to abstain from alcohol, as the ‘safe’ alcohol limit in the 
context of NAFLD is unknown. Immunisation for Hepatitis B should be considered. 
People with NAFLD associated cirrhosis are screened regularly for variceal disease, 
liver function and HCC. Management of individual complications of cirrhosis will not 
be discussed in detail here. People with decompensated cirrhosis should be 
considered for transplant. 
1.9.1 Weight loss 
Weight loss has been the only treatment identified to consistently reduce disease 
progression and also improve not only steatosis, but additionally inflammation and 
fibrosis. Prospective studies have shown that even modest weight loss of ≤5kg can 
be an independent predictor of disease progression. 19,245 One study of 293 individuals 
examining interval liver biopsies showed that weight loss as a result of lifestyle change 
of ≥3% improved steatosis, ≥5% improved inflammation, and ≥10% improved fibrosis. 
246 In a cohort of people with T2DM, it has been shown that moderate caloric restriction 
and increased physical activity with weekly support resulted in increased weight loss, 
and associated decline in hepatic steatosis compared to control. 247 As a result of 
these findings, guidelines have recommended lifestyle management with target 
weight loss of 5-10%.7,217 However it is known that weight loss through lifestyle 
change is challenging, and historically only 10-20% of people are able to lose ≥10% 
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body weight over 1-2 year period, with maintenance even more difficult although 
results in a different group of people with T2DM (DiRECT) are slightly more promising. 
248,249 
The role of weight loss through bariatric surgery has been assessed. One key study 
looked at 109 people with biopsy-proven NASH who underwent bariatric surgery. 250 
At one year post surgery 85% people had improvement in NASH and fibrosis reduced 
in 34%. Importantly, those who showed less improvement tended to have more 
advanced initial disease, and to have lost less weight post-surgery. This suggests the 
link is related to weight loss rather than another consequence of surgery though this 
is not conclusive.  
1.9.2 Pharmacological therapy 
Attempts have been and are being made to identify targets in NAFLD pathogenesis 
that would be amenable to pharmacological therapy. They include those that may 
alter fatty acid metabolism (for example peroxisome proliferator-activated receptor 
(PPAR)α/δ/γ modulators), antioxidants such as Vitamin E, agents that modulate 
glucose regulation (such as PPARγ agonists, glucagon like peptide (GLP)-1 receptor 
agonists and sodium-glucose co-transporter-2 (SGLT-2) inhibitors), apoptosis 
inhibitors, anti-inflammatory and anti-fibrotic agents (such as Galectin 3 inhibitors, 
lipopolysaccharide antagonists, farsenoid X receptor agonists) and the intestinal 
microbiome (such as probiotics which may target an endotoxin linked to NASH). 244 
This next paragraph will focus in on agents already used in the context of T2DM. 
PPARγ modulators, such as pioglitazone, are thought to act by reducing inappropriate 
fat storage, improving insulin sensitivity and upregulating adiponectin. These have 
been shown to improve steatosis and inflammation but not fibrosis, and in addition 
primary trial outcomes have never been reached. 147,251 Furthermore, pioglitazone is 
associated with complications including osteopaenia, fluid retention and a potential 
risk of bladder cancer and so is not without risk. A small study of 84 people with 
NAFLD and T2DM showed that the combined treatment with the SGLT-2 inhibitor 
dapagliflozin and omega-3 resulted in reduced MRI determined liver proton density 
fat fraction and improvement in ALT, AST, GGT and cytokeratin-18 at 12 weeks. 252 
Treatment with dapagliflozin and dapagliflozin and omega-3 resulted in weight loss, 
with only the combination affecting liver MRI proton density fat fraction. A recent study 
of 320 people with biopsy confirmed NASH and liver fibrosis showed that taking a 
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GLP-1 agonist, semaglutide, resulted in a significantly higher percentage of people 
experience NASH resolution compared to placebo over 72 week follow-up. However, 
there was no significant improvement in fibrosis and the significant weight decrease 
in the semaglutide group was not corrected for. 253  
Of all other treatments in development, vitamin E has been shown to have the most 
profound anti-steatohepatitic effect, but it does not reduce fibrosis. 251 Whilst it is not 
within the remit of this thesis to discuss all agents individually, in summary no 
pharmacological agent has yet been found that improves fibrosis without significant 
adverse events. 147 
It is important to acknowledge the challenges faced in the search for a NAFLD 
pharmacological therapeutic agent. Firstly, the complex and dynamic natural history 
makes trial endpoint interpretation difficult because of the variable placebo response 
rate of up to 34%.244 Associated with this, knowledge of the natural history of NAFLD, 
key pathogenic drivers and thus identification of those at risk of progressive disease 
is incomplete. 244 Secondly, the ability to assess therapeutic response is hindered by 
the lack of validation of non-invasive predictive biomarkers to identify disease 
response, and even biopsy results, the ‘gold standard’ but invasive investigation, must 
be interpreted in the context of known sampling variability, variability in processing, 
reading strategies and inter-observer agreement for key features of NASH. 147,244 In 
addition, primary endpoints are highly variable between trials. Thirdly, there is 
inadequate knowledge of in vitro and animal models to mimic disease and test new 
targets. 244 
In conclusion, the search for appropriate therapeutic agents in NAFLD still presents 
many ongoing challenges and uncertainties. Weight loss whether through lifestyle 
change or bariatric surgery does seem to be effective and should be the cornerstone 
of clinical management. Developing other therapeutic strategies in NAFLD is 
dependent, however, on more accurately identifying those truly at ‘high risk’ for the 
development of complicated disease and understanding which non-invasive markers 
reliably predict disease progression or remission. 
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1.10 Summary and Aims 
There is a substantial body of evidence demonstrating the clinical significance of 
NAFLD, both from an individual patient and population perspective. Nonetheless, the 
disease burden in community populations is poorly understood. In addition, the 
evidence that the concurrent presence of NAFLD and T2DM worsens prognosis 
suggests that there may be merit in active screening of high risk populations to enable 
the implementation of potential NAFLD treatment, cardiovascular risk prevention and 
identification and treatment of complications. 36 In particular, the increasing 
awareness that up to 50% of HCC in NAFLD can occur in those without cirrhosis 
enhances the need to develop improved surveillance strategies to improve outcome 
(which is currently poor at 18% 5 year survival). 165,186 Consequently, UK defined key 
goals for the development of liver treatment include strengthening the detection of 
early disease and the use of new diagnostic pathways to identify people with NAFLD.3 
However, there is no consensus on prognostic indicators and whilst EASL-EASD-
EASO guidelines suggest possible pathways of care for patients with NAFLD but there 
is ongoing doubt about their applicability to the T2DM population. 217,254 
Accordingly, there is a need for better understanding of the natural history and 
incidence of NAFLD in people with diabetes, and to discern those predictive factors 
that can potentially identify those at high risk of developing complicated disease and 
be utilised in screening strategies. 
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This thesis will address the following specific aims: 
1. Define the absolute and relative cohort incidence of liver disease to date in the 
ET2DS cohort 
2. Determine whether current non-invasive fibrosis risk prediction tools reliably 
identify incident cirrhosis and hepatocellular carcinoma in a community cohort of 
older people with T2DM 
3. Determine whether the addition of other biomarkers to existing fibrosis risk 
prediction tools improve their performance in predicting incident cirrhosis and 
hepatocellular carcinoma in a community cohort of older people with T2DM 
4. Identify whether potential non-invasive screening tests for NAFLD (those 
identifying steatosis, serum liver enzymes, markers of fibrosis) associated with 
incident cirrhosis, hepatocellular carcinoma and mortality in people with T2DM 
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Chapter 2 Methods 
This Chapter will discuss general methods used in the study. Methods used for 
individual analyses will be discussed in specific chapters. 
2.1 The study population: The Edinburgh Type 2 
Diabetes Study 
The ET2DS is a population based prospective cohort study. It was designed to 
examine cognitive function and factors associated with cognitive decline in a 
population of older people with T2DM. At year 1 a second assessment arm was 
initiated to examine the prevalence of liver disease in this cohort, to study the natural 
history of liver disease progression and to identify factors associated with this 
progression in this cohort.  
Participants were selected from over 20,000 patients with T2DM on the Lothian 
Diabetes Register. The Lothian Diabetes Register (now incorporated into SCI-
Diabetes) is a computerised database established in 2001. It contains details of 
people with diabetes (as defined by WHO criteria) living in Lothian, Scotland, UK. It 
includes both those cared for in primary care and in hospital clinics. Work by the 
Lothian Diabetes Services Advisory Group demonstrated that this database contains 
almost everyone diagnosed with diabetes in the area (Sarah Wild, personal 
communication). 255 
Participants were selected by gender and 5-year age bands from a computer-
randomised list. Inclusion criteria were age 60-74 on 01/08/2006 and a diagnosis of 
T2DM. Exclusion criteria were non-English speaking (as fluent English was required 
for cognitive testing), visual acuity worse than 6/36 at distance, or unable to read large 
print text (as this was required for the testing), who were unwilling or unable to give 
informed consent or physically unable to complete the clinical or cognitive 
examination.  
Criteria to confirm the presence of diabetes were: currently having treatment with oral 
antihyperglycaemic medication and/or insulin; or currently treated with dietary 
modification alone and an HbA1c>6.5%. If recruits were treated with dietary 
modification alone and had an HbA1c ≤6.5%, their medical records were reviewed by 
a consultant Diabetologist (Mark Strachan) to ensure that the diagnosis of diabetes 
was robust. The diagnosis of T2DM was additionally reviewed if the participant had 
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commenced insulin within 1 year of diagnosis, if they had reported a history of 
pancreatic surgery at the research clinic or if the participant was treated with insulin 
and had been diagnosed aged <35 years. Participants in whom it was not possible to 
confirm a diagnosis of T2DM were excluded.  
A total of 5,454 invitations to participate were sent out between 20th June 2006 and 
1st June 2007; 3,286 people replied, of whom 1,252 were interested in the study. Of 
these 1,077 attended the baseline clinic and 1,066 were included in the study (unable 
to complete tests n=4, did not fulfil study criteria for the diagnosis of T2DM n=7). Every 
effort was made to ensure participants attended the research clinics. This included 
multiple attempts to contact the participant to arrange appointments, providing a 
choice of clinic dates, paid travel or provision of transport to clinic and reminder calls 
prior to the clinic attendance. 
2.1.1 Representativeness of Data  
Non-identifiable data gathered from the Lothian Diabetes Register was able to confirm 
that the baseline study participants (1,066) were representative to the randomly 
selected 5,454 patients in age, HbA1c, duration of T2DM, proportion requiring insulin 
treatment and total cholesterol. It was thus considered that the study participants were 
largely representative of the target population (Table 4). 256 It is important to note that 
there was a significant difference in the proportion of men the study invited compared 
to the target population. This was due to the selection of participants in age range 
brackets. 
2.1.2 Power and sample size 
The study aimed to recruit 1,000 subjects which would allow 90% power at the 2-
sided 5% significance level to detect a Pearson correlation coefficient of ≥0.10 
between a continuous outcome measure and predictor variable; and estimated to 
allow for the detection of any risk factor that contributed 1% or more to the variance 
in the outcome for observed associations. 255 Using a post-hoc power calculation, the 
study had 82% power to detect a 3% difference in rates of incident cirrhosis and HCC 
with a putative baseline rate of 1%. The study had 89% power to detect a 10% 
difference in all-cause mortality rates with a baseline rate of 29% and 88% power to 
detect a 7.5% difference in cardiovascular mortality rates with a baseline rate of 12% 
(2-tailed, probability of a type 1 error 0.05). 
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Table 4. Representativeness table. Baseline characteristics of ET2DS study 
population compared with non-responders (adapted from Marioni et al. 2010) 
256 
  ET2DS  
(n = 1066) 
Non-responders  
(n = 4386*) 
Age  67.9  (4.2)  67.9  (4.4) 
Sex - Male   547  (51.3%)  1839  (41.9%) 
Systolic blood pressure (mmHg)  133.3  (16.4)  137.2  (18.2) 
Total cholesterol (mmol/L)  4.3  (0.9)  4.2  (1.0) 
HbA1c  (%Hb)  7.4  (1.1)  7.4  (1.4) 
HbA1c (mmol/mol)  57  (12.4)  57  (14.9) 




Up to 5 years  516  (48.4%)  2135  (48.7%) 




1 (most deprived)  127  (11.9%)  736  (16.8%) 
2  208  (19.5%)  1134  (25.9%) 
3  188  (17.6%)  820  (18.7%) 
4  194  (18.2%)  782  (17.8%) 
 5 (least deprived)  349  (32.7%)  897  (20.5%) 
Values are mean (sd) or n (%); *4388 was actual number of non-responders but two 
subjects from the Lothian Diabetes Register did not have any data so were discarded 
from analyses 
HbA1c glycated haemoglobin, mmHg millimetres of mercury, mmol/L millimol/litre 
 
2.1.3 Ethics and consent 
Ethics permission for the study was granted by Lothian Medical Research Ethics 
Committee (REC reference 16/SS/0098). The Lothian Diabetes Services Advisory 
Group and the Caldicott guardian for NHS Lothian provided permission for the use of 
the Lothian Diabetes register (now SCI-diabetes) in patient selection. Participants 
renewed written informed consent at all clinic visits. 
2.2 Data Collection 
 
2.2.1 Study Phases 
Assessment took place primarily at baseline, year 1, year 4 and year 10. Assessment 
included attendance at dedicated research clinics, collection of biochemical samples, 
physical examination, cognitive testing, completion of self-assessment questionnaires 
by participants and GPs, data linkage to the information services division in Scotland 
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(ISD) (www.isdscotland.org), National Records Scotland and SCI-diabetes, and 
assessment of hospital electronic patient records (Table 5). 
All participants who were alive and who had consented to be contacted about 
additional studies were invited to return to Year 1, 4 and 10 assessment. At year 1, 
1,054 were invited (died n=2, declined n=5, medically unsuitable for contact n=3, 
withdrawn from further contact n=2). 940 attended (died n=13, unable to contact n=19, 
unable to attend for health reasons n=23, unable to attend for other reasons n=38, 
did not attend appointment n=21). Of these 940, one participant was unable to 
complete the research assessment. At year 4, 974 were invited (died n=81, withdrawn 
from contact n=11). 830 attended (unable to contact n=15, declined to attend n=100, 
withdrew from further contact n=30). At year 10, 845 were invited of whom 581 were 
able to complete assessment (died n=84, unable to attend n=112, declined 
appointment n=44, unable to contact n=24). 
2.2.2 Research Clinics 
All research clinics took place at the Wellcome Trust Clinical Research Facility, 
Western General Hospital, Edinburgh, UK. Standardised operating procedures were 
used for every aspect of data collection. Detailed assessment of modifiable risk 
factors and cognitive testing was undertaken and has been documented   previously. 
255 Individuals with clinically significant findings during testing were referred to an 
appropriate clinician for follow up. 
2.2.3 Questionnaires 
Questionnaires were completed by participants at the time of the clinic appointment. 
These recorded demographic data, data regarding diabetes history, other past 
medical history including a history of liver or joint disease, medication use, alcohol 
and smoking history, and chest pain and claudication scales. If participants were 
unable to attend clinic at Year 4 and 10, modified questionnaires to obtain 
demographic data, diabetes history, updated medical history and medication use 
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Table 5. Data Collection Undertaken throughout Study 
Baseline Year 1  Year 4  Year 6 Year 10  Data Collected 
     General questionnaire: 
Demographics, Past Medical 
History, current medications, 
alcohol consumption, smoking 
     Diabetes questionnaire: Diabetes 
history, diabetes medication 
history, history of hypoglycaemia 
     Liver questionnaire: liver disease 
history, joint disease history, 
hepatotoxic medication use 
     Cardiovascular questionnaire: 
chest pain and claudication scales 
     Physical examination (including 
BMI, bp, waist circumference) 
     Cognitive testing 
     Fasting venous blood sample 
(including HbA1c, cholesterol, 
AST, ALT, ALP, GGT, bilirubin, 
albumin, platelets, HA, TNFα, IL-6, 
CRP, triglycerides and blood for 
DNA at baseline, ELF at year 1) 
     Liver Ultrasound  
     Transient Elasstography 
     ECG 
     Data linkage with ISD Scotland 
     Data from SCI-diabetes 
     Data linkage with electronic 
secondary care record 
     Death Certificate data from 
National Records Scotland 
BMI body mass index bp blood pressure AST aspartate aminotransferase ALT alanine 
aminotransferase ALP alkaline phosphatase GGT gamma glutamyltransferase HA hyaluronic 
acid TNFα tumour necrosis factor alpha IL-6 interleukin 6 CRP C-reactive protein ELF 
Enhanced Liver Fibrosis Score 
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2.2.4 Routine data collection 
Data was collected for all participants from general and acute inpatient (excluding 
psychiatric and obstetric wards) discharge records and death certification using 
record linkage to the SMR01 scheme at NHS National Services Scotland, Information 
Services Division (www.isdscotland.org). This data linkage was undertaken at 
baseline (data acquired 1981-2007), with follow up linkage up to 2011 and 2015. This 
was used to supplement and confirm self-reported history. In addition, death data was 
collected in 2018 from National Records Scotland.              
Selected data held on the Lothian Diabetes Register (SCI-diabetes) was extracted to 
provide routinely recorded HbA1c data and data on medication prescription during the 
period of the study. 
Secondary care records from Lothian Hospitals were interrogated to supplement and 
confirm liver, cardiovascular, dementia and death events. To undertake this, the 
TRAK electronic patient record was reviewed (TrakCare, InterSystems Corp., 
Cambridge, USA) at year 4 and 10. 
2.2.5 Variable collection 
Discussed below in detail are the variables collected relevant to this project. Full 
details of data collection can be found in previous publications. 255 Unless otherwise 
specified, blood samples were analysed using a Vitros Fusion chemistry system 
(Ortho Clinical Diagnostics, Bucks, UK) at the Western General Hospital (Edinburgh, 
UK). 
Demographics: Date of birth and sex was obtained from self-report questionnaire 
and confirmed against clinical records. Ethnicity was obtained from self-report 
questionnaire. Socio-economic status was measured using the Scottish Index of 
Multiple Deprivation (SIMD) 2006 converted from patient home postcodes at baseline 
(see http://openscotland.gov.uk/Topics/Statistics/SIMD/FAQs#lookups) and defined 
as quintiles (1 most deprived, 5 least deprived). 
Diabetes Background: Duration of Diabetes was calculated based on date of 
diagnosis on self-report questionnaire. Hba1c at baseline was measured on venous 
blood samples. For those people who did not have an HbA1c taken due to failure of 
venepuncture at baseline clinic, baseline HbA1c was obtained from routine data 
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download of care records if possible, with an HbA1c within 6 months of the baseline 
clinic appointment accepted as a valid value.  
Lifestyle Factors: Smoking and alcohol were assessed on self-report questionnaire. 
For alcohol, average weekly alcohol intake was determined using two questions 
adapted from the AUDIT-C screening tool: “How often did you have a drink containing 
alcohol in the past year? Consider a “drink” to be a can or bottle of beer, a glass of 
wine, or one cocktail or a measure of spirits (like scotch, gin or vodka)” 257. (A drink 
was considered to be the equivalent of one and a half units of alcohol); and “How 
many drinks did you have on a typical day when you were drinking in the last year?”. 
Alcohol excess was defined according to established criteria as alcohol intake >14 
units/ week (female) or >21 units/ week (male) or subject self-report of current or 
previous alcohol excess. 
Metabolic Factors: Height was measured (to nearest mm) standing without shoes. 
Weight was measured (to nearest 0.1kg) without outdoor clothing or shoes using 
SECA 761 electronic weighing scales. BMI was calculated as height (m)/ (weight 
(kg))2. Waist and hip circumference were measured (to nearest 0.5cm) using a non-
expandable tape measure. Waist circumference was measured at the level midway 
between the lower rib margin and the iliac crest, with the subject standing with their 
feet 30 cm apart and with their hands by their sides, during exhalation. The average 
of 2 readings was taken. Total cholesterol and triglycerides were collected from fasting 
venous blood samples. 
Inflammatory markers: CRP, IL-6 and TNFα were assessed from venous blood 
samples. CRP was measured using an immunonephelometric assay, and IL-6 and 
TNF-α were measured using the ELISA system (R&D Systems, Oxon, UK), Glasgow 
Royal Infirmary, UK. 
Non-invasive liver markers: ALT, AST, ALP, GGT, bilirubin, albumin, platelets and 
HA were measured on fasting venous blood samples at baseline. ELF was measured 
on fasting venous blood samples at the year 1 clinic and was analysed using the 
ADVIA Centaur immunoassay system (Siemens Healthcare Diagnostics Inc, New 
York, USA) at the iQur laboratory (London, UK). HA was measured using a 
radiometric assay (Pharmacia, Uppsala, Sweden).  
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Hepatic steatosis was determined by USS measurement following a 4 hour fast at the 
year 1 clinic (Sonoline Elegra Ultrasound Imaging System (Siemens Medical Systems 
Inc, Washington, USA), software version 6, with a 3.5 MHz transducer). The technique 
has previously been described in detail. 258 Briefly, a single sonographer, blinded to 
clinical history, undertook all scanning and graded using established criteria (normal, 
indeterminate steatosis (possible slight increase in echogenicity or slightly impaired 
visualization of the diaphragm/ intrahepatic vessels/ difficult to grade as a result of 
diseased or absent R kidney), mild steatosis (definite increased echogenicity and/ or 
definite impaired visualisation of intrahepatic vessels and diaphragm, no/ little 
evidence of focal fatty sparing), severe steatosis (marked increase echogenicity and 
or poor or no visualization of the diaphragm and intrahepatic vessels, with or without  
focal fatty sparing). To confirm results and assess for inter- and intra-observer 
variation, a subset of the USS (71) were re-graded (still images only) by 2 additional 
independent graders (a consultant radiologist and a medical trainee in radiology) 
within 1 month of the USS. ≥2 months later, all 3 graders regraded all 71 USS by still 
image assessment. Graders were blinded to the other graders results and clinical and 
lab results of the participants. No significant inter or intra-observer variability was 
seen. In addition, a subset (50 participants) underwent 1H MRI spectroscopy (the gold 
standard non-invasive tool for assessing hepatic steatosis) to assess the validity of 
USS as a technique to identify steatosis. This has been described in detail previously 
258. In brief, this showed a median fat fraction in those with ‘severe’ steatosis of 19.4% 
(interquartile range 12.9-27.5), compared to 4.1% (interquartile range 3.1-8.5) in 
those with ‘indeterminate’/ ‘mild’ steatosis and 4.2% (interquartile range 1.2-5.7) in 
those with ‘no steatosis’. As a result of this validation which showed significant overlap 
between graded ‘normal’, ‘indeterminate’ and ‘mild’ steatosis, only those with severe 
steatosis on USS assessment were deemed to have ‘definite steatosis’. Individuals 
with any other USS grading were considered to have ‘no definite steatosis’.   
Calculated variables: A wide range of markers of fibrosis were measured and 
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Steatosis and Fibrosis scores were calculated and cut-off levels used as per published 
literature.  
- AST to platelet ratio index (APRI) was calculated as: ((AST(U/L)/Upper limit 
normal) /platelets(x109/L)) x100. Cut-point low to medium/high risk of fibrosis 
>0.5.220 
- AST: ALT ratio was calculated as: AST(U/L)/ALT(U/L). cut-point ≥0.8. 221 
- Fibrosis-4 index (FIB-4) was calculated as 
((age(years)xAST(U/L))/(plt(x109/L)x√ALT(U/L))). Cut point low-medium risk 
≥1.3 and medium-high risk >2.67. 227,229,234 
- NAFLD Fibrosis Score (NFS) was calculated as: 
1.675+(0.037xage(years))+(0.094xBMI(kg/m2))+(1.13xIFG/diabetes (yes=1, 
no=0))+(0.99x(AST(U/L)/ALT(U/L))- (0.013xplatelet count(×109/L))-
(0.66xalbumin (g/dL)). Cut-point for low-medium risk ≥-1.455, medium-high risk 
>0.676. 230 
- Fatty liver index (FLI) was calculated as: ey/(1+ey)x100 where y=0.953 x 
ln(triglycerides, mg/dl) + 0.139 x BMI, kg/m2 + 0.718 x ln (GGT, U/L) + 0.053 x 
waist circumference, cm – 15.745). 259 
- The EASL-EASD-EASO referral decision algorithm (Figure 2) was used. 217 
Outcomes- development of cirrhosis, HCC, varices, ascites, encephalopathy 
and hepato-renal syndrome: The presence of cirrhosis, HCC and other cirrhosis 
complications (varices, ascites, encephalopathy or hepato-renal syndrome) were 
determined, with data collection mechanisms discussed below.  
Possible prevalent liver disease was identified through a patient clinical history 
questionnaire at the baseline clinic. Possible cases were confirmed if a clinician 
diagnosis was recorded in primary or secondary care medical records. 
Incident liver disease was identified and corroborated using multiple sources of 
information: retrospective review of all participants’ secondary care medical notes 
(TrakCare, InterSystems Corp., Cambridge, USA), patient and GP questionnaires 
provided at year 4 and year 10 follow-up, ISD (Information Services Division, NHS 
Scotland) discharge summary coding of hospital admissions and death coding. Cases 
were confirmed if a clinician diagnosis was recorded in secondary care medical notes. 
All cases identified through data linkage were able to be confirmed in secondary care  
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Figure 2. EASL-EASD-EASO Algorithm217 
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 medical notes. Date of diagnosis was determined as the date of the first clinical 
documentation of the diagnosis in the medical notes (clinic letter or inpatient stay 
discharge summary). 
ICD codes analysed and correlated with medical records were: B18 (chronic viral 
hepatitis), B19  (unspecified viral hepatitis), C22.0 (liver cell carcinoma), C22.7 (other 
specified carcinomas of liver), C22.9 (malignant neoplasm of liver, unspecified), K70 
(alcoholic liver disease), K71 (toxic liver disease), K72.0 (acute and subacute hepatic 
failure), K72.1 (chronic hepatic failure), K72.9 (hepatic failure, unspecified), K73 
(chronic hepatitis not elsewhere classified), K74.0 (hepatic fibrosis), K74.1 (hepatic 
sclerosis), K74.2 (hepatic fibrosis with hepatic sclerosis), K74.3 (PBC), K74.4 
(secondary biliary cirrhosis), K74.5 (biliary cirrhosis, unspecified), K74.6 (other and 
unspecified cirrhosis of the liver), K76.0 (fatty liver not elsewhere classified), K76.1 
(chronic passive congestion of the liver), K76.2 (central haemorrhage necrosis of 
liver), K76.3 (infarction of liver), K76.4 (peliosis hepatitis), K76.5 (hepatic vena-
occlusive disease), K76.6 (portal hypertension), K76.7 (hepatorenal syndrome), 
K76.8 (other specified diseased of liver), K76.9 (liver disease, unspecified), K77.0 
(liver disorders in infectious and parasitic diseases), K92.0 (haematemesis), K92.1 
(Melaena), K92.2 (GI haemorrhage, unspecified), R16.0 (hepatomegaly not 
elsewhere classified), R16.1 (splenomegaly not elsewhere classified), R16.2 
(hepatomegaly with splenomegaly not elsewhere classified), R17 (unspecified 
jaundice), R18 (ascites), R58 (haemorrhage, not elsewhere classified). 
It should be noted that some incident cirrhosis/ HCC was identified following referral 
after year 1 and year 4 clinic screening. Referral criteria for hepatology review were 
any of: routine liver enzyme tests above the laboratory upper limit of normal (ALT >50 
U/L, AST >45 U/L, GGT >55 U/L, ALP >125 U/L); AST:ALT ratio >1; positive 
autoantibodies (anti-nuclear antibody, anti-smooth muscle antibody, anti-
mitochondrial antibody), ferritin >1000ng/ml, positive hepatitis B or C serology, 
hyaluronic acid >100 microg/L (in the absence of known joint disease), spleen >13cm 
(in the absence of known haematological cause), platelets <150 x109/L (in the 
absence of known haematological cause), suspected cirrhosis on USS or alpha-feto 
protein >6ng/l. Participants were identified as having ‘screen-detected’ cirrhosis/HCC 
if they were referred to hepatology as a result of year 1 or 4 investigation and remained 
under hepatology follow-up until definitive diagnosis was made (Figure 3). 
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Outcomes- Cause of Death: Cause of death was identified through data linkage to 
death coding in ISD data (collected up to year 8 follow-up). For those where ISD data 
was not available, cause of death was identified from death certification in secondary 
care medical records or the analysis of death certificates at National Records 
Scotland.  
Death data was reviewed manually to ascertain primary cause of death. 
Cardiovascular Death was determined to be a primary cause of death termed as any 
of fatal myocardial infarction, fatal cerebrovascular accident, other fatal ischaemic 
heart disease, other fatal cerebrovascular disease (note this did not include vascular 
dementia), fatal other cardiovascular disease. Death from cirrhosis or HCC was 
determined to be a primary cause of death as cirrhosis, HCC or as a direct 
complication of these. 
2.3 Data Entry 
All data obtained was entered onto a master Microsoft Access database (Microsoft 
Access 2003/2010, Microsoft Corporation, Washington, USA). At baseline, the 
majority of data from paper records was double entered and discrepancies resolved 
by reference to the original documentation. At follow up years, at least 10% of the 
data from paper records was double entered.  
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2.4 Personal contribution to data collection 
My personal contribution was to the following parts of the data collection and entry for 
the year 10 follow-up of the study: 
- An interrogation of participants’ electronic secondary care records from NHS 
Lothian hospitals, Lothian, UK (TrakCare, InterSystems Corp., Cambridge, USA) 
was undertaken. The records of all 1066 participants in the study were searched 
for liver outcomes (at any point in the study), dementia and cardiovascular 
outcomes (from the point at which records had previously been interrogated (2010 
and 2014 respectively)), and death records. Specifically for liver outcomes; 
evidence of a diagnosis of cirrhosis, hepatocellular carcinoma, cirrhosis related 
variceal disease, ascites, subacute bacterial peritonitis, encephalopathy or 
hepato-renal syndrome, attendance at liver clinic or enrolment into an HCC or 
varices surveillance programme was recorded. 
- With other team members, a data download from the SCI-Diabetes database to 
obtain retinopathy screening, blood pressure, HbA1c, lipid and medication 
prescription data was organised. 
- The National Records Scotland database was searched to identify additional 
death certificate details for those participants who have died but for whom the 
study did not have cause of death details. Through this search, out of over 300 
participants who have passed away, the study now has cause of death for all but 
20. 
- I contributed to sending self-assessment questionnaires to participants and GPs 
(for those where the study was unable to contact the participant), the completion 
of the database data entry for the 10 year follow up clinics, the double data entry 
process for the 10 year follow up clinic data and reviewing and ensuring correct 
coding of conditions and causes of death in the database to facilitate future 
database searching. 
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2.5 Data analysis 
Data was analysed using R (R Core Team (2017). R: A language and environment 
for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL 
https://www.R-project.org/). 
2.5.1 Missing Data 
There are three generally accepted approaches to dealing with missing data. Firstly, 
if it is considered that in those people who had missing data, that data is missing at 
random, then it is reasonable to use only those with complete data sets in the analysis. 
However, if the data is not missing at random then there is a risk of introducing 
systematic bias. 260,261 Additionally, if a large subsection of the research population 
has missing data, then excluding them will reduce the power of the analysis. 
Secondly, it is possible to use incomplete data but add in a random effects term to 
any model created, in recognition of the fact that the missing data may contribute an 
important but unknown effect. Thirdly, multiple imputation can be utilised. In this 
method, missing items are assigned a generated value and then incomplete records 
can be ‘topped up’ in this way and included in analysis alongside cases with full data 
sets. Analysis can be repeated multiple times with alternative imputed values to aim 
to ensure that the imputed values are not substantially affecting the results. This 
enables a fuller analysis of the whole cohort on one hand, however any imputed value 
is not a true reading and may in itself bias the results. 260,261 
For this study, initial paper records have been reviewed for all missing data by at least 
2 investigators to ensure that the data-set is as complete as possible, and that all 
missing data is truly missing. 
For this analysis, most explanatory variables have <5% missing data. In previous 
analysis of liver data undertaken in our cohort, assessment was made of the whole 
data set. If <5% of the participants had missing data for a particular variable and 
whether it was missing was presumed random, then analysis was undertaken on an 
available case analysis and participants with missing data were excluded. However, 
not all patients were available to return to follow up for the year 1 follow-up and thus 
variables collected at this point (relevant to this analysis are ELF, USS assessment 
of hepatic steatosis) have >5% missing data. In addition, the variables with >5% 
missing data are key variables where imputation would be difficult to determine (an 
average value would be difficult to obtain based on other variables as often they are 
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not linked). Multiple imputation analysis additionally was attempted for ELF in 
previous work undertaken by this group and results were not significantly different 
from those obtained from available case analysis. 240 
The decision was thus made that analysis would be undertaken on an available case 
analysis basis, understanding the potential limitations of power this approach might 
present. 
An assessment was undertaken assessing the baseline characteristics of the whole 
population compared to the available case populations for each analysis, which 
showed these were broadly similar 
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Table 6). 
2.5.2 Outliers 
Outliers were identified using the Tukey boxplot method, looking at any value greater 
than 1.5 times the interquartile range from the median value. All values in this category 
were manually checked for clinical plausibility, with extreme outliers checked with 
paper records to exclude the possibility of transcription error. As a result of these 
checks, no items were excluded. 
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Used in Question: 1 - 3, 5 2 3 4 
Age  67.9  (4.2) 0  67.9  (4.2)  67.9  (4.2)  67.8  (4.2)  67.9  (4.2) 








 127  (11.9)   125  (11.8)  107  (11.5)  81  (11.9)  119  (11.9) 
2  208  (19.5)   206  (19.5)  176  (18.9)  128  (18.8)  196  (19.6) 
3  188  (17.6)   187  (17.7)  161  (17.3)  116  (17.0)  178  (17.8) 
4  194  (18.2)   193  (18.2)  169  (18.1)  117  (17.2)  180  (18.0) 
5 (least 
deprived) 
 349  (32.7)   348  (32.9)  320  (34.3)  239  (35.1)  326  (32.6) 
Duration T2DM (years)  8.1  (6.5) 13  8.1  (6.5)  8.0  (6.4)  7.8  (6.3)  8.0  (6.5) 
HbA1c (%)  7.4  (1.1) 9 7.4 (1.1)  7.4  (1.1)  7.4  (1.1)  7.4  (1.1) 
HbA1c (mmol/mol)  57  (12) 9  57  (12)  57  (12)  57  (12)  57  (12) 
BMI (kg/m2)  31.4  (5.7) 1  31.4  (5.7)  31.3  (5.7)  31.2  (5.7)  31.3  (5.6) 
Waist-Hip Ratio  0.97  (0.1) 5  0.97  (0.1)  0.96  (0.1)  0.96  (0.1)  0.96  (0.1) 
Smoker (current)  154  (14.4) 0  153  (14.4)  122  (13.1)  89  (13.1)  143  (14.3) 
Alcohol (excess)a  207  (19.9) 27  204  (19.8)  187  (20.0)  139  (20.1)  195  (19.5) 
Cholesterol (mmol/L)  4.3  (0.9) 9  4.3  (0.9)  4.3  (0.9)  4.3  (0.9)  4.3  (0.9) 
ALT (U/L)  43.2  (14.3) 9  43.2  (14.3)  43.5  (14.4)  44.0  (14.1)  43.4  (14.4) 
AST (U/L)  31.0  (10.5) 11  31.0  (10.4)  31.1  (10.3)  31.1  (9.8)  31.1  (10.4) 
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GGT (U/L)  29.9  (42.3) 11  29.4  (40.3)  29.1  (40.0)  28.6  (39.3)  29.7  (40.9) 
Bilirubin (𝝁mol//L)  10.1  (5.0) 9  10.0  (4.7)  10.1  (4.9)  10.2  (5.0)  10.0  (4.7) 
Albumin (g/L)  44.8  (3.3) 11  44.8  (3.3)  44.8  (3.2)  44.9  (3.2)  44.8  (3.3) 
Platelets (109/L)  258.0  (69.9) 21  258.7  (69.3)  257.9  (68.7)  260.9  (70.4)  258.5  (69.8) 
Hyaluronic Acid (ng/ml)  57.9  (58.9) 9  56.1  (46.6)  56.1  (46.8)  55.9  (48.6)  56.4  (47.1) 
TNF-∝ (pg/ml)  1.4  (1.5) 3  1.4  (1.5)  1.4  (1.6)  1.3  (1.1)  1.4  (1.6) 
IL-6 (pg/ml)  3.9  (3.5) 2  3.9  (3.5)  3.8  (3.4)  3.7  (3.3)  3.9  (3.4) 
CRP (mg/L)  3.9  (6.0) 24  3.9  (6.0)  3.6  (5.6)  3.6  (5.7)  3.8  (6.0) 
Values are mean(sd) or n(%) 
a Defined as females >14 units/week, males >21 unis/week or patient disclosed history of a current or prior alcohol 
problem  
HbA1c glycated haemoglobin, BMI  body mass index, ALT  alanine aminotransferase,  AST  aspartate 
aminotransferase,  ALP alkaline phosphatase, GGT gamma glutamyltransferase, TNF-∝ tumour necrosis factor-alpha, 
IL-6 Interleukin-6, CRP c-reactive protein, mmol/L milimol per litre, kg/m2 kilograms per square metre, U/L international 
units per litre, 𝝁mol//L micromol per litre, g/L grams per litre, pg/ml pico-grams per mililitre, mg/L milligrams per litre, 
ng/ml nanograms per mililitre  
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Chapter 3 Non-invasive risk scores do not 
reliably identify future cirrhosis or 
hepatocellular carcinoma in Type 2 
diabetes: The Edinburgh Type 2 
Diabetes Study 
This section was published in Liver International under the same title by Sheila M 
Grecian (SMG), Stela McLachlan (SM), Jonathan A Fallowfield (JF), Patrick KA 
Kearns (PK), Peter C Hayes (PH), Indra Neil Guha (NG), Joanne R Morling (JM), 
Stephen Glancy (SG), Rachel M Williamson (RW), Rebecca M Reynolds (RR), Brian 
M Frier (BF), Nicola N Zammitt (NZ), Jackie F Price (JP) and Mark WJ Strachan (MS). 
262 SMG wrote the manuscript. JP was principal investigator of the ET2DS, designed 
the study, analysed and interpreted the data. MS was lead investigator of the ET2DS 
liver sub-study, designed the study, analysed and interpreted the data. RR, BF, PH, 
JF, RW, NG and SG contributed to study design. SMG, SM, RW, JM and PK 
contributed to data collection, analysis and interpretation. All authors contributed to 
revision and final approval of the article. 
There is increased incidence of cirrhosis and HCC in people with T2DM, with the 
primary aetiology being NAFLD (section 1.4). However, although it has been 
suggested that it may be beneficial to screen high risk population groups for NAFLD 
in order that advice can be targeted about lifestyle modification to reduce rate of 
disease progression or reverse disease progression, cardiovascular risk management 
optimised and complications identified and treated promptly, there is no consensus 
on which tools work best to predict clinically significant disease. 217 In addition, it has 
been shown that existing risk prediction tools tend to perform worse in populations 
with diabetes. 237 In this study we investigated the incidence of cirrhosis and HCC in 
a community cohort of older people with T2DM. Furthermore, we assessed the ability 
of existing non-invasive risk prediction tools to identify incident liver disease in our 
community population with T2DM. 
Please note- formulae used for the calculation of incidence and the predictive ability 
of risk prediction tools can be found in appendix 2. 
Please note- all tables for this section sit at the end of the chapter text. 
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3.1 Abstract 
Background: The incidence of cirrhosis and hepatocellular carcinoma (HCC) is 
increased in Type 2 diabetes, primarily secondary to non-alcoholic fatty liver disease 
(NAFLD). European guidelines recommend screening for NAFLD in Type 2 diabetes. 
American guidelines, while not advocating a screening protocol, suggest using non-
invasive markers of fibrosis for risk-stratification and guiding onward referral.  
Aims: To test the ability of individual fibrosis scores and the European screening 
algorithm to predict 11-year incident cirrhosis/HCC in an asymptomatic community 
cohort of older people with Type 2 diabetes. 
Methods: The Edinburgh Type 2 Diabetes Study investigated men and women with 
Type 2 diabetes (n=1,066, aged 60–75 at baseline). Liver markers were measured at 
baseline and year 1; steatosis and fibrosis markers were calculated according to 
independently published calculations. During 11-years of follow-up, cases of cirrhosis 
and HCC were identified.  
Results: 43/1059 participants with no baseline cirrhosis/HCC developed incident 
disease. All scores were significantly associated with incident liver disease by odds 
ratio (p<0.05). The ability of the risk-stratification tools to accurately identify those who 
developed incident cirrhosis/HCC was poor with low positive predictive values (5-
46%) and high false negative and positive rates (up to 60% and 77%) respectively. 
When fibrosis risk scores were used in conjunction with the European algorithm, they 
performed modestly better than when applied in isolation. 
Conclusions: In a cohort with a moderately low incidence of cirrhosis/HCC, existing 
risk scores did not reliably identify participants at high-risk. Better prediction models 
for cirrhosis/HCC in people with Type 2 diabetes are required. 
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3.2 Introduction 
People with Type 2 diabetes have a higher incidence of cirrhosis and hepatocellular 
carcinoma (HCC) than the general population. 20,21,75 The commonest cause of liver 
disease in Type 2 diabetes is non-alcoholic fatty liver disease (NAFLD) with estimates 
of prevalence from 40-70%.9-11,263   
It would be valuable to identify those at high-risk of developing cirrhosis/HCC because 
NAFLD (at the pre-cirrhotic stage) is potentially reversible by weight loss, and it would 
direct screening and early treatment for varices and HCC, while promoting intensive 
management of increased cardiovascular risk. 7,217  
A significant problem in creating appropriate risk assessment tools for NAFLD is that 
no consistent risk factors for progressive disease have been identified. Cohort studies 
report variable results and in meta-analyses the only consistent factor predicting 
progressive disease is histological identification of liver fibrosis. 179,180 However, liver 
biopsy is an invasive procedure, with a complication rate that is not acceptable for 
population screening. Several groups have developed non-invasive risk scoring 
models to identify those with fibrosis (including the Fibrosis 4 Index (FIB-4), the 
NALFD Fibrosis Score (NFS), AST:ALT ratio, the AST to Platelet Ratio Index (APRI) 
and the Enhanced Liver Fibrosis test (ELF)). 220,221,224,227,230 These scores have been 
validated in cohorts with NAFLD. However, subsequent studies have shown variable 
performance with the strength of association with incident cirrhosis, HCC, the need 
for liver transplantation and death varying significantly between cohorts. 185,189,225,231,234 
Most of these studies have been small and only included people under secondary 
care hepatology services. In addition, when applied to specific groups, literature 
based cut-offs result in very variable proportions of populations being classed as 
‘high-risk’ with poor agreement between the top 5% of the distribution of risk 
scores.202,264 
Consensus guidelines on the management of NAFLD, published by the European 
Association for the Study of the Liver, the European Association for the Study of 
Diabetes and the European Association for the Study of Obesity (EASL-EASD-EASO) 
recommend screening for NAFLD as part of routine care in Type 2 diabetes. 217 These 
guidelines suggest a screening algorithm that advises referral for specialist 
hepatology assessment if there is evidence of steatosis and non-invasive markers 
suggest medium or high-risk of fibrosis; or if there is a raised alanine aminotransferase 
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(ALT), aspartate aminotransferase (AST) or gamma-glutamyltransferase (γGT) 
(Figure 1). The American Association for the Study of Liver Diseases (AASLD), while 
not recommending a specific screening algorithm, states that there should be ‘a high 
index of suspicion for NAFLD and NASH in Type 2 diabetes’. 7 The AASLD suggests 
the use of existing liver fibrosis risk scores or assessment methodologies (such as 
the FIB-4, NFS or transient elastography) to assess at-risk patients. 7  
One study of the EASL-EASD-EASO referral algorithm reported that around one third 
of people routinely attending a diabetes clinic would fulfil the criteria for hepatology 
referral; the incidence of subsequent cirrhosis and HCC in that cohort was not 
reported. 254 It is possible that the ability of the non-invasive tests to accurately identify 
incident disease may be affected by low event rates in community populations. 
Moreover, it has been suggested that current risk scores may be less accurate in 
people with Type 2 diabetes than in those without. 237 There remains significant 
uncertainty about the utility of these screening methods in Type 2 diabetes.  
3.3 Aims  
We aimed to assess the ability of individual fibrosis scores and of the EASL-EASD-
EASO screening algorithm to predict 11-year incident cirrhosis and/or HCC in an 
asymptomatic community cohort of older people with Type 2 diabetes. 
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3.4 Methods 
 
The Edinburgh Type 2 Diabetes Study  
The Edinburgh Type 2 Diabetes Study (ET2DS) is a population based prospective 
cohort study, designed to investigate the progression of complications in people with 
Type 2 diabetes. The full methods have been described previously. 255 In summary, 
in 2006/07 participants aged 60-74 with Type 2 diabetes were randomly selected (in 
age and sex bands) from the Lothian Diabetes Register (a database of almost 30,000 
patients with diabetes living in Lothian, Scotland, UK, managed in both primary and 
secondary care). Invitations to participate were sent to 5454 people, of whom 1066 
(20%) attended baseline assessment. These people have been shown to be 
representative of all those invited and thus of the target population. 255 All who 
attended the baseline clinic were invited to re-attend a clinical and liver assessment 
at year 1 and 4. A total of 939 attended the year 1 clinic (of the original baseline cohort, 
deceased n=15, unable to contact n=19, unable to attend n=93) and 831 at year 4 (of 
the baseline cohort, deceased n=88, unsuitable for clinical reasons n=26, unable to 
contact n=23, unable to attend n=98). The characteristics of the cohort who attended 
the year 1 clinic were similar to the whole cohort at baseline. 9 All 1066 participants 
were followed up for outcome assessment to death (320 participants throughout the 
study) or end of follow-up. 
Data Collection - Baseline biomarker assessment  
Research clinics were undertaken at the Wellcome Trust Clinical Research Facility, 
Western General Hospital, Edinburgh, UK. Standardised Operating Procedures were 
used for every aspect of data collection as previously detailed. 255 ALT, AST, γGT, 
platelets and triglycerides were measured on fasting venous samples at the baseline 
research clinic and were analysed using a Vitros Fusion chemistry system (Ortho 
Clinical Diagnostics, Bucks, UK). The Enhanced Liver Fibrosis test (ELF) was 
measured on fasting venous blood samples from the year 1 clinic and was analysed 
using the ADVIA Centaur immunoassay system (Siemens Healthcare Diagnostics 
Inc., New York, USA) at the iQur laboratory (London, UK). Ultrasound was undertaken 
at the year 1 clinic following a 4-hour fast (Sonoline Elegra Ultrasound Imaging 
System (Siemens Medical Systems Inc., Washington, USA)). Ultrasounds were 
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graded for hepatic steatosis using established criteria (0=normal liver, 
1=indeterminate, 2=mild steatosis, 3=severe steatosis) and validated by three 
different graders and 1H MRI spectroscopy in a subset, as previously described. 258 
This showed a median fat fraction in those with ‘severe’ steatosis of 19.4% 
(interquartile range 12.9-27.5), compared to 4.1% (interquartile range 3.1-8.5) in 
those with ‘indeterminate’/ ‘mild’ steatosis and 4.2% (interquartile range 1.2-5.7) in 
those with ‘no steatosis’. As a result of this validation which showed significant overlap 
between grade 0-2 steatosis, only those with grade 3 steatosis on ultrasound 
assessment were deemed to have ‘definite steatosis’. Individuals with an ultrasound 
grading of 0-2 were considered to have ‘no definite steatosis’.   
Participants underwent full diagnostic liver screen (including Hepatitis B and C 
serology, liver autoantibody titres, alpha-feto protein, ferritin) and history to assess 
alcohol status, medication use and past medical history. Any participant with routine 
liver enzyme tests above the laboratory upper limit of normal (ALT >50 U/L, AST >45 
U/L, γGT >55 U/L, alkaline phosphatase >125 U/L), AST:ALT ratio >1, hyaluronic acid 
>100μg/L (in the absence of known joint disease), positive liver autoantibodies, ferritin 
>1000ng/mL, alpha-feto protein >6ng/mL, positive hepatitis B or C serology, spleen 
diameter >13cm, platelets <150x109/L in the absence of known haematological 
cause, or suspected cirrhosis on ultrasound was referred for specialist hepatology 
review. 
Steatosis and Fibrosis scores were calculated and cut-off levels used as per published 
literature.  
- AST to platelet ratio index (APRI) was calculated as: ((AST(U/L)/Upper limit 
normal) /platelets(x109/L)) x100. Cut-point low to medium/high risk of fibrosis 
>0.5. 220 
- AST: ALT ratio was calculated as: AST(U/L)/ALT(U/L). cut-point ≥0.8 221.  
- Fibrosis-4 index (FIB-4) was calculated as 
((age(years)xAST(U/L))/(plt(x109/L)xsqrt ALT(U/L))). Cut point low-medium risk 
≥1.3 and medium-high risk >2.67. 227,229,234  
- NAFLD Fibrosis Score (NFS) was calculated as: 
1.675+(0.037xage(years))+(0.094xBMI(kg/m2))+(1.13xIFG/diabetes (yes=1, 
no=0))+(0.99x(AST(U/L)/ALT(U/L))- (0.013xplatelet count(×109/L))-
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(0.66xalbumin (g/dL)). Cut-point for low-medium risk ≥-1.455, medium-high risk 
>0.676. 230  
- Fatty liver index (FLI) was calculated as: ey/(1+ey)x100 where y=0.953 x 
ln(triglycerides, mg/dl) + 0.139 x BMI, kg/m2 + 0.718 x ln (γGT, U/L) + 0.053 x 
waist circumference, cm – 15.745). 259   
- The EASL-EASD-EASO referral decision algorithm (Figure 2) was used. 217 
Data Collection - Identification of liver disease  
Possible prevalent liver disease was identified through a patient clinical history 
questionnaire at the baseline clinic. Possible cases were confirmed if a clinician 
diagnosis was recorded in primary or secondary care medical records. 
Incident cirrhosis and HCC cases were identified and corroborated using multiple 
sources of information: retrospective review of all participants’ secondary care 
medical notes (TrakCare, InterSystems Corp., Cambridge, USA), patient and GP 
questionnaires provided at year 4 and year 10 follow-up, ISD (Information Services 
Division, NHS Scotland) discharge summary coding of hospital admissions and death 
coding (data from year 0-8). Cases were confirmed if a clinician diagnosis was 
recorded in secondary care medical notes. Participants were identified as having 
‘screen-detected’ cirrhosis/HCC if they were referred to hepatology as a result of year 
1 or 4 investigation and remained under hepatology follow-up until definitive diagnosis 
was made. Prevalence and 10-year incidence data from the Year 1 cohort have 
previously been reported; these data include only those individuals who attended for 
the year 1 visit, by contrast with the present study which has reported data from the 
entire cohort. 265 
Data Analysis  
Data were analysed using R (R Core Team (2017). R: A language and environment 
for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL 
https://www.R-project.org/.). Logistic regression was used to identify the strength of 
association between baseline prediction scores and incident cirrhosis/HCC in our 
cohort. Complete case analysis was undertaken; <5% data was missing for any 
variable with the exception of ELF and ultrasound measurement (calculated at year 1 
attendance; (n=681 for ELF, n=933 for ultrasound). Aikaike Information Criterion (AIC) 
and C-statistic were used to assess performance of the regression models. C-statistic 
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assesses discrimination (the ability for a model to correctly identify those in two 
different groups). In logistic regression it is calculated as a comparison between the 
odds of each individual having the outcome based on the model variables and the 
actual outcome achieved and examines if the model performs better than chance; a 
value of >0.8 considered to be good. AIC assesses overall model performance using 
a combination of discrimination and calibration (the ability of the model to rank 
increased risk appropriately); it has no scale but lower values suggest improved 
performance. Due to our mixed population of screen-detected and clinician-diagnosed 
outcomes, possibly skewing our time-to-event data as those who were screen-
detected were often diagnosed at a pre-symptomatic stage, our primary analysis 
(logistic regression) does not include a time component. We additionally ran a 
sensitivity analysis using competing risks regression to assess whether there was a 
significant impact of the competing risk of non-liver death on model performance. The 
Bayesian Information Criterion (BIC) was used to assess model performance for the 
competing risks regression, with lower values suggesting improved performance. 
Performance was additionally assessed through calculation of sensitivity, specificity, 
positive predictive value, negative predictive value, false positive and false negative 
level.  
Ethics  
Ethical permission for the study was granted by Lothian Medical Research Ethics 
Committee (REC reference 16/SS/0098). All participants gave written informed 
consent. 
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3.5 Results 
 
Subject characteristics at baseline  
Participants were aged 60-74 years (mean 67.9), 51.3% male. Mean duration of Type 
2 diabetes was 8 years, mean HbA1c 57mmol/mol (7.4%) and mean BMI 31.4 kg/m2. 
Alcohol intake was above recommended limits in 19.9% and 14.4% were current 
smokers (Table 7). Seven people had prevalent cirrhosis/HCC. 
Incident cirrhosis/HCC  
Of 1059 people without cirrhosis/HCC at baseline, 43 developed this outcome over 
11 years of follow-up (11-year incidence 4.1%) (  
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Figure 3). Twenty-three cases were ‘screen-detected’ from year 1 clinic, and 8 from 
year 4 clinic. Twelve cases were diagnosed following clinical referral. Range of time 
to diagnosis overlapped between the ‘screen-detected’ group (163-2251 days) and 
the ‘clinician-detected’ group (920-3977 days). Of the 43 people identified with 
cirrhosis/HCC, 37 cases were attributed to NAFLD, NAFLD with alcohol above the 
recommended limit as a cofactor, or mixed aetiology NAFLD and alpha-1-antitrypsin 
deficiency; 30 developed cirrhosis, 9 both cirrhosis and HCC and 4 HCC. Of those 
with cirrhosis, 58% developed varices, ascites and/or encephalopathy. This equated 
to an 11-year incidence of 3.7% (3.66/ 1000 person years) (cirrhosis) and 1.2% (1.31/ 
1000 person years) (HCC).  
Performance of fibrosis risk scores in predicting incident cirrhosis/HCC  
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Table 8 describes the association of existing fibrosis risk scores, using published cut-
points, with the development of cirrhosis/HCC. All risk scores revealed a significant 
relationship by odds ratio (OR) with incident cirrhosis/HCC (p<0.05). Confidence 
intervals for the OR were wide. The score with the highest C-statistic was APRI (cut-
point >0.5), that with the lowest AIC was ELF (cut-point ≥10.51).  
The ability of the risk scores to correctly identify people who developed cirrhosis/HCC 
was variable (sensitivity 33-93%, specificity 22-98%, PPV 5-46%) The NPV’s for all 
scores were 97-99%, probably because the outcome (cirrhosis/HCC) was relatively 
rare. All except two scores had false negative rates >20% (with some 60%).  For 
example, using FIB-4 (cut-point >2.67) or AST:ALT (cut-point ≥0.8), 24 out of 40 
people who developed cirrhosis/HCC were wrongly classified as ‘low-risk’. For scores 
with false negative rates <20%, the false positive rates were very high (41-78%); 
indicating that if a score was used where a false negative was less likely, a significant 
proportion of the population who would not develop cirrhosis/HCC would be classified 
as ‘high-risk’.  For example, using NFS (cut-point ≥1.455), 806 people would have 
been classified as ‘high-risk’ (of whom only 37 developed cirrhosis/HCC). Using APRI 
(the score with the best performing C-statistic), 19/40 people who developed incident 
cirrhosis/HCC would have been classified as ‘low-risk’; 78 people would have been 
classified as ‘high-risk’ and referred, of whom 21 developed cirrhosis/HCC. 
Performance of the EASL-EASD-EASO algorithm in predicting incident 
cirrhosis/HCC  
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Table 8 describes how the EASL-EASD-EASO algorithm outcome was associated 
with the development of cirrhosis/HCC in our cohort. Different steatosis and fibrosis 
scores were used within this algorithm to see whether combinations of different scores 
within the algorithm affected algorithm performance. No significant difference was 
observed in how well the algorithm ‘advise to refer’ outcome associated with incident 
cirrhosis/HCC based on the marker of steatosis used (
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Table 8). Irrespective of the fibrosis score used in the algorithm, people categorised as requiring referral were significantly more likely to 
develop cirrhosis/HCC (OR’s range 0.1-13.7 with wide CIs, all p < 0.05). When used within the algorithm, the fibrosis score that resulted in 
the greatest ability to discriminate and appropriately associate algorithm ‘advise to refer’ outcome with cirrhosis/HCC was APRI, based on 
a C-statistic of 0.82. AIC was lowest when ELF was used within the algorithm, though APRI provided not dissimilar AIC performance.  
The algorithm, regardless of steatosis marker or fibrosis score inserted, performed variably in how the ‘advise to refer’ outcome associated 
with incident cirrhosis/HCC (sensitivity 79%-90%, specificity 36%-73%). PPV was low (5-10%) indicating that a ‘advise to refer’ outcome 
was not a good predictor of incident cirrhosis/HCC. NPV was high at 99% but may again reflect the relative rarity of the outcome. False 
negative rates were lower when using algorithm compared to fibrosis score alone, but were still 10-20%, which would have resulted in 4-
8/40 who developed cirrhosis/HCC being classified as ‘low-risk’. False positive rates ranged from 27-64%, with higher false positive rates 
seen in using risk score combinations with lower false negative rates. This again demonstrates that if scores are chosen that reduce the 
number who were at true risk of cirrhosis/HCC to being classified as ‘low-risk’, a very large number of people who are not at risk of developing 
cirrhosis/HCC over 11 years would be advised to be referred to hepatology. For example, using NFS (cut-off ≥1.455), 671 people would 
obtain a ‘advise to refer’ outcome, of whom only 36 developed cirrhosis/HCC. Using APRI, the model with the highest C-statistic, 8/40 
people who developed incident cirrhosis/HCC would have been classified as ‘low-risk’ while 306 (using ultrasound steatosis as the steatosis 
marker) and 313 (using the FLI steatosis score as steatosis marker) would have been classified as ‘high-risk’ and referral advised, with only 
32 of those developing incident cirrhosis/HCC.  
Sensitivity Analysis  
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Two sensitivity analyses were undertaken. The first demonstrates that there is no improvement in test performance when an outcome of 
‘presence of varices, ascites or encephalopathy in the context of cirrhosis or HCC’ was used (Table 9). The second excluded all those with 
definite non-NAFLD disease (n=3) and showed similar results to those presented for the whole cohort with mixed aetiology disease above 
(Table 10). 
Additionally, analysis was re-run using competing risks regression methodology with the competing risk being non-liver death. Results were 
similar to those obtained from logistic regression methodology with all risk scores showing a significant association with the development of 
cirrhosis/HCC and APRI providing the best improvement from null model by BIC (T
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Table 11- Table 13). 
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3.6 Discussion 
In this study cohort of older people with Type 2 diabetes, during 11 years of follow-up 
a moderate rate of incident cirrhosis (3.66 per 1000 person years) and HCC (1.31 per 
1000 person years) was identified. These are substantially higher than reported 
population rates (0.36-0.54 per 1000 person-years for cirrhosis; 0.41-0.58 per 1000 
person years for ‘liver cancer’) (www.isdscotland.org) 23. However, despite these 
findings (and consistent with other studies showing that Type 2 diabetes is a risk factor 
for the development of cirrhosis/HCC), the performance of existing non-invasive risk 
stratification tools in identifying those at risk of developing disease was poor. 
A significant association was demonstrated between all NAFLD fibrosis risk scores, 
and the EASL-EASD-EASO algorithm ‘advise to refer’ outcome, and incident 
cirrhosis/HCC by OR. However, confidence intervals of the OR were wide. The model 
that yielded the highest C-statistic, both in isolation, and as part of the EASL-EASD-
EASO algorithm, suggesting best discriminatory ability, was APRI with a cut point of 
>0.5. However, this score in isolation would have resulted in 47.5% (19/40) people 
who developed cirrhosis/HCC being classified as ‘low-risk’.  Using APRI within the 
EASL-EASD-EASO algorithm, 20% (8/40) people who developed cirrhosis/HCC 
would have been classified as ‘low-risk’ (received a ‘do not refer’ outcome), while 29% 
(306 or 313 individuals using ultrasound steatosis or FLI respectively) would have 
been classified as ‘high-risk’ (receiving a ‘advise to refer’ outcome), with only 32 of 
those developing cirrhosis/HCC over 11 years. Using any model, significant numbers 
of people would have been classified as ‘high-risk’ who did not develop cirrhosis/HCC 
over 11 years, while a large proportion of those who developed cirrhosis/HCC would 
have been classified inappropriately as ‘low-risk’. It is important to note that many of 
the risk scores were designed to identify advanced fibrosis as opposed to 
cirrhosis/HCC. However, given the time span of follow-up we would have expected 
those with advanced fibrosis to progress to cirrhosis over 11 years and there thus to 
be a correlation. In addition, a significant proportion of our population underwent 
ultrasound at year 1. All abnormal ultrasounds were followed up and those diagnosed 
with fibrosis at year 1 progressed to cirrhosis over the period of the study.  
ET2DS is a study of moderate size that has reviewed long-term liver outcomes in 
individuals with Type 2 diabetes who were asymptomatic of liver disease at baseline. 
Almost all other studies have examined outcomes in people recruited from secondary 
care hepatology clinics, with known NAFLD and a higher likelihood of cirrhosis/HCC. 
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Although the ET2DS studied a cohort at higher risk of cirrhosis/HCC than the general 
population, the absolute probability of cirrhosis/HCC was moderately low. Therefore, 
validated risk scores and a European consensus algorithm have been tested in a 
cohort where the pre-test probability is low; in contrast to previous studies. However, 
this represents precisely the scenario in which European guidelines recommend 
screening for liver disease. Participants in the ET2DS were well characterised at 
baseline allowing accurate documentation of baseline risk factors, and have been 
followed longitudinally and extensively using multiple sources of information.  
There are limitations to our study. ET2DS is a single centre study, undertaken in 
people aged 60-75 years, of predominantly Caucasian origin (98.3%). Whilst this was 
a representative sample of people with Type 2 diabetes in the population sampled 
(Lothian, Scotland, UK), care should be taken in extrapolating to other populations. 
All-cause cirrhosis and HCC was investigated. While aetiology was predominantly 
NAFLD, individuals with advanced liver disease due to other causes or with known 
co-factors (e.g. alcohol above the NAFLD threshold) were also included. Determining 
the precise aetiology of cirrhosis/HCC can often be difficult in a real-world setting. It 
is likely that some individuals had liver disease where both alcohol and obesity 
contributed, therefore including individuals with all-causes of liver disease seemed 
more clinically relevant. A sensitivity analysis excluding the 3 participants who had 
definite non-NAFLD disease did not reveal significantly different results (Table 10). 
Medication exposure data was not analysed, so any modifying effect will not have 
been detected.  
The main outcome was cirrhosis/HCC. It is possible that some participants developed 
cirrhosis/HCC during follow-up, but were asymptomatic or did not seek medical advice 
for symptoms. These individuals would not have been identified as research 
screening for cirrhosis/HCC was not repeated at 11-year follow-up. A substantial 
proportion of the diagnoses were made after hepatology referral following year 1 and 
year 4 screening investigations. This has two implications. Firstly, as the natural 
history of NAFLD progression is very prolonged, it is possible that those who were 
diagnosed following referral from screening had cirrhosis/HCC at baseline and had 
prevalent rather than incident disease. However, the range of time from year 1 clinic 
to diagnosis overlaps significantly in the ‘screen-detected’ and ‘clinician-detected’ 
groups. Moreover, several of those who were ‘screen-detected’ were not identified 
with cirrhosis/HCC on initial hepatology review but follow-up was continued because 
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of concern regarding ‘high-risk’ features and they were diagnosed with cirrhosis/HCC 
several years later. Therefore, we defined prevalent disease as that which was 
clinically apparent at baseline. Secondly, the screening process may have led to an 
earlier diagnosis of cirrhosis/HCC in some people who may have died from other 
causes before cirrhosis/HCC was clinically apparent, inflating incidence rates. 
However, 58% of those identified with cirrhosis developed varices, ascites and/or 
encephalopathy and 23% developed HCC, so while investigation may have advanced 
the time of diagnosis, many would likely have presented during the period of follow-
up. While all other biomarkers were measured at baseline, ELF and liver ultrasound 
were undertaken at the year 1 clinic, so analyses using these markers have examined 
slightly different ‘baseline’ time points. However, the performance of the EASL-EASD-
EASO algorithm did not differ when using Fatty Liver Index (measured at baseline) 
and ultrasound as the steatosis marker, so with respect to the steatosis assessment, 
it is unlikely that this had a material effect on the present results. Due to limitations in 
the time to diagnosis data, both a logistic regression analysis and a competing risks 
regression approach (as a sensitivity analysis) were used.  The former analysis has 
the disadvantage of not taking into account deaths during follow-up, whereas in the 
latter approach, time-to-event discrepancies may also introduce bias. Results of the 
competing risks regression were similar to the logistic regression assessment (Table 
12- Table 13) suggesting that neither the proportion of non-liver death in our 
population nor the mixed screen-detected and clinician-detected events substantially 
affected results. 
Several studies have compared non-invasive markers of fibrosis to clinical outcome 
in NAFLD, mostly undertaken in populations of people under secondary care 
hepatology clinic follow-up, who had an initial liver biopsy. Three studies (median 5-
12 year follow-up) showed increased hazard ratios (HR) for all-cause mortality, 
decompensated cirrhosis, rates of HCC or liver transplant in those with raised NFS, 
APRI or FIB-4 scores (16-36% participants had diabetes). 185,231,234 None reported 
sensitivity, specificity, PPV or NPV. Three studies compared non-invasive scores with 
severity of fibrosis on biopsy at the time of testing and showed strong associations 
between NFS, APRI, FIB-4 and AST: ALT ratio, and biopsy with an area under the 
receiving curve of 0.7-0.88, depending on score used (19-50% participants had 
diabetes). 221,229,232 However, all described decreasing specificity with increasing 
sensitivity, for risk score cut-points used. A recent study examined median 4 year 
outcomes in a cohort of 284 participants under hepatology clinic follow up for NAFLD 
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(>80% biopsy confirmed, 53% had diabetes). 237 As expected in a hepatology clinic 
population, rates of cirrhosis/HCC were high (9.2% liver-related death or transplant, 
14.8% decompensated cirrhosis, 9.9% HCC). A diagnosis of diabetes conferred an 
increased HR of developing a liver outcome (death/transplantation HR 3.4 (95% 
confidence interval 1.2-9.1), decompensated cirrhosis HR 4.7 (2-11.3) and HCC HR 
2.9 (1.2-7.3)). However, NFS, APRI or FIB-4 scores in the people with diabetes were 
substantially less good (by C-statistic comparison) at predicting outcome than in the 
individuals without diabetes. In those with diabetes, 21% of those with a ‘low-risk’ 
NFS, 15% with ‘low-risk FIB-4’ and 15% ‘low-risk’ APRI developed decompensated 
cirrhosis, and 27% with ‘low-risk’ scores developed HCC. By contrast, in individuals 
without diabetes, no participant with a ‘low-risk’ fibrosis score developed 
decompensated cirrhosis or HCC during follow-up. Therefore, the results of our study 
confirm what is reported in previous publications; that non-invasive risk scores do 
associate with outcome, but false positive and negative levels are high.  
Current risk prediction scoring fails to identify a significant proportion of people with 
Type 2 diabetes who develop incident cirrhosis/HCC. Our population representative 
approach implies that general use of current risk scores and algorithms in people with 
Type 2 diabetes will result in unnecessary additional referral and investigation in large 
numbers of people who will not develop incident cirrhosis/HCC over 11 years. This 
has significant resource implications for hepatology services. Our study importantly 
examines outcomes from an unselected community population, for which these 
screening algorithms are advocated. 
It is unclear why the fibrosis risk scores perform better in people without diabetes than 
those with diabetes. It is possible that there are confounders influencing the 
biomarkers used in the non-invasive scores that are affected by diabetes. For 
example, it has been described that measurements of AST and ALT in mouse models 
are affected by hyperglycaemia. 237 Future research is required to identify improved 
methods of predicting incident cirrhosis/HCC in this high-risk population, possibly 
through combining existing risk scores, examining whether serial monitoring is a more 
effective screening strategy or investigating novel or alternative biomarkers. 
Type 2 diabetes is associated with an increased rate of cirrhosis/HCC. 21,75 Risk 
prediction scores and international guidelines have attempted to provide non-invasive 
methods of assessing risk of incident disease in this high-risk population. The present 
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study shows only modest performance of these risk scores and screening algorithm. 
Use would lead to significant pressure on hepatology services from high referral rates 
coupled with increased patient anxiety generated by false positive results. 
Furthermore, the risk scores fail to identify a significant proportion of the population 
that are potentially vulnerable to incident disease. Future work to improve prediction 
methods in this population is necessary. 
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3.7 Additional Information 
Further studies have been published that relate to this work since this paper was 
submitted for publication. Of particular note are two studies. The first used the 
database from the National Health and Nutrition Examination Survey (NHANES) in 
the US and undertook a cross-sectional analysis of 2940 adults with T2DM, applying 
the EASL-EASD-EASO algorithm to them. Using FLI as the steatosis marker, around 
40% of participants with T2DM in that study would have been identified as requiring 
referral to hepatology services. 266 There is no associated data on outcome in these 
participants. Secondly, a study has examined the association between FIB-4 and 
transient elastography (an imaging method of identifying hepatic fibrosis), showing a 
poorer association between FIB-4 score and elastography result in those with T2DM 
than those without. 238 These two studies are consistent with the findings of this study 
which highlight that risk-stratification tools perform sub-optimally in people with T2DM 
and work to improve risk-stratification methods is needed. 
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Table 7. Baseline characteristics of the study population 
Baseline Characteristic ET2DS Population (n=1066) 
Age (years)  67.9  (4.2) 
Sex (male)  547 (51.3)  




1 (most deprived)  12  (11.9) 
2  208 (19.5) 
3  188 (17.6) 
4  194 (18.2) 
5 (least deprived)  349 (32.7) 
Duration Type 2 diabetes (years)  8.1  (6.5) 
HbA1c (%)  7.4  (1.1) 
HbA1c (mmol/mol)  57.0 (12.0) 
BMI (kg/m2)  31.4  (5.7) 
Smoker (current)  154 (14.4) 
Alcohol (excess)†  207 (19.9) 
Values are mean (sd) or n (%) 
† Defined as females >14 units/week, males >21 units/week or patient disclosed 
history of a current or prior alcohol problem 
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ELF (≥10.51) †  30.4  (11.3-83.5)*** 198.6 0.67 39 (22-59) 98 (97-99) 46 (26-67) 97 (96-98)  13 (2)  17  (61) 
APRI (>0.5)  23.7  (11.5-49.8)*** 276.0 0.80 53 (36-68) 94 (93-96) 27 (18-39) 98 (97-99)  57  (6) 19  (48) 
AST:ALT (≥0.8)  3.9  (2.1-7.6)*** 334.0 0.70 41 (26-58) 26 (23-29)  2  (1-14) 92 (88-95) 261 (26) 24  (59) 
NFS (≥-1.455)  3.7   (1.3-15.6)* 336.1 0.65 93 (80-98) 22 (20-25)  5  (3-6) 99 (96-100) 769  (78)  3  (8) 
NFS (>0.676)  8.2  (4.2-15.9)*** 309.7 0.73 45 (29-62) 91 (89-93)  17 (10-26) 98 (96-98)  88  (9) 22  (56) 
FIB 4 (≥1.3)  8.1   (3.7-20.6)*** 311.6 0.75 82 (67-93) 59 (56-63)  8  (5-11) 99 (98-100) 402  (41)  7  (18) 
FIB4 (>2.67)  39.5  (17.4-91.9)*** 277.1 0.76 40 (25-57) 98 (97-99) 46 (29-63) 98 (96-98)  19  (2) 24  (60) 
SCORES USED WITHIN EASL-EASD-EASO ALGORITHM, USS STEATOSIS AS STEATOSIS MARKER 
ELF (≥10.51) †  10.1  (4.6-25.6)*** 275.7 0.79 82 (66-92) 66 (63-69) 10  (7-14) 99 (97-99) 276  (34)  7  (18) 
APRI (>0.5) †  13.0  (6.1-31.0)*** 291.6 0.82 80 (64-91) 73 (70-75) 10  (7-14) 99 (98-100) 274  (27)  8  (20) 
AST:ALT (≥0.8) †  0.1  (0.1-0.3)*** 315.7 0.77 80 (65-91) 63 (60-66)  8  (6-11) 99 (98-99) 367  (37)  8  (20) 
NFS (≥-1.455) †  6.0  (2.5-17.6)*** 319.1 0.72 88 (73-96) 44 (41-47)  6  (4-9) 99 (97-100) 527  (56)  5  (13) 
FIB 4 (≥1.3) †  11.7  (5.0-34.5)*** 300.3 0.79 88 (73-96) 60 (57-64)  8  (6-11) 99 (98-100) 384  (40)  5  (13) 
SCORES USED WITHIN EASL-EASD-EASO ALGORITHM, FATTY LIVER INDEX AS STEATOSIS MARKER 
ELF (≥10.51) †  9.1  (4.3-21.7)*** 285.9 0.78 79 (64-91) 67 (64-70) 10  (7-14) 99 (97-99) 277  (33)  8  (21) 
APRI (>0.5)  12.6  (5.9-30.1)*** 292.8 0.82 80 (64-91) 72 (69-75) 10  (7-14) 99 (98-100) 281 (28)  8  (20) 
AST:ALT (≥0.8)  0.1  (0.1-0.2)*** 306.4 0.79 76 (60-88) 73 (70-76) 10  (7-14) 99 (98-99) 273  (27) 10  (24) 
NFS (≥-1.455)  5.6  (2.2-19.0)** 327.0 0.70 90 (76-97) 36 (33-39)  5 (4-7) 99 (97-100) 635  (64)  4  (10) 
FIB 4 (≥1.3)  13.7  (5.4-46.2)*** 301.1 0.79 90 (76-97) 58 (55-61)  8  (6-11) 99 (98-100) 422  (42)  4  (10) 
† ELF and ultrasound measured at year 1 only- so calculated 10 not 11-year incident cirrhosis/HCC 
* p<0.05, ** p<0.01, ***p<0.001 
OR odds ratio (age and sex adjusted), C-Stat C-statistic, AIC akaike information criterion, sens sensitivity, spec specificity, PPV positive predictive 
value, NPV negative predictive value, ELF Enhanced Liver Fibrosis panel, NFS NAFLD Fibrosis Score, APRI AST:Platelet ratio index, FIB 4 Fibrosis 4 
Index, EASL-EASD-EASO European Association for the Study of the Liver, the European Association for the Study of Diabetes and the European 
Association for the Study of Obesity algorithm (Figure 2)  
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Table 9. Performance of fibrosis scores in prediction of 11-year incident cirrhosis related varices, ascites, encephalopathy, or 
HCC 
Fibrosis score (cut-
point value used) 













ELF (≥10.51) †  25.41 (8.45-76.40)*** 38 (18-62) 98 (96-99) 33 (16-55) 98 (97-99)  16  (2)  13 (62) 
APRI (>0.5)  31.30 (13.57-75.97)*** 61 (41-78) 94 (92-95) 22 (13-33) 94 (92-95)  61  (6) 11 (39) 
AST:ALT (≥0.8)  5.50  (2.55-12.57)*** 34 (18-54) 26 (23-29)  1  (1-2) 93 (90-96) 754 (74) 19 (66) 
NFS (≥-1.455)  4.05  (1.18-25.44) 93 (76-99) 22 (20-25)  3  (2-5) 99 (97-100) 780 (78)  2  (7) 
NFS (>0.676)  8.48  (3.85-18.47)*** 46 (28-66) 91 (89-92) 12  (7-20) 98 (97-99)  93  (9) 15 (54) 
FIB 4 (≥1.3)  15.67 (5.28-67.35)*** 89 (72-98) 59 (56-62)  6  (4-8) 99 (99-100) 410 (41)  3 (11) 
FIB4 (>2.67)  59.99 (24.00-
157.79)*** 
50 (31-69) 98 (97-99) 40 (24-58) 99 (98-99)  21  (2) 14 (50) 
SCORES USED WITHIN EASL-EASD-EASO ALGORITHM, USS STEATOSIS AS STEATOSIS MARKER 
ELF (≥10.51) †  6.32  (2.75-16.36)*** 75 (55-89) 65 (62-69)  7  (4-10) 99 (97-99) 286 (35)  7  (25) 
APRI (>0.5) †  10.74  (4.51-29.76)*** 79 (59-92) 72 (69-75)  7  (5-11) 99 (98-100) 284 (28)  6  (21) 
AST:ALT (≥0.8) †  5.45  (2.41-13.97)*** 76 (56-90) 62 (59-65)  6  (3-8) 99 (98-100) 378 (38)  7  (24) 
NFS (≥-1.455) †  3.70  (1.51-11.14)** 82 (63-94) 44 (40-47)  4  (3-6) 99 (97-100) 539 (56)  5  (18) 
FIB 4 (≥1.3) †  7.34  (2.98-22.07)*** 82 (63-94) 60 (57-63)  5  (4-8) 99 (98-100) 396 (40)  5  (18) 
SCORES USED WITHIN EASL-EASD-EASO ALGORITHM, FATTY LIVER INDEX AS STEATOSIS MARKER 
ELF (≥10.51) †  6.53 (2.84-16.89)*** 75 (55-89) 66 (63-69)  7  (4-10) 99 (97-100) 287 (34)  7  (25) 
APRI (>0.5)  10.47 (4.40-29.01)*** 79 (59-92) 71 (68-74)  7  (4-10) 99 (98-100) 291 (29)  6  (21) 
AST:ALT (≥0.8)  7.52  (3.07-22.54)*** 83 (64-94) 60 (57-63)  6  (4-8) 99 (98-100) 407 (40) 15 (17) 
NFS (≥-1.455)  4.96 (1.71-21.00)** 89 (72-98) 36 (33-39)  4  (2-5) 99 (98-100) 646 (64)  3  (11) 
FIB 4 (≥1.3)  12.23 (4.23-51.78)*** 89 (72-98) 57 (54-60)  5  (4-8) 99 (98-100) 433 (43)  3  (11) 
† ELF and ultrasound measured at year 1 only- so calculated 10 not 11-year incident cirrhosis/HCC 
* p<0.05, ** p<0.01, ***p<0.001 
OR odds ratio (age and sex adjusted), sens sensitivity, spec specificity, PPV positive predictive value, NPV negative predictive value, ELF 
Enhanced Liver Fibrosis panel, NFS NAFLD Fibrosis Score, APRI AST:Platelet ratio index, FIB 4 Fibrosis 4 Index 
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Table 10. Sensitivity Analysis- Performance of the fibrosis scores in the prediction of 11 year incident cirrhosis/HCC (excluding 
those with definite non-NAFLD disease (n=3)) 
Fibrosis score (cut-
point value used) 













ELF (≥10.51) †  35.44 (12.90-100.18)*** 44 (24-65) 98 (97-99) 46 (26-67) 99 (96-99)  13  (2)  14  (56) 
APRI (>0.5)  24.80 (11.80-53.60)*** 54 (37-71) 94 (93-96) 26 (17-37) 98 (97-99)  57  (6) 17  (46) 
AST:ALT (≥0.8)  3.36  (1.73-6.60)*** 45 (29-62) 26 (23-29)  2  (1-4) 93 (89-95) 747 (74) 21  (55) 
NFS (≥-1.455)  5.28  (1.58-32.83)* 95 (82-99) 22 (20-25)  4  (3-6) 99 (97-100) 769 (78)  2  (5) 
NFS (>0.676)  8.48  (4.22-16.88)*** 46 (29-63) 91 (89-93) 16 (10-25) 98 (97-99)  88  (9) 20  (54) 
FIB 4 (≥1.3)  8.86  (3.82-24.22)*** 84 (68-94) 59 (56-62)  7  (5-10) 99 (98-100) 402 (41)  6  (16) 
FIB4 (>2.67)  40.72 (17.48-97.37)*** 41 (25-58) 98 (97-99) 44 (27-62) 98 (97-99)  19  (2) 22  (59) 
SCORES USED WITHIN EASL-EASD-EASO ALGORITHM, USS STEATOSIS AS STEATOSIS MARKER 
ELF (≥10.51) †  11.26  (4.88-30.65)*** 83 (66-93) 66 (63-69) 10  (6-13) 99 (98-100) 276 (34)  6  (17) 
APRI (>0.5) †  14.18  (6.40-36.03)*** 81 (65-92) 73 (70-75) 10  (7-14) 99 (98-100) 274 (27)  7  (19) 
AST:ALT (≥0.8) †  8.36  (3.83-20.99)*** 82 (66-92) 63 (60-66)  8  (5-11) 99 (98-100) 367 (37)  7  (18) 
NFS (≥-1.455) †  7.13  (2.79-24.16)*** 89 (75-97) 44 (41-47)  6  (4-8) 99 (98-100) 527 (56)  4  (11) 
FIB 4 (≥1.3) †  13.98  (5.47-47.34)*** 89 (75-97) 60 (57-64)  8  (6-11) 99 (98-100) 384 (40)  4  (11) 
SCORES USED WITHIN EASL-EASD-EASO ALGORITHM, FATTY LIVER INDEX AS STEATOSIS MARKER 
ELF (≥10.51) †  9.89 (4.47-25.08)*** 81 (64-92) 67 (64-70)  9  (6-13) 99 (97-100) 277 (33)  7  (19) 
APRI (>0.5)  13.81 (6.23-35.07)*** 81 (65-92) 72 (69-75) 10  (7-13) 99 (98-100) 281 (28)  7  (19) 
AST:ALT (≥0.8)  7.38  (3.39-18.49)*** 82 (66-92) 61 (57-64)  7  (5-10) 99 (98-100) 397 (39)  7  (18) 
NFS (≥-1.455)  5.22 (2.04-17.68)** 89 (75-97) 36 (33-39)  5  (3-7) 99 (97-100) 635 (64)  4  (11) 
FIB 4 (≥1.3)  12.70 (4.97-43.01)*** 89 (75-97) 58 (55-61)  7  (5-10) 99 (98-100) 422 (42)  4  (11) 
† ELF and ultrasound measured at year 1 only- so calculated 10 not 11-year incident cirrhosis/HCC 
* p<0.05, ** p<0.01, ***p<0.001 
OR odds ratio (age and sex adjusted), sens sensitivity, spec specificity, PPV positive predictive value, NPV negative predictive value, 
ELF Enhanced Liver Fibrosis panel, NFS NAFLD Fibrosis Score, APRI AST:Platelet ratio index, FIB 4 Fibrosis 4 Index  
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Table 11. Performance of fibrosis scores in prediction of 11-year incident 
cirrhosis/HCC, competing risks regression analysis with non-liver death as 
the competing risk 
Fibrosis score (cut-
point value used) 
CRR Hazard (95% CI) BIC 
INDIVIDUAL SCORES 
Null Model n/a 348.95 
ELF (≥10.51) †  24.84  (9.98-61.83)*** 310.64 
APRI (>0.5)  18.94  (9.96-35.99)*** 313.66 
AST:ALT (≥0.8)  3.85  (2.00-7.40)*** 342.88 
NFS (≥-1.455)  3.65  (1.14-11.63)* 353.06 
NFS (>0.676)  7.59  (4.06-14.19)*** 331.11 
FIB 4 (≥1.3)  7.77  (3.48-17.31)*** 332.79 
FIB4 (>2.67)  30.52  (15.18-61.35)*** 309.52 
SCORES USED WITHIN EASL-EASD-EASO ALGORITHM, USS STEATOSIS AS 
STEATOSIS MARKER 
Null model n/a 348.95 
ELF (≥10.51) †  9.56  (4.13-22.12)*** 333.82 
APRI (>0.5) †  12.09  (5.54-26.35)*** 329.59 
AST:ALT (≥0.8) †  7.38  (3.41-15.97)*** 338.60 
NFS (≥-1.455) †  5.70  (2.28-14.78)*** 348.16 
FIB 4 (≥1.3) †  11.11  (4.31-28.65)*** 337.66 
SCORES USED WITHIN EASL-EASD-EASO ALGORITHM, FATTY LIVER INDEX 
AS STEATOSIS MARKER 
Null model n/a 348.86 
ELF (≥10.51) †  8.60  (3.87-19.11)*** 333.96 
APRI (>0.5)  11.77  (5.39-25.72)*** 330.31 
AST:ALT (≥0.8)  7.72  (3.41-17.46)*** 333.03 
NFS (≥-1.455)  5.48  (1.93-15.56)** 346.70 
FIB 4 (≥1.3)  13.02  (4.58-37.07)*** 331.15 
† ELF and ultrasound measured at year 1 only- so calculated 10 not 11-year incident 
cirrhosis/HCC 
* p<0.05, ** p<0.01, ***p<0.001 
CRR Hazard Exponentiated coefficient of the subdistribution hazard model (Fine and 
Gray), adjusted for age and sex, BIC Bayesian Information Criterion, ELF Enhanced 
Liver Fibrosis panel, NFS NAFLD Fibrosis Score, APRI AST:Platelet ratio index, FIB 4 
Fibrosis 4 Index, EASL-EASD-EASO European Association for the Study of the Liver, 
the European Association for the Study of Diabetes and the European Association for 
the Study of Obesity algorithm (Figure 2)  
Note- all available case analysis used for calculation of the CRR hazard, complete 
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Table 12. Sensitivity Analysis- Performance of the fibrosis scores in the 
prediction of 11-year incident Cirrhosis/HCC (excluding those with definite 
non-NAFLD disease (n=3)), competing risks regression analysis with non-liver 
death as the competing risk 
Fibrosis score (cut-
point value used) 
CRR Hazard (95% CI) BIC 
INDIVIDUAL SCORES 
Null Model n/a 348.78 
ELF (≥10.51) †  29.04  (11.17-75.49)*** 310.54 
APRI (>0.5)  20.61 (10.59-40.10)*** 313.57 
AST:ALT (≥0.8)  3.33  (1.71-6.51)*** 342.78 
NFS (≥-1.455)  5.21  (1.27-21.37)* 352.92 
NFS (>0.676)  7.85  (4.12-14.98)*** 331.01 
FIB 4 (≥1.3)  8.55  (3.60-20.28)*** 332.75 
FIB4 (>2.67)  31.76 (15.45-65.29)*** 309.41 
SCORES USED WITHIN EASL-EASD-EASO ALGORITHM, USS STEATOSIS AS 
STEATOSIS MARKER 
Null model n/a 348.78 
ELF (≥10.51) †  10.61  (4.29-26.28)*** 333.75 
APRI (>0.5) †  13.22  (5.74-30.46)*** 329.53 
AST:ALT (≥0.8) †  8.03 (3.52-18.34)*** 338.53 
NFS (≥-1.455) †  6.91  (2.44-19.61)*** 348.00 
FIB 4 (≥1.3) †  13.24  (4.65-37.73)*** 337.60 
SCORES USED WITHIN EASL-EASD-EASO ALGORITHM, FATTY LIVER INDEX AS 
STEATOSIS MARKER 
Null model n/a 348.69 
ELF (≥10.51) †  9.34 (3.98-21.97)*** 333.89 
APRI (>0.5)  12.89  (5.59-29.74)*** 330.25 
AST:ALT (≥0.8)  7.12  (3.12-16.25)*** 332.99 
NFS (≥-1.455)  5.10  (1.78-14.58)*** 346.64 
FIB 4 (≥1.3)  12.11 (4.23-34.70)*** 331.11 
† ELF and ultrasound measured at year 1 only- so calculated 10 not 11-year incident 
cirrhosis/HCC 
* p<0.05, ** p<0.01, ***p<0.001 
CRR Hazard Exponentiated coefficient of the subdistribution hazard model (Fine and 
Gray), adjusted for age and sex, BIC Bayesian Information Criterion, ELF Enhanced 
Liver Fibrosis panel, NFS NAFLD Fibrosis Score, APRI AST:Platelet ratio index, FIB 4 
Fibrosis 4 Index, EASL-EASD-EASO European Association for the Study of the Liver, 
the European Association for the Study of Diabetes and the European Association for 
the Study of Obesity algorithm (Figure 2)  
Note- all available case analysis used for calculation of the CRR hazard, complete case 
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Table 13. Sensitivity Analysis- Performance of fibrosis scores in prediction of 
11-year incident cirrhosis related varices, ascites, encephalopathy or HCC, 
competing risks regression analysis with non-liver death as the competing 
risk 
Fibrosis score (cut-
point value used) 
CRR Hazard (95% CI) BIC 
INDIVIDUAL SCORES 
Null Model n/a 258.30 
ELF (≥10.51) †  24.46  (8.11-73.77)*** 233.20 
APRI (>0.5)  26.31  (12.08-57.32)*** 231.13 
AST:ALT (≥0.8)  5.45  (2.45-12.15)*** 252.95 
NFS (≥-1.455)  4.02  (0.96-16.82) 262.65 
NFS (>0.676)  8.04  (3.79-17.10)*** 246.64 
FIB 4 (≥1.3)  15.07  (4.55-49.92)*** 243.71 
FIB4 (>2.67)  46.02  (20.89-101.38)*** 226.42 
SCORES USED WITHIN EASL-EASD-EASO ALGORITHM, USS STEATOSIS AS 
STEATOSIS MARKER 
Null model n/a 258.30 
ELF (≥10.51) †  6.18  (2.58-14.80)*** 254.92 
APRI (>0.5) †  10.39  (4.20-25.71)*** 251.67 
AST:ALT (≥0.8) †  5.36  (2.29-12.56)*** 257.07 
NFS (≥-1.455) †  3.66  (1.40-9.57)** 262.05 
FIB 4 (≥1.3) †  7.16  (2.68-19.12)*** 255.91 
SCORES USED WITHIN EASL-EASD-EASO ALGORITHM, FATTY LIVER INDEX AS 
STEATOSIS MARKER 
Null model n/a 258.24 
ELF (≥10.51) †  6.38  (2.66-15.33)*** 254.99 
APRI (>0.5)  10.13  (4.09-25.14)*** 252.10 
AST:ALT (≥0.8)  7.37  (2.80-19.44)*** 252.31 
NFS (≥-1.455)  4.92  (1.48-16.38)* 260.40 
FIB 4 (≥1.3)  11.91  (3.58-39.62)*** 250.28 
† ELF and ultrasound measured at year 1 only- so calculated 10 not 11-year incident 
cirrhosis/HCC 
* p<0.05, ** p<0.01, ***p<0.001 
CRR Hazard Exponentiated coefficient of the subdistribution hazard model (Fine and 
Gray), adjusted for age and sex, BIC Bayesian Information Criterion, ELF Enhanced Liver 
Fibrosis panel, NFS NAFLD Fibrosis Score, APRI AST:Platelet ratio index, FIB 4 Fibrosis 
4 Index, EASL-EASD-EASO European Association for the Study of the Liver, the 
European Association for the Study of Diabetes and the European Association for the 
Study of Obesity algorithm (Figure 2)  
Note- all available case analysis used for calculation of the CRR hazard, complete case 
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Chapter 4 Addition of hyaluronic acid to the 
FIB-4 liver fibrosis score improves 
prediction of incident cirrhosis and 
hepatocellular carcinoma in Type 2 
diabetes: The Edinburgh Type 2 
Diabetes Study 
This section has been submitted and is published in Obesity Science & Practice under 
the same title by Sheila M Grecian (SMG), Stela McLachlan (SM), Jonathan A 
Fallowfield (JF), Peter C Hayes (PH), Indra Neil Guha (NG), Joanne R Morling (JM), 
Stephen Glancy (SG), Rachel M Williamson (RW), Rebecca M Reynolds (RR), Brian 
M Frier (BF), Nicola N Zammitt (NZ), Jackie F Price (JP) and Mark WJ Strachan (MS). 
SMG wrote the manuscript. JP was principal investigator of the ET2DS, designed the 
study, analysed and interpreted the data. MS was lead investigator of the ET2DS liver 
sub-study, designed the study, analysed and interpreted the data. RR, BF, PH, JF, 
RW, NG and SG contributed to study design. SMG, SM, RW and JM contributed to 
data collection, analysis and interpretation. All authors contributed to revision and final 
approval of the article. 
In summary, in the previous chapter it was discussed that whilst it is considered 
beneficial to screen for NAFLD in the context of T2DM, existing NAFLD fibrosis risk 
prediction tools perform less well. In this study we investigated whether combining 
additional biomarkers with existing risk prediction tools could improve the associative 
and predictive ability of these tools in the identification of incident cirrhosis and HCC 
in a cohort of people with diabetes. 
Further information regarding how potential biomarkers were identified, and additional 
detail on validation of the models built can be found in appendix 3. Formulae used for 
predictive ability calculations can be found in appendix 2. 
Please note- all tables for this section sit at the end of the chapter text. 
 
  
Chapter 3: Incidence, Association with fibrosis score  
   104 
4.1 Abstract 
Background: Type 2 diabetes is associated with increased risk of progression to 
cirrhosis and hepatocellular carcinoma (HCC) in people with chronic liver diseases, 
particularly non-alcoholic fatty liver disease (NAFLD). However, the absolute risk of 
progression is low so it is crucial to accurately identify patients who would benefit most 
from hepatology referral and intensified management. Current risk-stratification tools 
are sub-optimal and perform worse in people with diabetes. 
Aims: To determine whether the addition of complementary biomarker(s) to  current 
NAFLD risk-stratification tools in people with Type 2 diabetes could improve the 
identification of people who are at increased risk of developing incident cirrhosis or 
HCC. 
Methods: The Edinburgh Type 2 diabetes Study (ET2DS) is a cohort study of men 
and women with Type 2 diabetes (n=1066, age 60-75 at baseline). Cases of cirrhosis 
and HCC were identified over 11-years of follow-up. Biomarkers were measured at 
baseline and year one and association with incident disease assessed using logistic 
regression. 
Results: Of existing risk-stratification scores tested, the Fibrosis-4 (FIB-4) index and 
the AST:platelet ratio index (APRI) performed best in our cohort. Addition of 
hyaluronic acid (cut-point ≥50μg/L) to FIB-4 (cut-point ≥1.3) maintained a false 
negative rate  ≤25% and reduced the number of people incorrectly identified as ‘high-
risk’ for incident disease by ~50%. 
Conclusions: The addition of hyaluronic acid to FIB-4 reduced the proportion of people 
inappropriately identified as ‘high-risk’ for development of cirrhosis/HCC in a 
community population of otherwise asymptomatic people with Type 2 diabetes. These 
findings require validation in independent cohorts. 
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4.2 Introduction 
Non-alcoholic fatty liver disease (NAFLD) is recognised as the liver component of the 
metabolic syndrome, a cluster of conditions including abdominal obesity, impaired 
glucose regulation or diabetes, hypertension, hypercholesterolaemia and 
hypertriglyceridaemia, which are associated with increased cardiovascular risk. 84 
With rising population levels of obesity, prevalence of NAFLD is rising and 25% of 
people globally may be affected. 8 Type 2 diabetes is associated with a further 
increased prevalence of NAFLD, the prevalence of NAFLD steatosis being 40-70%.9-
11,263 Furthermore, people with Type 2 diabetes have a higher incidence of, and risk 
of progression to, cirrhosis and hepatocellular carcinoma (HCC). 20,21,71,75,265  
In Type 2 diabetes, identifying those at increased risk of developing cirrhosis/HCC is 
important to prompt intensified lifestyle interventions, enhanced monitoring of disease 
progression and timely initiation of surveillance for varices and HCC. Screening for 
NAFLD in Type 2 diabetes is advocated in European guidelines (European 
Association for the Study of the Liver, European Association for the Study of Diabetes, 
European Association for the Study of Obesity (EASL-EASD-EASO)). 217  
Liver biopsy is the gold standard test for staging NAFLD, with histological fibrosis the 
most important factor predictive of disease progression in meta-analyses. 179,180 
However, biopsy is not suitable for population screening as it is an invasive procedure 
with a risk of serious complications. Consequently, interest in the identification of non-
invasive markers that predict those at risk of disease progression has increased. 
Many scores have been developed and validated in NAFLD, including the Fibrosis-4 
Index (FIB-4), NAFLD Fibrosis Score (NFS), aspartate aminotransferase 
(AST):alanine aminotransferase (ALT) ratio, AST to Platelet Ratio Index (APRI) and 
Enhanced Liver Fibrosis (ELF) test). 220,221,224,227,230 While these were initially 
developed to identify liver fibrosis at the time of testing, their ability to predict incident 
cirrhosis and HCC has also been validated. 71,185,225,231,234   
The performance of these scores varies between research cohorts. 185,189,225,231,234 
Typically, study populations have consisted of patients attending hepatology 
secondary care services and there is much less evidence to support their utility in 
community populations. Furthermore, these scores perform less well in people with 
Type 2 diabetes, with one study reporting that, over 4 years follow-up, 15% of people 
with diabetes with a ‘low-risk’ FIB-4 score developed decompensated cirrhosis, and 
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17% developed HCC; by contrast, in individuals without diabetes, no participant with 
a ‘low-risk’ score developed decompensated cirrhosis or HCC. 237 This group has 
reported that use of current risk-stratification tools would have resulted in large 
numbers of people who did not develop cirrhosis/HCC over 11-years follow-up being 
classified as ‘high-risk’ (41% with FIB-4), while a significant proportion (18% with FIB-
4) who did develop cirrhosis/HCC were classified as ‘low-risk’ at baseline. 262 
This study hypothesised that the addition of a complementary biomarker(s) could 
improve the performance of current risk-stratification tools for the accurate 
identification of people with Type 2 diabetes who are at increased risk of developing 
cirrhosis or HCC. 
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4.3 Methods 
 
The Edinburgh Type 2 Diabetes Study 
The Edinburgh Type 2 Diabetes Study (ET2DS) is a community-based prospective 
cohort study of older people with Type 2 diabetes. Full methods have been described 
previously. 255 Briefly, in 2006/07 participants aged 60-74 with Type 2 diabetes were 
randomly selected (in age and sex bands) from the Lothian Diabetes Register (a 
database of almost all people with Type 2 diabetes living in Lothian, Scotland), and 
were subsequently found to be largely representative of this sampling population. 256 
Invitations to participate were sent to 5454 people, of whom 1066 (20%) attended 
baseline clinic. All 1066 were invited to re-attend a clinical and liver assessment after 
1 and 4 years. 939 attended the year 1 clinic (deceased n=15, unable to contact n=19, 
unable to attend n=93) and 831 the year 4 clinic (deceased n=88, unsuitable for 
clinical reasons n=26, uncontactable n=23, unable n=98). All 1066 participants were 
followed up for outcomes until death (320 participants) or end of follow-up in 2018. 
Data collection- baseline biomarker assessment 
Assessments were undertaken at dedicated research clinics  at the Wellcome Trust 
Clinical Research Facility, Western General Hospital, Edinburgh, UK by specially 
trained research staff using Standard Operating Procedures. 255 Fasting venous blood 
samples were collected at baseline. Glycated haemoglobin (HbA1c), ALT, AST, 
alkaline phosphatase (ALP), gamma-glutamyltransferase (γGT), albumin, bilirubin 
and platelets were analysed using a Vitros Fusion chemistry system (Ortho Clinical 
Diagnostics, Bucks, UK) at the Western General Hospital. C-reactive protein (CRP) 
was measured using an immunonephelometric assay; interleukin-6 (IL-6) and tumour 
necrosis factor-alpha (TNFα) were measured using ELISA (R&D Systems, Oxon, UK), 
Glasgow Royal Infirmary, UK. Hyaluronic acid was measured using a radiometric 
assay (Pharmacia, Uppsala, Sweden). The Enhanced Liver Fibrosis test (ELF) was 
measured on fasting venous blood samples from the year-1 clinic and analysed using 
the ADVIA Centaur immunoassay system (Siemens Healthcare Diagnostics Inc., New 
York, USA) at the iQur laboratory (London, UK).  
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Participants attending the year-1 research clinics underwent a full diagnostic liver 
screen if serum liver enzymes or abdominal ultrasound was abnormal (including 
Hepatitis B and C serology, liver autoantibody titres, alpha-fetoprotein, ferritin) and all 
completed standard questions on  alcohol consumption (AUDIT-C questionnaire), 
medication use and past medical history. Any participant with routine liver enzyme 
tests above the laboratory upper limit of normal (ALT >50 U/L, AST >45 U/L, γGT >55 
U/L, alkaline phosphatase (ALP) >125 U/L), AST:ALT ratio >1, hyaluronic acid 
>100μg/L (in the absence of known joint disease), positive liver autoantibodies, ferritin 
>1000ng/mL, alpha-feto protein >6ng/mL, positive hepatitis B or C serology, spleen 
diameter >13cm, platelets <150x109/L (in the absence of known haematological 
cause), or suspected cirrhosis on ultrasound, was referred for specialist hepatology 
review. 
Fibrosis scores were calculated and cut-point levels used as per published work.  
- AST to Platelet Ratio Index (APRI) was calculated as: ((AST(U/L)/Upper limit 
normal)/platelets(x109/L))x100. 220 
- AST:ALT ratio was calculated as: AST(U/L)/ALT(U/L). 221  
- Fibrosis-4 index (FIB-4) was calculated as 
((age(years)xAST(U/L))/(plt(x109/L)xsqrt ALT(U/L))). 227,229,234,267 
- NAFLD Fibrosis Score (NFS) was calculated as: 
1.675+(0.037xage(years))+(0.094xBMI(kg/m2))+(1.13xIFG/diabetes (yes=1, 
no=0))+(0.99x(AST(U/L)/ALT(U/L))- (0.013xplatelet count(×109/L))-
(0.66xalbumin (g/dL)). 230  
Data Collection - Identification of liver disease 
Possible prevalent liver disease was identified by self-completion questionnaire at 
baseline with subsequent confirmation if a clinician diagnosis was recorded in primary 
or secondary care medical records. Incident cirrhosis/HCC was identified and 
confirmed using multiple data sources, including review of all participants’ hospital 
medical notes (TrakCare, InterSystems Corp., Cambridge, USA) at 11-year follow-up; 
responses recorded in patient and GP questionnaires sent at year 4 and year 10 
follow-up; hospital discharge data (diagnosis and death codes) collated by ISD 
(Information Services Division, NHS Scotland)  and collected at year 8 follow-up). All 
confirmed cases required clinician diagnosis in secondary care medical notes. 
Participants were identified as having ‘screen-detected’ cirrhosis/HCC if they were 
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referred to hepatology following year 1 or 4 research clinic investigation and remained 
under hepatology follow-up until definitive diagnosis was made. People with prevalent 
cirrhosis or HCC at baseline were excluded from analysis on incident disease. 
Data Analysis 
Data were analysed with R (R Foundation for Statistical Computing, Vienna, Austria. 
https://www.R-project.org/.) using complete-case analysis. <5% of data was missing 
for all variables with the exception of ELF (n=681) and ultrasound (n=933). Logistic 
regression was used to identify the strength of association between baseline scores 
and biomarkers, and incident cirrhosis/HCC in this cohort. Best performing existing 
risk scores were chosen as the base models; assessed on performance using C-
statistic (to assess discrimination), the Hosmer-Lemeshow test for Logistic 
Regression (to assess calibration, >0.05 accepted) and Aikaike Information Criterion 
(AIC) (a measure of overall model performance). Correlation between FIB-4 and APRI 
risk scores was assessed using Pearson correlation coefficient.  
The strength of association of additional baseline variables that have been previously 
reported as potentially associated with pathogenesis or progression of liver disease 
were assessed. These were demographics (sex, deprivation index (SIMD), smoking 
status and alcohol intake), duration of Type 2 diabetes and HbA1c, metabolic 
variables (BMI, waist-hip ratio, cholesterol), markers of liver function and injury (ALP, 
γGT, bilirubin, albumin and hyaluronic acid) and markers of inflammation (IL-6, CRP 
and TNF∝).  Hyaluronic acid, TNFα and γGT were log-transformed (natural log) to 
ensure linearity of response to the logit. Biomarkers that remained significantly 
associated with outcome after correction for markers in the base models, age and 
sex, were assessed individually and in combination when added to the base models 
using C-statistic, AIC and Hosmer-Lemeshow test. Because of the number of cases 
of cirrhosis/HCC in this cohort (n=43) a maximum of 3 additional biomarkers were 
added.  
Due to this cohort’s mixed population of screen-detected and clinician-diagnosed 
outcomes, possibly skewing time-to-event data as those who were screen-detected 
were often diagnosed at a pre-symptomatic stage, the primary analysis (logistic 
regression) did not include a time component. A sensitivity analysis was undertaken 
using competing risks regression to assess whether there was a significant impact of 
the competing risk of non-liver death on final model performance. The Bayesian 
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Information Criterion (BIC) was used to assess model performance for the competing 
risks regression. A second sensitivity analysis was undertaken excluding any 
participant with definite non-NAFLD disease. 
The impact of adding the biomarkers that best improved the performance of models 
by AIC was assessed through calculation of sensitivity, specificity, positive predictive 
value (PPV), negative predictive value (NPV), false positive and false negative rate. 
To undertake this, dichotomous cut-points needed to be allocated for values of the 
base model and for biomarkers used. A complete-case analysis was undertaken for 
model development, with only those participants with all biomarker information 
available included (n=999, of whom 39 developed cirrhosis/HCC). 
 
Ethics 
Ethical permission for the study was granted by Lothian Medical Research Ethics 
Committee (REC reference: 16/SS/0098). All participants gave written informed 
consent. 
  
  Chapter 3: Incidence, Association with fibrosis scores 
   111 
4.4 Results 
 
Participant characteristics and incident events 
Baseline characteristics are detailed in Table 14. Mean age was 67.9 years and 
51.3% were male. Mean duration of Type 2 diabetes was 8 years, HbA1c 7.4% 
(57mmol/mol) and BMI 31.4 kg/m2. Participants were predominantly of Caucasian 
ethnicity (98.3%) and 7 (0.01%) had cirrhosis/HCC. During follow-up, 43 participants 
were identified with incident cirrhosis/HCC. Of these, 39 developed cirrhosis of whom 
58% developed varices, ascites or encephalopathy. There were 13 cases of HCC (9 
participants developed both cirrhosis and HCC). The aetiology of incident disease 
was NAFLD (n=31), mixed NAFLD and alcohol (n=6), mixed NAFLD and α-1 
antitrypsin deficiency (n=1), alcohol (n=2), autoimmune (n=1), or no clear diagnosis 
(n=3). 
Identification of base risk-stratification model 
The performance of 5 pre-selected risk scores in the ET2DS study population is 
shown in 
 
Table 15. The risk scores that showed best association between score and outcome 
(cirrhosis/HCC) by logistic regression assessment were FIB-4 (C-statistic 0.86, AIC 
244.5) and APRI (C-statistic 0.85, AIC 246.5) and these were chosen as base models 
to assess any incremental benefit of additional biomarkers. Correlation between APRI 
and FIB-4 scores in the individuals with and without incident cirrhosis/HCC was high 
(Pearson's r>0.9). 
Association of individual biomarkers with incident cirrhosis/HCC 
Individual baseline biomarkers, in addition to those already in the FIB-4 and APRI risk 
scores, were assessed for their association with incident cirrhosis/HCC by odds ratio 
(OR) (Table 16). SIMD, HbA1c, BMI, ALP, γGT, bilirubin, hyaluronic acid, TNF∝, IL-6 
and CRP were associated (p<0.1) in univariable analysis. SIMD, BMI, HbA1c, γGT, 
hyaluronic acid, IL-6 and CRP remained  associated (p<0.05) after adjustment for 
Chapter 3: Incidence, Association with fibrosis score  
   112 
age, sex and individual factors already in the base models (AST and platelets in both 
FIB-4 and APRI, plus ALT and age in FIB-4) (Table 16).  
Addition of individual biomarkers to base prediction model 
Individual biomarkers were added to the base models, and the association with 
incident cirrhosis/HCC was assessed using logistic regression (Table 17). Those that 
improved FIB-4 model performance most in terms of AIC were HbA1c (improvement 
in AIC of base model from 238.2 to 228.7), hyaluronic acid (209.4) and γGT (205.5). 
Hyaluronic acid and γGT addition also showed the greatest increase in C-statistic 
performance (from 0.85 to 0.89 and 0.93 respectively). For APRI, improvement in AIC 
was also seen most clearly with HbA1c (from 243.8 to 236.2), hyaluronic acid (211.2) 
and γGT (219.1), though with only modest C-statistic improvements. When hyaluronic 
acid alone was added to APRI, the Hosmer-Lemeshow test was significant, indicating 
poor calibration.  
Hyaluronic acid, γGT and HbA1c were chosen to fit to mixed models (Table 17). 
Regardless of the base model used, the addition of both hyaluronic acid and γGT 
further improved model performance, with AIC decreasing to 184.5 (FIB-4 as base 
model) or 192.9 (APRI as base model). The addition of HbA1c to either hyaluronic 
acid, γGT or both did not improve AIC or C-statistic substantially beyond the 
improvement gained by hyaluronic acid and γGT alone. 
A sensitivity analysis was undertaken using competing risk regression analysis (non-
liver death as the competing risk), which supports the finding that the addition of 
hyaluronic acid and/ or γGT provides the best improvement in model performance 
(Table 18).  
Predictive accuracy of the base models plus additional biomarkers  
The models that performed best according to AIC and C-statistic (base models plus 
hyaluronic acid, γGT, HbA1c or combinations) were assessed for accuracy in the 
prediction of incident cirrhosis/HCC using sensitivity, specificity, PPV, NPV, false 
positive and negative rates. APRI plus hyaluronic acid alone was not assessed further 
due to poor calibration. Cut-points used were: for FIB-4 the ‘high risk’ of fibrosis 
(>2.67), ‘medium to high risk’ of fibrosis (≥1.3) and the ‘medium to high risk’ adjusted 
for age (>2) cut-point; for APRI the ‘medium to high risk’ of fibrosis (>0.5) cut-point; 
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for hyaluronic acid ≥100μg/L (appropriate for identification of fibrosis) and ≥50μg/L; 
for γGT the laboratory cut-point of >55U/L, and >20U/L; for HbA1c >7.5. The second 
lower cut-points for hyaluronic acid and γGT were chosen arbitrarily, with the aim of 
attempting to reduce false negative results.  
Hyaluronic acid (cut-point >50μg/L) plus FIB-4 (≥1.3) was the only model with a false 
negative rate ≤25% (n=10/40), thus correctly identifying the majority of those truly at 
high risk at baseline (
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Table 19). FIB-4 plus hyaluronic acid (cut-point ≥50μg/L) reduced the number of 
people assessed as ‘high-risk’ that did not develop cirrhosis/HCC during follow-up 
(i.e. false positive rate) by 46% (399 to 214). Results were similar using the combined 
fibrosis marker as part of the EASL-EASD-EASO algorithm. Using APRI as a base 
model, false negative rates were ≥50%.  
Two sensitivity analyses were undertaken, one excluding participants with definite 
non-NAFLD disease and another excluding participants who developed HCC in a 
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4.5 Discussion 
Serum hyaluronic acid in conjunction with the FIB-4 risk-stratification score reduced 
the number of false positive results in this cohort, without substantially increasing false 
negative results, either in isolation or within the EASL-EASD-EASO algorithm. To this 
team’s knowledge, this is the first study to examine the use of hyaluronic acid for risk-
stratification of liver disease in a community population with Type 2 diabetes.  
Addition of hyaluronic acid improved the association of the FIB-4 model with incident 
cirrhosis/HCC. Moreover, when hyaluronic acid (cut-point ≥50μg/L) was added to the 
FIB-4 risk-stratification tool, the number of people inappropriately classified as ‘high-
risk’ was reduced by 46% (n=399 to n=214), while increasing those inappropriately 
classified as ‘low-risk’ from 18% to 25% (n=7 to n=10). APRI performed similarly to 
FIB-4 as a base model. Both have similar component factors and the scores were 
highly correlated. Therefore, the additive effect of using both markers in combination 
was not assessed. The addition of hyaluronic acid to APRI had poor calibration and 
was not assessed further in isolation. A ‘high-risk’ FIB-4 plus hyaluronic acid score 
was associated with a median time-to-diagnosis of cirrhosis/HCC of approximately 3 
years, with the majority presenting within 6 years. Due to the often asymptomatic 
course of NAFLD, it seems likely that a significant proportion of these individuals had 
undiagnosed cirrhosis at the time of the baseline assessment, while the remainder 
had at least advanced fibrosis.  
Strengths and weaknesses of the study 
The ET2DS specifically studied liver outcomes in a community population of 
otherwise asymptomatic individuals with Type 2 diabetes, who did not necessarily 
have liver disease. Almost all other studies have identified outcomes in cohorts 
recruited from secondary care hepatology clinics, with established NAFLD diagnoses 
and likely advanced pathology. European guidelines recommend screening in 
populations like the one represented by the ET2DS cohort, making this a suitable 
testbed for assessing the impact of potential population screening strategies. 217 The 
ET2DS is a moderate sized cohort. Participants were well-characterised at baseline 
to allow accurate determination of any potential additional baseline risk factors and 
were followed up using multiple sources of information to accurately identify incident 
disease.  
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There are limitations to this study. The ET2DS is a single-centre study, undertaken in 
people aged 60-75 years, of predominantly Caucasian origin (98.3%) and care should 
be taken in extrapolating results to other populations. While the aetiology of incident 
disease was almost entirely NAFLD, cirrhosis/HCC of other aetiologies was included. 
There are known difficulties in determining the exact contributions of different 
aetiologies (or cofactors) in cirrhosis/HCC development, thus investigation of all liver 
disease seemed more relevant in a real-world setting. 268 A sensitivity analysis that 
excluded participants who developed definite non-NAFLD disease did not materially 
affect results. Medication exposure data was not analysed.  
The incidence data may be an underestimate as it is possible that some asymptomatic 
participants who developed cirrhosis/HCC during follow-up were not identified, as 
screening for cirrhosis/HCC at 11-year follow-up was not repeated. Alternatively, our 
the incidence data may overestimate the clinical burden as a substantial proportion of 
diagnoses were made after hepatology referral following year 1 and year 4 screening 
investigations. NAFLD cirrhosis can have a silent natural history and may not manifest 
clinically for many years. Thus, some people who may never have developed overt 
cirrhosis, or may have died before their disease became clinically apparent may have 
been identified. However, 58% of those identified with cirrhosis developed varices, 
ascites and/or encephalopathy and 23% developed HCC, so it is likely that a large 
majority would have presented with clinical sequelae during follow-up.  
Those who were diagnosed following screening in year 1 may have had undiagnosed 
cirrhosis/HCC at baseline. However, the study considered prevalent disease to be 
only that which was clinically apparent at baseline because the diagnosis of cirrhosis 
for some referred post-screening came many years following that referral (people 
were kept under active follow-up due to high-risk features for progression). 
Additionally, the time-to-diagnosis for those who were diagnosed following year 1 
screening and those diagnosed following routine clinical referral significantly 
overlapped, suggesting that stage of disease in the two groups at baseline did not 
differ significantly. 262 
ELF was measured at the year 1 clinic (all other biomarkers at baseline), so this 
analysis used slightly different ‘baseline’ time points. However, this group has 
demonstrated previously that there is no significant difference in model performance 
using baseline or year 1 data; in addition, no participant was identified with incident 
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disease prior to the year 1 clinics. 262 Hyaluronic acid is known to be raised in the 
context of joint, as well as liver disease. As accurate data on joint disease prevalence 
for the whole cohort at baseline were not available, individuals with joint disease were 
not excluded. However, as hyaluronic acid was used in conjunction with other markers 
of liver fibrosis, isolated elevation of hyaluronic acid due to joint disease should not 
have had a material impact on the models.  
This group has previously described the performance of current risk-stratification 
models in predicting cirrhosis and HCC in different cohorts. 262 In addition, risk-
stratification scores perform worse in populations with diabetes than in those without. 
237 Previous cohort studies have failed to consistently identify individual non-invasive 
biomarkers that are associated NAFLD progression. 179,180 This study demonstrates 
that using serum hyaluronic acid in conjunction with the FIB-4 risk-stratification score 
can reduce the burden of false positive results. Hyaluronic acid is a 
glycosaminoglycan found in connective tissue that is almost exclusively cleared by 
liver metabolism. Raised levels of hyaluronic acid are known to be associated with 
cirrhosis. 269 However, few studies have assessed it as a prognostic marker. In 
combination with other biomarkers as part of the ELF risk-stratification tool, hyaluronic 
acid is associated with fibrosis in NAFLD. 224 One study found a significant association 
with rising hyaluronic acid and all-cause mortality, liver mortality and liver transplant-
free survival. 270 Thus, the present data, finding suggesting its utility in predicting those 
who are at ‘high-risk’ of developing incident cirrhosis/HCC, is consistent with 
published data. 
The present findings derive from a single moderately-sized cohort and need validation 
in other independent cohorts. A change in FIB-4 plus hyaluronic acid over time was 
not examined. Moreover, there were too few individuals who developed cirrhosis/HCC 
to determine reliably if the median time-to-diagnosis was more prolonged in those with 
a ‘low-risk’ score compared to those with a ‘high-risk’ score. If the time-to-diagnosis 
was more prolonged in those with a ‘low-risk’ score, repeat assessment at intervals 
of several years might successfully identify additional individuals who would develop 
cirrhosis/HCC. 
In conclusion, the prevalence of both NAFLD and Type 2 diabetes are rising in 
association with the rising population prevalence of obesity. Type 2 diabetes is 
associated with an increased risk of cirrhosis/HCC. 21,75 As a result, both European 
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and American guidelines advocate a high index of suspicion for liver disease in Type 
2 diabetes, with European guidelines recommending routine screening. 7,217 However, 
current risk-stratification tools perform suboptimally, especially in diabetes. 237,262 This 
study shows that using a combination of FIB-4 and hyaluronic acid for risk-
stratification can significantly reduce false positive rates without substantially 
increasing false negative rates. This makes this combination a possible candidate for 
community screening, as it would lead to identification of a substantial proportion of 
cases while reducing stress on health systems from false positive results. These 
findings are promising, but require further validation. Furthermore, the false positive 
rates for the FIB-4 and hyaluronic acid combination remain high and so it is 
acknowledged that better biomarkers are required for the identification of people with 
Type 2 diabetes at risk of developing cirrhosis/HCC. 
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Table 14. Baseline characteristics of the study population 
Baseline Characteristic ET2DS Population (n=1066) 
Age  67.9  (4.2) 
Sex (male)  547.0 (51.3)  




1 (most deprived)  12  (11.9) 
2  208 (19.5) 
3  188 (17.6) 
4  194 (18.2) 
5 (least deprived)  349 (32.7) 
Duration T2DM (years)  8.1  (6.5) 
HbA1c (%)  7.4  (1.1) 
HbA1c (mmol/mol)  57.0 (12.0) 
BMI (kg/m2)  31.4  (5.7) 
Smoker (current)  154.0 (14.4) 
Alcohol (excess)†  207.0 (19.9) 
Values are mean (sd) or n (%) 
† Defined as females >14 units/week, males >21 units/week or patient disclosed history of 
a current or prior alcohol problem 











for age and 






ELF 6.89-17.40 3.20 (2.18-4.84) <0.001 195.2 0.83 <0.001 
APRI 0.07-1.76 3.02 (2.37-3.94) <0.001 246.5 0.85 0.10 
AST:ALT 0.33-1.67 2.03 (1.61-2.57) <0.001 318.4 0.73 0.03 
NFS -5.91-2.98 3.11 (2.21-4.46) <0.001 297.3 0.80 0.001 
FIB-4 0.41-7.82 3.42 (2.60-4.62) <0.001 244.5 0.86 0.16 
OR odds ratio, AIC Akaike Information Criterion.  
OR calculated per increase of one standard deviation in marker. 
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age and sex 




Age  67.9  (4.2)  68.5  (4.7)  67.9  (4.2) 1.17 (0.86-1.60) 0.31 - - 





 125  (11.8)  9  (20.9)  116  (11.4) 3.78 (1.38-10.79) 0.01 0.01 0.01 
 2  206  (19.5)  8  (18.6)  198  (19.5) 1.97 (0.7-5.69) 0.20 0.03 0.06 
 3  187  (17.7)  8  (18.6)  179  (17.6) 2.18 (0.77-6.3) 0.14 0.09 0.14 
 4  193  (18.2)  11  (25.6)  182  (17.9) 2.94 (1.14-8.12) 0.03 0.01 0.02 
 5 (least 
deprived) 
 348  (32.9)  7  (16.3)  341  (33.6) 
Duration T2DM (years)  8.1  (6.5)  9.1  (6.2)  8.0  (6.5) 1.17 (0.87-1.51) 0.27 - - 
HbA1c (%)  7.4  (1.1)  8.1  (1.5)  7.4  (1.1) 1.53 (1.21-1.90) <0.001 <0.001 <0.001 
HbA1c (mmol/mol)  57  (12)  65  (16.4)  57  (12) - - - - 
BMI (kg/m2)  31.4  (5.7)  33.7  (6.2)  31.3  (5.7) 1.44 (1.09-1.87) 0.008 0.02 0.02 
Waist-Hip Ratio  0.97  (0.1)  0.98  (0.1)  0.96 (0.1) 1.20 (0.88-1.63) 0.25 - - 
Smoker (current)  153  (14.4)  8  (18.6)  145  (14.3) 1.37 (0.58-2.87) 0.43 - - 
Alcohol (excess)†  204  (19.8)  13  (30.2)  191  (18.8) 1.81 (0.9-3.46) 0.08 0.73 0.71 
Cholesterol (mmol/L)  4.3  (0.9)  4.2  (0.8)  4.3 (0.9) 0.84 (0.59-1.16) 0.31 - - 
ALT (U/L)  43.2 (14.3)  53.4  (19.9)  42.8 (13.9) 1.56 (1.26-1.94) <0.001 0.07 - 
AST (U/L)  31.0 (10.4)  45.9  (15.4)  30.4 (9.7) 2.20 (1.78-2.74) <0.001 - - 
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age and sex 




ALP (U/L)  91.7 (27.3) 106.1 (33.5)  91.1 (26.9) 1.45 (1.15-1.82) 0.001 0.21 0.12 
𝜸GT (U/L)†  29.4  (40.3)  96.7  (86.7)  26.7 (34.7) 3.55 (2.66-4.86) <0.001 <0.001 <0.001 
Bilirubin (𝝁mol//L)  10.0  (4.7)  11.2  (4.1)  9.9 (4.7) 1.24 (0.94-1.56) 0.09 0.63 0.57 
Albumin (g/L)  44.8  (3.3)  44.7  (3.8)  44.8 (3.3) 0.97 (0.71-1.33) 0.86 - - 
Platelets (109/L)  258.7 (69.3) 201.5 (77.4)  261.1 (68.0) 0.33 (0.22-0.49) <0.001 - - 
Hyaluronic Acid 
(𝝁g/L)‡ 
 56.1  (46.6) 132.2 (85.3)  52.8 (41.3) 5.29 (3.42-8.47) <0.001 <0.001 <0.001 
TNF-∝ (pg/mL)‡  1.4  (1.5)  1.6  (0.8)  1.3 (1.5) 1.63 (1.19-2.23) 0.002 0.05 0.08 
IL-6 (pg/mL)  3.9  (3.5)  5.7  (3.9)  3.8 (3.5) 1.38 (1.12-1.66) 0.001 0.01 0.02 
CRP (mg/L)  3.9  (6.0)  6.0  (8.3)  3.8 (5.9) 1.26 (1.00-1.52) 0.03 0.03 0.03 
Values are mean(sd) or n (%) 
† Defined as females >14 units/week, males >21 units/week or patient disclosed history of a current or prior alcohol 
problem ‡ results for the natural log of these values § for continuous variables, odds ratio represents change in odds for 
standard deviation change in variable  
SIMD Scottish Index of Multiple Deprivation, T2DM Type 2 diabetes, HbA1c glycated haemoglobin, ALT  alanine 
aminotransferase,  AST  aspartate aminotransferase,  ALP alkaline phosphatase, 𝜸GT gamma-glutamyltransferase, TNF-∝ 
tumour necrosis factor-alpha, IL-6 Interleukin-6, CRP C-reactive protein 
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Table 17. Performance of the baseline models (FIB-4 and APRI) with the 






FIB-4 0.85 0.35 238.2 
Addition of one additional variable 
FIB-4 + HbA1c 0.87 0.43 228.7 
FIB-4 + 𝜸GT† 0.93 0.98 205.5 
FIB-4+ HA† 0.89 0.06 209.4 
FIB-4 + BMI 0.87 0.32 232.9 
FIB-4 + SIMD 0.87 0.79 239.6 
FIB-4 + IL-6 0.87 0.16 235.0 




0.93 0.86 199.2 
FIB-4, Hba1c, 
HA† 
0.90 0.10 203.5 
FIB-4, 𝜸GT†, HA† 0.93 0.23 184.5 
Full Model FIB-
4, HbA1c, 𝜸GT†, 
HA† 
0.94 0.71 181.0 
Base Model 
APRI 0.85 0.92 243.8 
Addition of one additional variable 
APRI + HbA1c 0.86 0.93 236.2 
APRI + 𝜸GT † 0.91 0.84 219.1 
APRI + HA† 0.88 <0.01 211.2 
APRI + BMI 0.86 0.52 238.6 
APRI + SIMD 0.87 0.18 242.5 
APRI + IL-6 0.88 0.01 239.5 




0.91 0.84 213.6 
APRI, Hba1c, 
HA† 
0.89 <0.01 206.3 
APRI, 𝜸GT †, HA† 0.92 0.20 192.9 
Full Model APRI, 
HbA1c, 𝜸GT †, 
HA† 
0.93 0.14 189.7 
† log-transformed 𝜸GT/ HA variable 
HbA1c glycated haemoglobin, 𝜸GT gamma glutamyltransferase, 
HA Hyaluronic Acid, SIMD Scottish Index of Multiple Deprivation, 
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Table 18. Performance of the baseline models (FIB-4 and APRI) with the 
addition of complementary biomarkers, re-run using competing risk 
regression analysis with non-liver death as the competing risk 




Addition of one additional variable 
FIB-4 + HbA1c 460.27 
FIB-4 + 𝜸GT† 431.97 
FIB-4+ HA† 445.68 
FIB-4 + BMI 469.52 
FIB-4 + SIMD 470.47 
FIB-4 + IL-6 469.94 
FIB-4+ CRP 472.90 
Mixed Models 
FIB-4, Hba1c, 𝜸GT† 433.04 
FIB-4, Hba1c, HA† 444.16 
FIB-4, 𝜸GT†, HA† 418.36 
Full Model FIB-4, 




Addition of one additional variable 
APRI + HbA1c 457.17 
APRI + 𝜸GT† 436.10 
APRI + HA† 439.09 
APRI + BMI 459.60 
APRI + SIMD 462.82 
APRI + IL-6 460.00 
APRI + CRP 463.22 
Mixed Models 
APRI, Hba1c, 𝜸GT† 439.63 
APRI, Hba1c, HA† 439.80 
APRI, 𝜸GT†, HA† 419.49 
Full Model APRI, 
HbA1c, 𝜸GT†, HA† 
423.29 
† log-transformed 𝜸GT / HA variable, HbA1c 
glycated haemoglobin, BMI body mass index, 
𝜸GT gamma glutamyltransferase, HA 
Hyaluronic Acid, SIMD Scottish Index of 
Multiple Deprivation, IL-6 Interleukin-6, CRP 
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Table 19. Predictive ability of models by sensitivity, specificity, PPV, NPV, false positive rate and false negative rate 












FIB-4 >2.67  40  (25-57) 98 (97-99)  46  (29-63)  98  (96-98)  19  (2)  24  (60) 
FIB-4 >2.0  62 (46-77) 92 (90-93)  23 (16-33)  98 (97-99)  82  (8) 15  (37) 
FIB-4 ≥1.3  82  (67-93) 59 (56-62)  8  (5-11)  99  (98-100)  399  (41)  7  (18) 
As addition of further variables will increase false negative values, only FIB-4 ≥1.3 was taken 
forward. 
FIB-4  ≥1.3, 𝜸GT >55  45  (29-62) 95 (94-97)  28  (18-41)  98  (97-99)  46  (5)  22  (55) 
FIB-4  ≥1.3, 𝜸GT >20  72  (56-85) 82 (79-84)  14  (10-20)  99  (98-99)  176  (18)  11  (28) 
FIB-4  ≥1.3, HA ≥100  62  (46-77) 95 (93-96)  32  (22-44)  98  (97-99)  53  (5)  15  (38) 
FIB-4  ≥1.3, HA ≥50  75  (59-87) 78 (75-81)  12  (8-17)  99  (98-99)  214  (22)  10  (25) 
FIB4 ≥1.3, HbA1c >7.5  47  (32-64) 88 (85-90)  13  (8-20)  98  (96-99)  122  (12)  21  (53) 
FIB-4  ≥1.3, HA ≥50, 
 𝜸GT >20 
 65  (48-79) 90 (88-92)  22  (15-30)  98  (97-99)  94  (10)  14  (35) 
FIB4 ≥1.3, HA ≥50, 
HbA1c >7.5 
 45 (29-62) 93 (91-94)  20 (12-30)  98 (96-99)  72  (7)  22 (55) 
FIB4 ≥1.3,  𝜸GT >20, 
HbA1c >7.5 
 40 (25-57) 94 (92-95)  22 (13-33)  97 (96-98)  58  (6)  24 (60) 
Fib4 ≥1.3, HA ≥50, 
GGT >20, HbA1c >7.5 
 38  (23-54) 97 (95-98)  31  (19-46)  97  (96-98)  33  (3)  25  (63) 
APRI >0.5  53  (36-68) 94 (93-96)  27 (18-38)  98  (97-99)  57  (6)  19  (48) 
APRI >0.5, 𝜸GT >55  35  (21-52) 98 (97-99)  45  (27-64)  97  (96-98)  17  (2)  26  (65) 
APRI >0.5, 𝜸GT >20  50  (34-66) 96 (95-97)  36  (24-50)  98  (97-99)  35  (4)  20 (50) 
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APRI >0.5, HbA1c 
>7.5 
 33  (19-49) 98 (97-99)  37  (21-55)  97  (96-98)  22  (2)  27  (68) 
APRI >0.5, HA ≥50, 
𝜸GT >20 
 50  (34-66) 98 (96-98)  45  (30-61)  98  (97-99)  24  (2)  20  (50) 
APRI >0.5, HA ≥50, 
HbA1c >7.5 
 33 (19-49) 98 (97-99)  45 (26-64)  97 (96-98)  16  (2)  27 (68) 
APRI >0.5,  𝜸GT >20, 
HbA1c >7.5 
 30 (17-47) 99 (98-99)  50 (29-71)  97 (96-98)  12  (1)  28 (70) 
APRI >0.5, HA ≥50, 
GGT >20, HbA1c >7.5 
 30  (17-47) 99 (98-100)  57 (34-78)  97  (96-98)  9  (1)  28  (70) 
EASL guidelines- USS 
steatosis + FIB-4 
>=1.3 OR ALT>50 OR 
AST>45 OR 𝜸GT>55 
 86  (71-95) 60 (57-63)  8  (6-11)  99  (98-100)  346  (40)  5  (14) 
EASL (USS)+ HA ≥50  81  (64-92) 81 (78-84)  15  (10-21)  99  (98-100)  163  (19)  7  (19) 
EASL guidelines- FLI 
positive + FIB-4 ≥1.3 
OR ALT>50 OR 
AST>45 OR 𝜸GT>55 
 90  (76-97) 58 (55-61)  8  (6-11)  99  (98-100)  411  (42)  4  (10) 
EASL (FLI)+ HA ≥50  78  (62-89) 79 (76-81)  13  (9-18)  99  (98-99)  206  (21)  9  (23) 
𝜸GT gamma glutamyltransferase, HA Hyaluronic Acid, USS ultrasound assessed, ALT alanine 
aminotransferase, AST aspartate aminotransferase, FLI Fatty liver index,  HbA1c glycated haemoglobin, 
sens sensitivity, spec specificity, PPV positive predictive value, NPV negative predictive value 
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Table 20. Predictive ability of models by sensitivity, specificity, PPV, NPV, false positives and false negatives- final models, 
























FIB-4 ≥1.3 84 (68-94) 59 (56-62) 7 (5-10) 99 (98-100) 399 (41) 6 (16) 
FIB-4  ≥1.3, HA ≥50 78 (62-90) 78 (75-81) 12 (8-17) 99 (98-100) 214 (22) 8 (22) 
EASL guidelines- 
USS steatosis + FIB-
4 >=1.3 OR ALT>50 
OR AST>45 OR 
𝜸GT>55 
89 (75-97) 60 (57-64) 8 (6-11) 99 (98-100) 376 (44) 4 (11) 
EASL (USS)+ HA 
≥50 
78 (62-90) 81 (79-84) 14 (10-19) 99 (98-100) 179 (21) 8 (22) 
EASL guidelines- FLI 
positive + FIB-4 ≥1.3 
OR ALT>50 OR 
AST>45 OR 𝜸GT>55 
89 (75-97) 58 (55-61) 7 (5-10) 99 (98-100) 413 (43) 4 (10) 
EASL (FLI)+ HA ≥50 78 (62-90) 79 (76-81) 12 (8-17) 99 (98-100) 208 (21) 8 (22) 
𝜸GT gamma glutamyltransferase, HA Hyaluronic Acid, USS ultrasound assessed, ALT alanine 
aminotransferase, AST aspartate aminotransferase, FLI Fatty liver index,  HbA1c glycated haemoglobin, 
sens sensitivity, spec specificity, PPV positive predictive value, NPV negative predictive value 
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Table 21. Predictive ability of models by sensitivity, specificity, PPV, NPV, false positives and false negatives- final models, 


























FIB-4 ≥1.3 84 (68-94) 59 (56-62) 7 (5-10) 99 (98-100) 394 (41) 6 (16) 
FIB-4  ≥1.3, HA ≥50 76 (59-88) 78 (75-81) 12 (8-16) 99 (98-99) 211 (22) 9 (24) 
EASL guidelines- USS 
steatosis + FIB-4 
>=1.3 OR ALT>50 OR 
AST>45 OR 𝜸GT>55 
92 (78-98) 60 (57-63) 8 (6-12) 99 (98-100) 371 (40) 2 (8) 
EASL (USS)+ HA ≥50 92 (78-98) 67 (63-70) 10 (7-13) 100 (99-100) 315 (33) 3 (8) 
EASL guidelines- FLI 
positive + FIB-4 ≥1.3 
OR ALT>50 OR 
AST>45 OR 𝜸GT>55 
92 (78-98) 57 (54-61) 8 (5-11) 99 (98-100) 408 (43) 3 (8) 
EASL (FLI)+ HA ≥50 89 (75-97) 64 (61-67) 9 (6-12) 99 (98-100) 344 (36) 4 (11) 
𝜸GT gamma glutamyltransferase, HA Hyaluronic Acid, USS ultrasound assessed, ALT alanine 
aminotransferase, AST aspartate aminotransferase, FLI Fatty liver index,  HbA1c glycated 
haemoglobin, sens sensitivity, spec specificity, PPV positive predictive value, NPV negative predictive 
value 
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4.6 Additional Information 
Embedded in the discussion section of this chapter is the discussion of the 
biological rationale for hyaluronic acid and its use as a biomarker of liver 
disease. In this paragraph I wish to additionally discuss the biological 
rationale for the other biomarker that best performed in addition to FIB-4 in 
our model building; GGT. GGT is found in the cell membranes of many 
tissues  and is thought to be involved in amino acid transport, glutathione 
and leukotriene metabolism and maintenance of intracellular homeostasis 
in the context of oxidative stress. 271 Serum levels rise in the context of liver 
disease associated with liver cell disruption and cholestasis. One UK based 
observational study assessing the predictive ability of individual liver 
enzymes in identifying 2 year all-cause clinical liver outcomes showed that 
GGT was one of the most strongly associated with incident disease. 272 
However, care must be taken in the interpretation of this in the context of 
our study as the proportion of people with diabetes was low (1% derivation 
cohort, 12% validation cohort). Furthermore, many GGT readings were 
imputed. Interestingly, the cut-point of GGT used to provide best 
prognostication in this cohort was similar to our second cut point ot 20 U/L. 
Using a similar cut point in this study showed that >25% of our participants 
would have been inappropriately identified as low risk for the development 
of cirrhosis/ HCC over 10 years.   
  Chapter 5: Association of liver tests with outcomes 
   131 
Chapter 5 The association of non-alcoholic 
fatty liver disease screening tests 
with incident advanced chronic liver 
disease and mortality in people with 
Type 2 diabetes  
This section has been submitted and is under review in Diabetic Medicine under the 
same title by Sheila M Grecian (SMG), Jonathan A Fallowfield (JF), Stela McLachlan 
(SM), Peter C Hayes (PH), Indra Neil Guha (NG), Joanne R Morling (JM), Stephen 
Glancy (SG), Rachel M Williamson (RW), Rebecca M Reynolds (RR), Brian M Frier 
(BF), Nicola N Zammitt (NZ), Jackie F Price (JP) and Mark WJ Strachan (MS). SMG 
wrote the manuscript. JP was principal investigator of the ET2DS, designed the study, 
analysed and interpreted the data. MS was lead investigator of the ET2DS liver sub-
study, designed the study, analysed and interpreted the data. RR, BF, PH, JF, RW, 
NG and SG contributed to study design. SMG, SM, RW and JM contributed to data 
collection, analysis and interpretation. All authors contributed to revision and final 
approval of the article. 
In summary, in the previous chapters it was discussed that screening for NAFLD in 
the context of T2DM would be potentially beneficial and is recommended in 
international guidelines. 217 Whilst the presence of hepatic fibrosis is acknowledged 
as a key factor in predicting progression of NAFLD to cirrhosis and associated HCC, 
none of the non-invasive tools designed to identify fibrosis and thus additionally used 
as predictive tools for the identification of risk of progressive disease perform optimally 
in the context of T2DM. We then discussed that the addition of hyaluronic acid to the 
FIB-4 risk prediction tool may reduce the false positive rate. In this study we compared 
the predictive ability of any tests for NAFLD (ultrasound and the Fatty Liver Index as 
markers of hepatic steatosis, serum liver enzymes, fibrosis markers) or any 
combination in the identification of incident cirrhosis and HCC. Furthermore, as 
NAFLD is thought to be associated with an increased mortality we assessed whether 
any of these tests were associated with deaths during the study follow up period. 
Formulae used for the calculation of predictive ability can be found in appendix 2. 
Please note- all tables for this section sit at the end of the chapter text. 
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5.1 Abstract 
Background: Type 2 diabetes is associated with an increased risk of non-alcoholic 
fatty liver disease (NAFLD) and of progression to cirrhosis and hepatocellular 
carcinoma (HCC). Screening of people with Type 2 diabetes for NAFLD is 
recommended, but the optimum test to use is uncertain.   
Aims: To compare the ability of non-invasive tests for NAFLD to identify incident 
cirrhosis/HCC and mortality in a community cohort of older people with Type 2 
diabetes. 
Methods: Participants in the Edinburgh Type 2 Diabetes Study (n=1066, age 60-75 at 
baseline) were followed for over 11 years. Serum liver enzymes, fatty liver index (FLI), 
hepatic steatosis on ultrasound, Fibrosis-4 index (FIB-4) and hyaluronic acid were 
measured at baseline and year 1. Individual and composite tests were analysed for 
their ability to accurately identify incident cirrhosis/HCC and mortality. 
Results: Incidence of cirrhosis/HCC was 4.1% and 320 deaths occurred. All tests 
investigated had false positive or negative rates of >20% or 35% respectively for the 
identification of cirrhosis/HCC. A ‘positive’ FLI was associated with significantly 
increased mortality (hazard ratio (95% confidence interval 1.45 (1.13-1.87), p=0.004). 
FLI and other tests showed high false positive or negative rates (>20% or 75% 
respectively) for mortality.  
Conclusion: None of the tests provided a ‘good balance’ between false positive and 
negative rates in the identification of cirrhosis/HCC and are unlikely to be helpful in 
mortality assessment. Clinicians could choose tests with a low false positive rate to 
identify a proportion of cases of incident cirrhosis/HCC, while minimising unnecessary 
investigation.  
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5.2 Introduction 
People with Type 2 diabetes are at high risk of developing non-alcoholic fatty liver 
disease (NAFLD). Furthermore, Type 2 diabetes is associated with increased risk of 
progression to cirrhosis and hepatocellular carcinoma (hazard ratio (HR) 1.8).21,75 
Concurrent diagnoses of NAFLD and diabetes have been associated with increased 
mortality rates; in one study of 337 people with diabetes, the HR for death with 
concurrent NAFLD was 2.2.40 The European Association for the Study of the Liver, 
European Association for the Study of Diabetes and The European Association for 
the Study of Obesity (EASL-EASD-EASO) NAFLD guidelines recommend screening 
for NAFLD in people with Type 2 diabetes to enable targeted lifestyle modification to 
reduce the rate of (or reverse) disease progression and to allow prompt identification 
and treatment of complications.217 Several non-invasive biomarkers and tests for 
NAFLD are available, including serum liver enzymes (aspartate aminotransferase 
(AST), alanine aminotransferase (ALT), gamma-glutamyl transferase (GGT)), serum 
biomarker scores associated with NAFLD and/or fibrosis and imaging tests such as 
liver ultrasound or magnetic resonance imaging-proton density fat fraction for 
steatosis and transient elastography or MR elastography for fibrosis. In addition, 
algorithms that combine several tests have been developed, such as in the EASL-
EASD-EASO guideline (Figure 2).217 
Although many tests for NAFLD have been developed, no consensus exists as to 
which are most effective for screening large numbers of individuals in a diabetes out-
patient setting, with the aim of detecting those who are at greatest risk of developing 
cirrhosis/HCC. The ability of the chosen screening test to predict clinically significant 
disease is paramount, as well as having a test that is sufficiently practical and cost-
effective to be used at scale. To date, existing tests have been found to be sub-optimal 
in predicting cirrhosis/HCC in people with diabetes. For example, in one study (n=284, 
follow-up over 4 years), 15% of people with diabetes with a ‘low-risk’ Fibrosis-4 (FIB-
4) score developed decompensated cirrhosis, whereas in people without diabetes, 
no-one with a ‘low-risk’ score developed decompensated cirrhosis.227,237 Similarly, we 
have previously reported that in older people with diabetes, 18% of those with a ‘low-
risk’ FIB-4 score developed cirrhosis or HCC, while 41% of those who did not develop 
cirrhosis or HCC had a ‘high-risk’ FIB-4 score at baseline.262 
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5.3 Aims 
Given the on-going uncertainty regarding the optimal NAFLD screening test to use, 
the aim of the present study was to compare the ability of a range of commonly used 
NAFLD tests to identify incident cirrhosis/HCC in a community population of people 
with Type 2 diabetes. We also aimed to determine whether these tests were predictive 
of death during 11-years follow-up. 
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5.4 Methods 
 
The Edinburgh Type 2 Diabetes Study 
The Edinburgh Type 2 Diabetes Study (ET2DS) is a population based prospective 
cohort study which recruited 1066 participants aged 60-74 with Type 2 diabetes in 
2006/07. Detailed methodology has been described previously.255 All who attended 
the baseline clinic were invited to re-attend an assessment at year 1 and 4. A total of 
939 attended the year 1 clinic (of the original baseline cohort, deceased n=15, unable 
to contact n=19, unable to attend n=93) and 831 at year 4 (deceased n=88, unsuitable 
for clinical reasons n=26, unable to contact n=23, unable to attend n=98). 
Data collection 
Detailed biomarker assessment was undertaken at the baseline clinic. Assessments 
were undertaken at dedicated research clinics at the Wellcome Trust Clinical 
Research Facility, Western General Hospital, Edinburgh, UK, by specially trained 
research staff using Standard Operating Procedures.255 Fasting venous blood 
samples were collected at baseline. ALT, AST, alkaline phosphatase (ALP), GGT), 
triglycerides and platelets were analysed using a Vitros Fusion chemistry system 
(Ortho Clinical Diagnostics, Bucks, UK) at the Western General Hospital. Hyaluronic 
acid was measured using a radiometric assay (Pharmacia, Uppsala, Sweden). 
Height, weight and waist circumference were measured at the baseline clinic. Liver 
ultrasound was undertaken at the year 1 clinic (Sonoline Elegra Ultrasound Imaging 
System (Siemens Medical Systems Inc., Washington, USA)). Ultrasounds were 
graded for hepatic steatosis using established criteria (0=normal liver, 
1=indeterminate, 2=mild steatosis, 3=severe steatosis) and validated by three 
graders and 1H MRI spectroscopy in a subset, as previously described.259 This 
showed a median fat fraction in those with ‘severe’ steatosis of 19.4% (interquartile 
range 12.9-27.5), compared to 4.1% (interquartile range 3.1-8.5) in those with 
‘indeterminate’/ ‘mild’ steatosis and 4.2% (interquartile range 1.2-5.7) in those with ‘no 
steatosis’. As significant overlap between grade 0-2 steatosis was identified, only 
those with grade 3 steatosis on ultrasound assessment were deemed to have ‘definite 
steatosis’.  
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Participants attending the year-1 research clinic who had an abnormal liver ultrasound 
or liver enzymes above the laboratory reference range underwent a diagnostic liver 
screen (including Hepatitis B and C serology, liver autoantibody titres, alpha-
fetoprotein, ferritin). All participants completed standard questions about alcohol 
consumption (AUDIT-C questionnaire), medication use and past medical history. Any 
participant with routine liver enzyme tests above the laboratory upper limit of normal 
(ALT >50 U/L, AST >45 U/L, 𝛾GT >55 U/L, alkaline phosphatase (ALP) >125 U/L), 
AST:ALT ratio >1, hyaluronic acid >100𝜇g/L (in the absence of known joint disease), 
positive liver autoantibodies, ferritin >1000ng/mL, alpha-feto protein >6ng/mL, 
positive hepatitis B or C serology, spleen diameter >13cm, platelets <150x109/L (in 
the absence of known haematological cause), or suspected cirrhosis on ultrasound, 
was referred for specialist hepatology review. 
Only one fibrosis risk-stratification tool (FIB-4 at the low to medium risk cut-point of 
1.3) is presented in the present study - previous work by this group showed this to be 
the best-performing of the fibrosis scores in our cohort, especially when considering 
the combination of false positive and false negative rates.262 We have shown 
previously that other published FIB-4 cut points of 2.67 (the medium to high-risk cut 
point (6)) or 2.0 (a suggested age-specific cut point (10)) resulted in >35% false 
negative rate (7), and so a cut point of 1.3 was chosen for the present analysis. A 
novel combination of biomarkers (FIB-4 and hyaluronic acid assessment) was 
included, which was shown previously in our cohort to improve the false positive level, 
and additional combinations of biomarkers from those suggested in the EASL-EASD-
EASO algorithm.273  
Scores were calculated and cut-point levels used as per published work:  
- Fibrosis-4 index (FIB-4) was calculated as: 
((age(years)xAST(U/L))/(plt(x109/L)xsqrt ALT(U/L))) 262 
- Fatty liver index (FLI) was calculated as: ey/(1+ey)x100 where y=0.953 x 
ln(triglycerides, mg/dl) + 0.139 x BMI, kg/m2 + 0.718 x ln (GGT, U/L) + 0.053 x 
waist circumference, cm – 15.745) 274 
- The EASL-EASD-EASO referral decision algorithm was used 217 
 
For the purpose of this analysis, a ‘positive test’ was defined:  
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- Abnormal liver enzymes: above the upper limit of normal in the laboratory 
reference range of ALT, AST or GGT 
- Fatty liver index level: ≥60 
- Ultrasound: ‘definite’ steatosis 
- FIB-4 level: ≥1.3 
- Hyaluronic acid level: ≥50 𝜇g/L 
 
Participants were followed-up until death or the end of study (11 years). Mean follow-
up was 9.6 years (standard deviation 2.8 years). Incident cirrhosis and HCC were 
identified using multiple information sources (hospital patient record review 
(TrakCare, InterSystems Corp., Cambridge, USA), patient and GP questionnaire at 
year 4 and year 10 follow-up, discharge summary coding of hospital admissions and 
death coding (Information Services Division, NHS Scotland)). Cases were confirmed 
if a clinician diagnosis was recorded in medical notes. Death records were obtained 
from hospital patient records, national death coding (Information Services Division, 
NHS Scotland) and death certificates (National Records Scotland). We have 
previously published detailed data on prevalent and incident liver disease.262 In brief, 
7 people had prevalent cirrhosis/HCC and 43 people developed incident 
cirrhosis/HCC (an incidence of 4.1%). Of those 43, 37 cases were attributed to 
NAFLD, NAFLD with alcohol as a co-factor or mixed aetiology NAFLD and alpha-1-
antitrypsin deficiency. 320 participants died during study follow-up. 
Data Analysis 
Data were analysed using R (R Core Team (2017). R: A language and environment 
for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL 
https://www.R-project.org/.). Event rates were calculated for the cohorts with ‘positive’ 
and ‘negative’ test results. Association between test result and survival was assessed 
using Cox proportional hazards regression. Association between test result and liver 
outcomes has been reported previously.262 Performance was assessed through 
calculation of positive predictive value, negative predictive value, false positive rate 
(FPR) and false negative rate (FNR). We have previously reported these data for FIB-
4, ‘FIB-4 with hyaluronic acid’ and the EASL-EASD-EASO algorithm, but results are 
presented here to allow direct comparison.262 
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Ethics 
Ethical permission for the study was granted by Lothian Medical Research Ethics 
Committee (REC reference 16/SS/0098). All participants gave written informed 
consent. 
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5.5 Results 
 
Performance of NAFLD tests in predicting incident cirrhosis/HCC 
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Table 22 shows the ability of tests to predict incident cirrhosis or HCC. All tests either had a FPR >20% or FNR >35%. For the three tests 
with a FNR <10% (‘positive FLI’, ‘raised liver enzymes OR positive FLI’, ‘raised liver enzymes OR [positive FIB-4 with hyaluronic acid]’), all 
had a FPR >40%. For those tests with a FPR <20% (‘raised liver enzymes PLUS positive FLI’, ‘positive FLI PLUS [positive FIB-4 with 
hyaluronic acid]’, ‘raised liver enzymes PLUS [positive FIB-4 with hyaluronic acid]’), FNRs were >35%.  
In terms of clinical utility, the use of ‘raised liver enzymes PLUS FLI’ or ‘raised liver enzymes PLUS [FIB-4 with hyaluronic acid]’ would result 
in appropriate ‘negative’ results for 879/981 (89.6%) or 936/1013 (92.4%) of the disease-free cohort respectively but would lead to missing 
23 (56.1%) or 19 (45.2%) incident cases respectively. Conversely, the use of ‘FLI OR [FIB-4 with hyaluronic acid]’, ‘raised liver enzymes 
OR FLI’ or ‘raised liver enzymes OR [FIB-4 with hyaluronic acid]’ would limit missed incident cases to <10% (n≤3) but would result in 
inappropriate referral of 728 (72.9%), 713 (71.3%) or 411 (40.9%) of the cohort respectively. 
Association of NAFLD tests with survival 
Cause of death was predominantly cardiovascular disease (35%), with 30% of deaths due to malignancy and 2% from cirrhosis and HCC. 
We assessed five tests (raised liver enzymes, USS, FLI, FIB-4 and [FIB-4 with hyaluronic acid]) for their association with survival (
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Figure 4). People with a negative FLI, FIB-4 or [FIB-4 with hyaluronic acid] test tended 
to have slightly better survival compared to those with a positive test, HR (95% 
confidence intervals (CI)) were respectively 1.45 (1.13-1.87; p=0.004), 1.18 (0.93-
1.50; p=0.17) and 1.29 (1.00-1.66; p=0.05). Survival curves for people with negative 
and positive ‘raised liver enzyme’ and ‘hepatic steatosis on ultrasound’ tests showed 











Table 23 presents test performance statistics for all-cause mortality.  All tests either 
had a FPR >20% or a FNR >75%. The lowest FNR (20.8%) was for the ‘FLI OR 
[positive FIB-4 with hyaluronic acid]’ test, but the corresponding FPR was 71.6%. 
Similarly, for the two tests that had FPRs <20% (‘positive FLI PLUS [positive FIB-4 
with hyaluronic acid]’, ‘raised liver enzymes PLUS [positive FIB-4 with hyaluronic 
acid]’), FNRs were above 75%.  
Repeating either analysis using hepatic steatosis on ultrasound as the steatosis 
marker did not improve the accuracy of the tools (Table 24, Table 25). 
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5.6 Discussion 
When considering a population screening programme, WHO criteria state that any 
test should be acceptable to the population, suitable for use in a screening programme 
and have a high level of accuracy.274 False negative results can result in a patient 
ignoring important symptoms or lead to delays in diagnosis and treatment. False 
positive results can lead to unnecessary and expensive follow-up, tests that may 
cause the patient harm and the psychological distress of an inappropriate diagnosis. 
In the present study we have observed that in older people with Type 2 diabetes, none 
of the tests used had a ‘good balance’ of FPR and FNR with respect to the prediction 
of incident cirrhosis and HCC. These findings are consistent with a previous smaller 
study the present study was larger with longer follow-up.237 
FLI, FIB-4 and [FIB-4 with hyaluronic acid] were associated with increased mortality. 
This was statistically significant only for FLI. The incidence of cirrhosis and HCC were 
relatively low and it is likely that the biomarkers that showed a positive association 
with mortality were also identifying factors associated with other pathology (most likely 
cardiovascular disease). For example, FLI is calculated using triglycerides, BMI and 
waist circumference, all known to be associated with increased cardiovascular risk. 
No association was observed between USS-detected steatosis and mortality. This 
may reflect the fact that USS is a relatively insensitive test for identifying low levels of 
steatosis, so that an USS finding of ‘no steatosis’ or ‘indeterminate steatosis’ did not 
exclude the presence of at least some steatosis, which in turn may be associated with 
cardiovascular risk factors.258 Previous biopsy studies in cohorts attending secondary 
care services have shown an association between NAFLD related liver fibrosis and 
mortality, though a community cohort examining NAFLD in an unselected population 
(diagnosis based on USS steatosis) showed no increase in mortality.76,77,189,192  
Although associations were identified between some of the tests and increased 
mortality, when applied at individual patient level their performance was poor, with 
unacceptably high FPR and FNR. This is presumably because the overall effect size 
was small.  
Strengths and weaknesses of the study 
The ET2DS examined outcomes of liver disease in a community population of people 
with Type 2 diabetes, who did not necessarily have symptoms of liver disease. Almost 
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all other studies have identified outcomes in cohorts with established NAFLD 
diagnoses and were likely to have advanced pathology. EASL-EASD-EASO 
guidelines recommend screening in populations like the one represented by the 
ET2DS cohort, making this an appropriate cohort in which to examine the potential 
utility of screening tools.217 Participants were well-characterised at baseline and were 
followed up using multiple sources of information to accurately identify incident 
disease.  
ET2DS is a single centre study, undertaken in people with Type 2 diabetes, aged 60-
75 years at baseline, and of predominantly Caucasian origin (98.3%), so care should 
be taken in extrapolating these findings to other populations. All-cause cirrhosis/HCC 
were investigated. While aetiology was predominantly NAFLD, a small number of 
individuals with cirrhosis/HCC from other causes were included 262. However, 
determining the precise aetiology of cirrhosis/HCC can be difficult, particularly the 
relative contributions of alcohol excess and obesity, and so it seemed more clinically 
relevant to include individuals with all causes of liver disease. We have previously 
undertaken sensitivity analyses to show that excluding participants who had definite 
non-NAFLD pathology did not materially change outcomes.262 Participants did not 
undergo a liver biopsy, which is the gold standard technique for identification of liver 
disease. However, liver biopsy is an invasive procedure, and it would neither have 
been ethical nor feasible to perform this in an asymptomatic community population. 
Transient elastography data has not been included as this was only measured at year 
4. With respect to serum fibrosis biomarkers, we utilised FIB-4, cut-point ≥1.3 (with or 
without hyaluronic acid), as we have demonstrated that this was overall the best 
performing biomarker in this study; we have previously published data on the 
performance of the 2.67 and 2.0 cut-offs.262 
Our incidence data may be an underestimate as it is possible that we did not identify 
some participants who developed asymptomatic cirrhosis/HCC, as screening for 
cirrhosis/HCC at final follow-up was not repeated. Alternatively, our incidence may 
overestimate the clinical burden as a substantial proportion of our diagnoses were 
made after hepatology referral following year 1 or 4 investigations. NAFLD cirrhosis 
can have a silent natural history for many years. Thus, some people who may never 
have developed overt cirrhosis, or may have died before their disease became 
clinically apparent, may have been identified. However, 58% of those identified with 
Chapter 5: Association of liver tests with outcomes 
144   
 
cirrhosis developed varices, ascites and/or encephalopathy and 23% developed 
HCC, so it is likely that a large majority would have presented with clinical sequelae.  
Implications for practice 
NAFLD in the context of Type 2 diabetes fulfills many of the WHO recommended 
criteria for population screening, especially the ability to detect NAFLD at a pre-
cirrhotic stage, the ability to undertake timely surveillance for varices and HCC and 
commence specific treatments for complications. Current available tests do not have 
a ‘good balance’ between FPR and FNR. In an individual clinic setting, given the poor 
overall performance of the tests, clinicians may choose to use a test with a low FPR 
(such as ‘raised liver enzymes PLUS FLI’ or ‘raised liver enzymes PLUS [FIB-4 with 
hyaluronic acid]’), which would identify a proportion of cases while minimising service 
pressures through large numbers of people receiving unnecessary investigation. In 
our cohort, the Enhanced Liver Fibrosis test (cut point ≥10.51) and FIB-4 (cut-point 
>2.67) also had very low FPR, though both had a FNR >50%.262 The combinations of 
‘FLI OR [FIB-4 with hyaluronic acid]’, ‘raised liver enzymes OR FLI’ or ‘raised liver 
enzymes OR [FIB-4 with hyaluronic acid]’ would identify the majority of those who will 
develop cirrhosis/HCC, but would result in large numbers of people who will not 
develop advanced liver disease undergoing additional investigation. Care would have 
to be taken in both situations to explain the limitations of the tests to patients and 
clinical staff. Furthermore, while USS may not in isolation be a good screening tool 
(56.8% FPR, 38.5% FNR), it will always likely form part of an investigation pathway 
because of its ability to identify structural liver disease.  
Assessment of different combinations of existing biomarkers or development of 
alternative biomarkers is required. It would be interesting to investigate the utility of 
transient elastography in this context, acknowledging that this test may be less reliable 
in obese subjects and that employing imaging for population screening can impose 
system challenges and be more resource-intensive.275 Consideration also needs to 
be given as to whether serial screening may reduce FNR, increasing the utility 
particularly of those tests with low FPR. 
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Table 22. Performance of NAFLD  tests for  predicting incident cirrhosis or HCC 
Non-invasive test  Event rate for 
those with +/- 











Raised liver enzymes Test + 10.2 (6.9-14.5) 10 (7-14) 99 (98-99) 273 (27.1) 10 (24.4) 
Test - 1.3 (0.6-2.5) 
Positive Fatty Liver 
Index (FLI) 
Test + 5.3 (3.7-7.3) 5 (4-7) 99 (97-100) 662 (66.4) 4 (9.8) 
Test - 1.2 (0.3-3.0) 
Positive FIB-4 Test + 7.6 (5.2-10.7) 8 (5-10) 99 (98-100) 402 (40.6) 7 (17.5) 
Test - 1.2 (0.5-2.4) 
Positive FIB-4 with HA Test + 12.2 (8.3-17.5) 12 (8-17) 98 (97-99) 215 (21.4) 12 (28.6) 
Test - 1.5 (0.8-2.6) 
Combinations of individual components of the algorithm 
Raised liver enzymes 
PLUS positive FLI 
Test + 15 (8.9-23.7) 15 (9-23) 97 (96-98) 102 (10.4) 23 (56.1) 
Test - 2.5 (1.6-3.8) 
Raised liver enzymes 
OR positive FLI 
Test + 4.1 (3.6-6.9) 5 (4-7) 99 (97-100) 713 (71.3) 3 (7.3) 
Test - 1.0 (0.2-3.0) 
Positive FLI  PLUS  
[positive FIB-4 with HA] 
Test + 15.3 (10.1-22.3) 15 (10-22) 98 (97-99) 149 (14.9) 15 (35.7) 
Test - 1.7 (1.0-2.9) 
Positive FLI OR 
[positive FIB-4 with HA] 
Test + 5.2 (3.7-7.1) 5 (4-7) 100 (98-100) 728 (72.9) 1 (2.4) 
Test - 0.4 (0.0-2.0) 
Raised liver enzymes  
PLUS  [positive FIB-4 
with HA] 
Test + 23.0 (14.6-34.5) 23 (15-32) 98 (97-99) 77 (7.6) 19 (45.2) 
Test - 2.0 (1.2-3.1) 
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Non-invasive test  Event rate for 
those with +/- 











Raised liver enzymes 
OR [positive FIB-4 with 
HA] 
Test + 8.5 (6.0-11.6) 8 (6-11) 99 (9-100) 411 (40.9) 3 (7.9) 
Test - 0.5 (0.1-1.5) 
Full algorithm 
EASL-EASD-EASO 
algorithm+ (raised liver 
enzymes OR [positive 
FLI PLUS [positive FIB-
4 with HA]])   
Test + 
 
9.0 (6.2-12.4) 9 (6-12) 99 (98-100) 356 (35.5) 6 (14.6) 
Test - 0.9 (0.3-2.0) 
Raised Liver enzymes: Alanine aminotransferase, aspartate transaminase or gamma-glutamyl transferase 
above the reference range, HA hyaluronic acid, FLI Fatty Liver Index, FIB-4 Fibrosis-4 Index, CI confidence 
interval, PPV positive predictive value, NPV negative predictive value 
+ EASD-EASL-EASO Algorithm 217 
  Chapter 5: Association of liver tests with outcomes 
   147 
Table 23. Performance of NAFLD tests for prediction of mortality 
Baseline Predictor- 
raised required for 
positive test 
 Event rate for 
those with +/- 











Raised liver enzymes Test + 25.7 (20.3-32.0) 26 (21-31) 69 (66-72) 226 (30.5) 231 (74.8) 
Test - 31.0 (27.1-35.3) 
Positive Fatty Liver 
Index (FLI) 
Test + 31.0 (27.1-35.5) 31 (28-35) 75 (70-80) 482 (65.4) 84 (27.9) 
Test - 24.8 (19.8-30.7) 
Positive FIB-4 Test + 34.9 (29.6-41.0) 35 (30-40) 74 (71-78) 283 (39.0) 152 (50.0) 
Test - 25.5 (21.6-29.9) 
Positive FIB-4 with HA Test + 38.8 (31.4-47.4) 39 (33-45) 73 (70-76) 150 (20.4) 213 (69.2) 
Test - 26.6 (23.2-30.5) 
Combinations of individual components of the algorithm 
Raised liver enzymes  
PLUS  positive FLI 
Test + 27.0 (21.0-34.2) 73 (67-78) 30 (27-33) 184 (24.9) 238 (77.8) 
Test - 30.0 (26.3-34.0) 
Raised liver enzymes 
OR positive FLI 
Test + 30.2 (26.4-34.4 30 (27-34) 73 (68-78) 524 (71.1) 77 (25.3) 
Test - 26.6 (21.0-33.2) 
Positive FLI  PLUS  
[positive FIB-4 with HA] 
Test + 40.9 (32.1-51.5) 41 (34-49) 73 (70-76) 104 (14.1) 234 (76.5) 
Test - 27.0 (23.6-30.7) 
Positive FLI OR 
[positive FIB-4 with HA] 
Test + 31.3 (27.4-35.5) 31 (28-35) 7 (71-82) 528 (71.6) 63 (20.8) 
Test - 23.2 (17.8-29.6) 
Raised liver enzymes  




Test + 37.0 (26.1-51.0) 37 (28-47) 71 (68-74) 63 (8.5) 273 (88.1) 
Test - 32.7 (29.1-36.5) 
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Baseline Predictor- 
raised required for 
positive test 
 Event rate for 
those with +/- 











Raised liver enzymes 
OR [positive FIB-4 with 
HA] 
Test + 30.3 (25.4-35.8) 30 (26-35) 71 (67-75) 313 (42.4) 171 (55.7) 
Test - 28.7 (24.6-33.3) 
Full algorithm 
EASL-EASD-EASO 
algorithm+ (raised  liver 
enzymes OR [positive 
FLI  PLUS [positive FIB-
4 with HA]])   
Test + 
 
29.4 (24.3-35.3) 29 (25-34) 71 (67-74) 276 (37.4) 191 (62.4) 
Test - 29.3 (25.3-33.8) 
Raised Liver enzymes: Alanine aminotransferase, aspartate transaminase or gamma-glutamyl transferase 
above the reference range, HA hyaluronic acid, FLI Fatty Liver Index, FIB-4 Fibrosis-4 Index, CI confidence 
interval, PPV positive predictive value, NPV negative predictive value 
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Table 24. Performance of NAFLD  tests for  predicting incident cirrhosis or HCC, using ultrasound for assessment of steatosis 
Non-invasive test  Event rate for 
those with +/- 











Raised liver enzymes Test + 10.2 (6.9-14.5) 10 (7-14) 99 (98-99) 273 (27.1) 10 (24.4) 
Test - 1.3 (0.6-2.5) 
Positive Ultrasound for 
steatosis (USS) 
Test + 4.5 (2.9-6.7) 5 (3-7) 96 (94-98) 508 (56.8) 15 (38.5) 
Test - 3.7 (2.1-6.2) 
Positive FIB-4 Test + 7.6 (5.2-10.7) 8 (5-10) 99 (98-100) 402 (40.6) 7 (17.5) 
Test - 1.2 (0.5-2.4) 
Positive FIB-4  PLUS 
HA 
Test + 12.2 (8.3-17.5) 12 (8-17) 98 (97-99) 215 (21.4) 12 (28.6) 
Test - 1.5 (0.8-2.6) 
Combinations of individual components of the algorithm 
Raised liver enzymes  
PLUS positive USS 
Test + 9.5 (5.6-15.1) 10 (6-15) 98 (96-99) 171 (17.4) 20 (52.6) 
Test - 2.4 (1.5-3.7 
Raised liver enzymes 
OR positive USS 
Test + 5.7 (4.0-7.9) 6 (4-8) 98 (96-99) 610 (66.2) 5 (11.9) 
Test - 1.6 (0.5-3.7) 
Positive USS PLUS 
[positive FIB-4 with HA] 
Test + 15.0 (8.9-23.7) 15 (9-23) 97 (96-98) 102 (10.4) 23 (56.1) 
Test - 2.5 (1.6-3.8) 
Positive USS OR 
[positive FIB-4 with HA] 
Test + 5.5 (3.8-7.6) 5 (4-8) 99 (97-100) 621 (67.9) 4 (10.0) 
Test - 1.3 (0.4-3.4) 
Raised liver enzymes 




Test + 23.0 (14.6-34.5) 3 (15-32) 98 (97-99) 77 (7.6) 19 (45.2) 
Test - 2.0 (1.2-3.1) 
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Baseline Predictor- 
raised required for 
positive test 
 Event rate for 
those with +/- 











Raised liver enzymes 
OR [positive FIB-4 with 
HA] 
Test + 8.5 (6.0-11.6) 8 (6-11) 99 (9-100) 411 (40.9) 3 (7.9) 
Test - 0.5 (0.1-1.5) 
Full algorithm 
EASL-EASD-EASO 
algorithm+ (raised  liver 
enzymes OR [positive  
USS PLUS [positive 
FIB-4 with HA]])   
Test + 
 
9.7 (6.7-13.4) 10 (7-13) 99 (98-100) 327 (33.1) 6 (14.6) 
Test - 0.9 (0.3-2.0) 
Raised Liver enzymes: Alanine aminotransferase, aspartate aminotransferase or gamma-glutamyl transferase 
above the reference range, HA hyaluronic acid, FLI Fatty Liver Index, FIB-4 Fibrosis-4 Index, CI confidence 
interval, PPV positive predictive value, NPV negative predictive value 
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Table 25. Performance of NAFLD tests for prediction of mortality, using ultrasound for assessment of steatosis 
Baseline Predictor- 
raised required for 
positive test 
 Event rate for 
those with +/- 











Raised liver enzymes Test + 25.7 (20.3-32.0) 26 (21-31) 69 (66-72) 226 (30.5) 231 (74.8) 
Test - 31.0 (27.1-35.3) 
Positive Ultrasound for 
steatosis (USS) 
Test + 25.8 (21.6-30.4) 26 (22-30) 71 (66-75) 395 (58.2) 117 (46.1) 
Test - 29.2 (24.1-35.0) 
Positive FIB-4 Test + 34.9 (29.6-41.0) 35 (30-40) 74 (71-78) 283 (39.0) 152 (50.0) 
Test - 25.5 (21.6-29.9) 
Positive FIB-4 with HA Test + 38.8 (31.4-47.4) 39 (33-45) 73 (70-76) 150 (20.4) 213 (69.2) 
Test - 26.6 (23.2-30.5) 
Combinations of individual components of the algorithm 
Raised liver enzymes 
PLUS positive USS 
Test + 23.3 (16.9-31.3) 23 (17-30) 69 (66-72) 145 (20.2) 256 (85.3) 
Test - 30.1 (27.2-34.9) 
Raised liver enzymes 
OR positive USS 
Test + 26.4 (22.6-30.7) 26 (23-30) 71 (66-76) 476 (67.9) 92 (35.0) 
Test - 29.0 (23.4-35.6) 
Positive USS PLUS 
[positive FIB-4 with HA] 
Test + 35.0 (25.2-47.3) 35 (27-44) 72 (69-75) 78 (10.7) 254 (85.8) 
Test - 28.1 (24.8-31.8) 
Positive USS OR 
[positive FIB-4 with HA] 
Test + 28.9 (25.0-33.3) 29 (25-33) 74 (69-79) 467 (67.8) 76 (28.6) 
Test - 25.5 (20.1-31.9) 
Raised liver enzymes 




Test + 37.0 (26.1-51.0) 37 (28-47) 71 (68-74) 63 (8.5) 273 (88.1) 
Test - 32.7 (29.1-36.5) 
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Baseline Predictor- 
raised required for 
positive test 
 Event rate for 
those with +/- 











Raised liver enzymes 
OR [positive FIB-4 with 
HA] 
Test + 30.3 (25.4-35.8) 30 (26-35) 71 (67-75) 313 (42.4) 171 (55.7) 
Test - 28.7 (24.6-33.3) 
Full algorithm 
EASL-EASD-EASO 
algorithm+ (raised  liver 
enzymes OR [positive  
USS PLUS [positive 
FIB-4 with HA]])   
Test + 
 
27.6 (22.5-33.6) 28 (23-33) 71 (67-74) 262 (35.7) 197 (66.3) 
Test - 29.5 (25.5-33.9) 
Raised Liver enzymes: Alanine aminotransferase, aspartate aminotransferase or gamma-glutamyl transferase 
above the reference range, HA hyaluronic acid, FLI Fatty Liver Index, FIB-4 Fibrosis-4 Index, CI confidence 
interval, PPV positive predictive value, NPV negative predictive value 
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Figure 4. Kaplan-Meier plots for association between test result and survival 
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5.7 Additional Information 
Further to the information included in this chapter there is the question of the 
biological plausibility of the predictive factors.  
For many factors this has been discussed earlier in the thesis. In section 1.5 the 
pathogenesis of NAFLD is discussed including the importance of the development of 
steatosis and fibrosis as key stages of disease progression. Section 1.7 discusses 
cohort data in detail identifying which markers have been shown to be associated 
with disease progression; with the finding that the identification of fibrosis seems to 
be key. The  biological derivation of existing non-invasive risk prediction tools is 
discussed in section 1.8.2. Hyaluronic acid and GGT are discussed in sections 4.5 
and 4.6.  
It is important additionally to mention that some studies have identified GGT to be 
an independent predictor of cardiovascular events and mortality, independent of the 
presence of liver disease. It has been shown that GGT can accumulate in 
atherosclerotic plaques although the mechanism is not fully elucidated. Furthermore, 
rises in GGT within the laboratory normal range is associated with cardiovascular 
outcome. 276 We did not see an increase in mortality associated with raised liver 
enzymes; although we looked only at a combined marker of AST,ALT or GGT, at a 
level above the laboratory range. It would be interesting in future studies to 
investigate, in a new diabetes cohort, if GGT was a  predictor of cardiovascular 
morbidity and mortality.
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Chapter 6 General discussion and future 
directions 
 
6.1 Summary of objectives 
The worldwide prevalence of NAFLD is increasing, with NAFLD related liver disease 
contributing an ever-greater proportion of liver-related deaths. The prevalence of 
NAFLD is increased in people with diabetes. Additionally, diabetes is a risk factor for 
progression to cirrhosis and HCC and consistently associated with worse outcomes 
in NAFLD. 21 It is thought that early identification of NAFLD in people with diabetes by 
screening as advised in European guidelines could improve outcomes through 
adaptations that promote disease regression, and early referral for hepatology 
support and surveillance programmes (for example for HCC and varices). 217  
Furthermore, identifying which non-invasive markers are best associated with 
progressive disease could help monitor response to treatment in therapeutic trials. 
Identification of people at risk of progressive disease through accurate non-invasive 
testing could assist in the targeting of appropriate treatment to these groups. 
The ET2DS cohort, a prospective cohort study of a community population of 1066 
people with T2DM in Lothian, Scotland was used in this study to address four aims: 
1. Define the absolute and relative cohort incidence of liver disease to date in the 
ET2DS cohort 
2. Determine whether current non-invasive fibrosis risk prediction tools reliably 
identify incident cirrhosis and hepatocellular carcinoma in a community cohort of 
older people with T2DM 
3. Determine whether the addition of other biomarkers to existing fibrosis risk 
prediction tools improve their performance in predicting incident cirrhosis and 
hepatocellular carcinoma in a community cohort of older people with T2DM 
4. Identify whether potential non-invasive screening tests for NAFLD (those 
identifying steatosis, serum liver enzymes, markers of fibrosis) associated with 
incident cirrhosis, hepatocellular carcinoma and mortality in people with T2DM 
 
Chapter 6: Discussion 
156   
 
6.2 Non-invasive risk scores do not reliably identify 
future cirrhosis or HCC in T2DM. 
 
6.2.1 Description of incident cirrhosis and HCC in the ET2DS 
cohort 
The understanding and interpretation of the results of the questions asked in the 3 
main aims of this thesis, rests on first determining the burden of liver disease in the 
ET2DS cohort. 
It is generally believed that the prevalence of NAFLD, and the risk of progression to 
cirrhosis and HCC is increased in T2DM. 6,69,70 In this community population of older 
people with T2DM and no known NAFLD, the incidence of cirrhosis over 11 year 
follow-up was 3.92 per 1000 person years and HCC was 1.28 per 1000 person years. 
Of those in the study with cirrhosis or who developed incident cirrhosis, 58% 
developed variceal disease, ascites related to their liver disease or hepatic 
encephalopathy. NAFLD contributed to the aetiology of incident disease in 37/43 
(86%) participants.  
The incidence of cirrhosis and HCC in this population was substantially higher than 
reported population rates (for cirrhosis age-matched UK data report 0.36-0.54 per 
1000 person-years, for liver cancer age-matched Scottish data report 0.41-0.58 per 
1000 person years) (www.isdscotland.org). In addition, the prevalence of NAFLD as 
the predominant aetiology was greater than in the general population, where <10% 
cirrhosis (all age groups) and 19% HCC (age >60) has been attributed to NAFLD. 277 
We therefore found an increased burden of liver cirrhosis and HCC, of primary NAFLD 
aetiology, in a community cohort of older people with T2DM, consistent with previous 
observations in other populations. The findings have clinical implications for holistic 
care of people with T2DM and provoke consideration of whether screening or 
surveillance strategies for uncommon but severe liver disease should be implemented 
in routine care. 
6.2.2 Ability of non-invasive fibrosis risk scores to identify 
incident cirrhosis or HCC 
The presence of hepatic fibrosis is considered to be the most important indicator of 
disease likely to progress to cirrhosis and HCC, and to be associated with increased 
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liver-related and cardiovascular mortality. However, the gold standard test for fibrosis 
is liver biopsy which, as an invasive procedure, is not suitable for population 
screening. There is thus considerable interest in the development of non-invasive 
tools to identify hepatic fibrosis, and their use to identify people at high risk of 
developing clinically significant liver disease. Both European and American guidelines 
for NAFLD advocate consideration of the use of such tools in high risk community 
populations, such as people with T2DM. 7,217 Yet previous studies have suggested 
that the non-invasive tools recommended may be less accurate in people with T2DM 
than in the general population and as such there is significant uncertainty about their 
utility in T2DM. 237,238  
This study found that, whilst the non-invasive tools assessed (AST:ALT, APRI, ELF, 
FIB-4, NFS) all had a significant association with incident cirrhosis or HCC, the ability 
of any risk score to correctly identify people who were going to develop incident 
disease was poor, with scores exhibiting low PPVs (5-46%) and demonstrating either 
exceptionally high false positive or false negative rates. Similar results were seen 
when using the non-invasive fibrosis risk prediction tools in the EASL-EASD-EASO 
screening algorithm. 
A brief discussion of the regression analysis technique chosen 
Regression analysis was undertaken to look at the association of the risk prediction 
tool result at baseline with incident cirrhosis or HCC. There are several regression 
analysis techniques that could have been used. Logistic regression looks at whether, 
over a study, there is an association with outcome; there is no time element. Taking 
time to event into account (such as in regression analyses based on Cox-Hazards 
regression) can be helpful, especially if looking at association over a long period of 
time, because it allows people to die or to leave follow-up for other reasons without 
biasing results. However, adding in a time element if there is inaccurate time to event 
data can introduce error and uncertainty into the estimate, and this error is 
exacerbated if there is a small number of events. It can also be useful to consider the 
fact that someone may experience a different, ‘competing’, event (for example, death) 
which may prevent them developing the predicted outcome (for example, cirrhosis or 
HCC) had they not died of a different cause in the interim. Competing risks regression 
analysis takes into account both time to event, and potential competing risks that may 
bias results. It is a type of proportional hazards regression model, where the 
Chapter 6: Discussion 
158   
 
exponential of the regression coefficient of the sub-distribution hazard model (Fine 
and Gray) can be interpreted as a relative change in the rate at a given time point 
(hazard) of the outcome of interest occurring in those who have not experience that 
event yet (including those who have succumbed to a competing event (e.g. death)). 
For example, one baseline factor could be associated with an x fold increase in hazard 
of cirrhosis, which could be interpreted as evidence that scores above the baseline 
factor cut-point are associated with an x fold increase in cirrhosis in participants who 
have not yet developed cirrhosis or experienced a mutually exclusive event (e.g. 
death from another cause). 278 Some caution is required in interpreting the magnitude 
of effect but the direction of change can be interpreted more confidently and if 
comparing models, bigger changes imply bigger changes in hazard. Likewise, exact 
values of output from logistic regression, cox-hazards regression and competing risk 
regression analysis cannot be directly compared whereas trends can be.  
In this study two issues needed addressing. Firstly, as a large proportion of cases 
were diagnosed at the pre-symptomatic stage following clinical test evaluation the 
study team was concerned about the utility of time to event data. Cirrhosis can be 
asymptomatic for many years and so, compared to those cases which were clinician-
identified during routine care and thus most likely as a result of symptomatic disease, 
it is likely that those cases which were screen-identified obtained a diagnosis relatively 
sooner in their clinical course, potentially by many years. So comparators of time to 
event for the screen-identified and clinician-identified cases seemed inappropriate for 
primary analysis. Secondly, a large number of participants (320/1066) died during the 
course of the study. Therefore, there would have been a risk of bias by not accepting 
the competing risk of non-liver death into the analysis. The decision was made, 
therefore, to undertake the primary analysis using logistic regression, using C-statistic 
and AIC to compare models. The entire analysis was then re-run using competing 
risks regression methodology, using BIC to compare models. Regression analysis 
was corrected for age and sex. 
Comparison with existing literature and importance of this study 
Several studies have shown that incident cirrhosis and HCC are associated with non-
invasive scores but they did not describe predictive ability. 185,231,234 Other studies have 
described varying specificity and sensitivity of non-invasive scores when compared 
with measures of fibrosis. 221,229,232 One study has specifically compared the 
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performance of these tools in people with and without diabetes, but within the context 
of a selected hepatology clinic population; it found that the tools’ ability to predict 
cirrhosis and HCC was less good in people with diabetes. 237 The mechanisms for this 
are not fully elucidated but may relate to the reliance on AST and ALT in the predictive 
tools, and the thought that their serum levels in people with diabetes may be altered 
by factors above and beyond those related to liver pathology. 242,243 
This community population study is important because it looks at the utility of these 
tools in a representative population without a prior diagnosis of NAFLD. This is exactly 
the population for which NAFLD screening is advocated in European guidelines 
despite there being very limited data on their performance in this setting, i.e. in a 
population that will naturally have a lower pre-test probability for disease than a 
population drawn from referrals to a secondary care hepatology service. Also, we 
have been able to examine the performance of these tools in a cohort of people all of 
whom had T2DM - a condition known to be associated with increased risk of liver 
disease and disease progression, but where doubt has been cast on the performance 
of standard risk prediction tools. This study shows that these currently recommended 
non-invasive risk prediction tools for NAFLD outcomes perform only modestly in an 
unselected group of people with T2DM. Further work to improve prediction methods 
in this population is necessary before routine surveillance can be advocated. 
  
Chapter 6: Discussion 
160   
 
6.3 Hyaluronic acid improves the ability of the FIB-4 
liver fibrosis score to predict incident cirrhosis 
and hepatocellular carcinoma in T2DM 
Whilst this study has shown that existing risk prediction tools perform sub-optimally in 
people with T2DM, accurate risk prediction tools would be valuable as, though there 
is increased risk of cirrhosis and HCC in the context of diabetes, the absolute risk of 
progression is low. If those who could benefit most from heptatology review and 
intensified risk management could be identified reliably it would help manage 
resources well and not subject those at low risk to unnecessary investigation, burden 
of care and health anxiety. 
This study identified that, in this cohort, combining a hyaluronic acid measurement 
(cut-point >50𝜇g/L) with the FIB-4 risk prediction tool (cut point ≥1.3) reduced the 
number of people identified as ‘high-risk’ but who did not develop cirrhosis or HCC 
during follow-up by 46% whilst retaining a false negative value of ≤25%.  
Discussion of the comparators used to evaluate model performance 
Tools have been developed which enable comparisons between the utility of 
regression models in practice. Tools such as C-statistic assess the discriminatory 
ability of a model - the ability of a model to split individuals appropriately into those 
who will or will not develop the outcome. 279 The C-statistic calculates the probability 
that an increased probability of outcome is assigned to those who develop an 
outcome, comparing the odds of each individual having the outcome based on the 
model variables and the actual outcome as a ratio. Any rise in score above 0.5 
represents an incremental improvement in model function above chance with a score 
of ≥0.8 considered as reasonable. It is known to be insensitive if there are a small 
number of people at high risk and a large number at low risk. 279 Tools such as the 
Hosmer-Lemeshow test assess the calibration of a model. Calibration looks at a 
model’s ability to accurately estimate absolute risk by measuring how well predicted 
probabilities agree with observed risk. 279 For Hosmer-Lemeshow testing, a p>0.05 is 
considered acceptable calibration. Measures such as AIC (for logistic regression) or 
the closely related Bayesian Information Criterion (BIC) (which can be used for 
competing risks regression) combine an assessment of discrimination and calibration, 
assessing the likelihood that a fitted model would produce the data that is truly 
observed. 279 They have no scale, but a lower value in comparison to another model 
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is considered to have improved performance. For the model building in this study, it 
was decided to compare models using one method to assess discrimination (C-
statistic), one to assess calibration (Hosmer-Lemeshow test) and one to assess 
overall model performance (AIC).  
Discussion of model building methodology 
Clinical risk prediction models combine multiple predictor variables and can be useful 
in identifying those individuals who may be more/ less likely to develop a condition or 
have a better/ worse prognosis from a condition. This can help guide clinicians in the 
identification of those who may benefit most from an intervention. It is important that 
to be useful in clinical practice factors included in models are plausible (i.e. have a 
plausible pathophysiological association) rather than just statistically associated and 
that they can be measured reliably. 280-282 Models are frequently built using regression 
techniques. Stepwise regression (either forwards, where increasing numbers of 
variables are added, or backwards where all variables are assessed and any 
detrimental impact of removing one at a time is assessed) are commonly used but, 
especially if event numbers are low, the model performance can be overestimated, 
and, additionally, especially using backwards regression a poorly parsimonious model 
can be created. 280 An alternative is to look at all sub-sets regression where the 
performance of regression models with all possible combinations of factors is 
assessed. This can be helpful, and can certainly identify factors that feature in most 
or all of better performing models, but, nonetheless, require care as there is a risk of 
overfitting the model (where the model fits the initial study data well but is not 
generalisable to other populations). 280 Following this reasoning, factors were 
restricted, from those assessed at baseline assessment, to those where thorough 
literature review showed they had plausible pathophysiological association. All-
subsets regression was used due to the relatively low event numbers. The risk of 
overfitting is acknowledged and the findings will need to be validated in larger, more 
diverse cohorts. 
Comparison with existing literature and importance of this study 
To the study team’s knowledge, this is the first study to examine the effect of 
hyaluronic acid in risk prediction in a community population of people with T2DM. 
Hyaluronic acid has previously been assessed as a prognostic marker of liver disease 
only in a few studies, but a significant association has been found between rising 
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hyaluronic acid and liver mortality. 270 Although hyaluronic acid is known to be raised 
in rheumatological as well as liver disease, it is hoped that its use in people with 
diabetes in conjunction with other markers of liver fibrosis would not have a material 
impact on the model. This study found that, in a community population with T2DM, 
the numbers of people inappropriately identified as ‘high risk’ for the development of 
cirrhosis or HCC could be reduced by adding serum hyaluronic acid to the FIB-4 
assessment.  
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6.4 The association of NAFLD screening tests with 
incident advanced chronic liver disease and 
mortality in people with T2DM  
To conclude this body of work, I investigated whether any existing potential screening 
tests for NAFLD would be acceptable for use for population screening in people with 
T2DM. Whilst there are many indications to screen for NAFLD in people with T2DM 
(it can be detected at a pre-cirrhotic stage with the potential for reversibility, while 
surveillance can prevent complications of cirrhosis and identify HCC at treatable 
stage), it was identified that none of the currently available screening tests that were 
evaluated (serum liver enzymes, FLI, hepatic steatosis on USS, FIB-4, FIB-4 with 
hyaluronic acid, and combinations of these) had a ‘good’ balance of false positive and 
false negative rates when considering the prediction of incident cirrhosis and HCC. 
This analysis was undertaken with the full cohort compared to the selected complete-
cases model cohort used in the previous chapter. The FIB-4 and hyaluronic acid 
combination marker, whilst still reducing false positives significantly in the whole 
cohort, resulted in more false negatives in the whole compared to the model cohort.  
In an individual clinical setting, clinicians may wish to choose a test with a low false 
positive rate (for example ‘raised liver enzymes PLUS FLI’ or ‘raised liver enzymes 
PLUS [FIB-4 with hyaluronic acid]’) as this would identify a proportion of cases at least 
(as opposed to not screening at all) but would minimise service pressure from people 
receiving unnecessary investigation. Care would need to be taken to explain the 
implications of a ‘negative’ result to the patient in this situation.  
No strong association was identified between NAFLD as determined by a ‘positive’ 
test result and increased mortality. Previous studies have found conflicting results 
when comparing NAFLD and mortality, although it has been previously identified as 
a risk factor for mortality in the context of diabetes. 40,76,77,192 In this cohort the trend 
was for FLI, FIB-4 and [FIB-4 with hyaluronic acid] to be associated with increased 
mortality - and it may be that in a larger study or with longer follow-up the trends may 
become statistically significant, though whether clinically significant is uncertain. 
Caution should also be taken in defining an increase in mortality to being a 
consequence of NAFLD as, for example in FLI where triglycerides, BMI and waist 
circumference are used in the calculation, biomarkers used in the tests are known to 
be associated with other risk (e.g., cardiovascular risk) apart from NAFLD.  
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Further evaluation needs to be undertaken in larger and more diverse cohorts. Whilst 
the combination of FIB-4 and hyaluronic acid holds promise by reducing false positive 
rates, more work needs to be undertaken to reduce false negative rates. 
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6.5 Strengths and weaknesses of this work 
 
6.5.1 Strengths 
The ET2DS is a study of moderate size that has reviewed long-term liver outcomes 
in individuals in a community population with T2DM who were asymptomatic of liver 
disease at baseline. This represents precisely the scenario in which existing 
guidelines recommend screening for liver disease providing an ideal study population. 
Almost all other studies have examined outcomes in people recruited from secondary 
care hepatology clinics, with known NAFLD and a higher likelihood of cirrhosis and 
HCC.  
Participants were recruited through the Lothian diabetes register, which includes 
almost all those with T2DM, and participants were randomly selected from this 
register. Thus, it included people with T2DM on all treatment types (diet, oral and 
injectable agents) and those under both community and hospital care. It has 
previously been confirmed that the participants at baseline were representative of the 
larger group of people selected at random from the register in terms of age, HbA1c, 
duration of T2DM, proportion requiring insulin and total cholesterol, and thus 
considered to be representative of the target population (Table 4). The study was 
conducted with a prospective design. Participants were well characterised with 
extensive phenotyping at baseline providing accurate documentation of risk factors.  
Completeness of data collection for incident events was maximised through the use 
of multiple sources of information (including patient and GP reporting at study follow-
up clinics, review of electronic patient records, review of death records and records of 
admissions to hospital). 
6.5.2 Weaknesses 
There are limitations to this study. ET2DS is a single centre study, undertaken in 
people with T2DM aged 61-76 years at the time of USS, and of predominantly 
Caucasian origin (98.3%). In addition an unusually large proportion of our population 
were in the least deprived SIMD quintile. This was a representative sample of people 
with T2DM in the age-matched population sampled (Lothian, Scotland, UK). However 
we are aware that these results may as such not be generalisable to the general 
population and care should be taken in extrapolating these findings to younger or 
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more diverse populations, or those who may have different lifestyle choices 
(particularly with regards to alcohol intake, dietary composition and exercise) and 
those managed using newer glucose-lowering agents.  
All-cause cirrhosis and HCC were investigated in this cohort. Whilst aetiology was 
predominantly NAFLD, individuals with cirrhosis and HCC from other causes were 
also included. Determining the precise aetiology of cirrhosis and HCC can be difficult, 
particularly the relative contributions of alcohol excess and obesity, and so including 
individuals with all-causes of liver disease seemed more clinically relevant. Sensitivity 
analyses were undertaken to exclude those where NAFLD was confirmed not to be a 
contributory aetiology and results did not differ significantly. Another limitation is that 
subjects did not undergo a liver biopsy, the gold standard technique for identification 
of steatosis and fibrosis. However, liver biopsy is an invasive procedure and it would 
not have been ethical or feasible to perform in an asymptomatic population of this 
size.  
It is important to note that a significant proportion of diagnoses were made after 
hepatology referral following year 1 and year 4 screening investigations. This has two 
implications. Firstly, as the natural history of NAFLD progression is prolonged, it is 
possible that those who were diagnosed following referral from screening had 
cirrhosis or HCC at baseline and thus had prevalent rather than incident disease. 
However, the range of time from year 1 clinic to diagnosis overlaps significantly in the 
‘screen-detected’ and ‘clinician-detected’ groups and several of those who were 
‘screen-detected’ were not identified with cirrhosis or HCC on initial hepatology review 
but were diagnosed several years later. Therefore, prevalent disease has been 
termed as only that which was clinically apparent at baseline. Secondly, the screening 
process may have led to an earlier diagnosis of cirrhosis or HCC, of whom some may 
have died from other causes before cirrhosis or HCC was clinically apparent and thus 
inflating incidence data. However, 58% of all those identified with cirrhosis developed 
varices, ascites and/or encephalopathy; and 23% developed HCC. Thus, it appears 
likely that a majority of participants would have been identified through routine clinical 
care during the course of the study. Additionally, sensitivity analyses were run using 
competing risks regression analysis with non-liver death as the competing risk - these 
sensitivity analyses demonstrated no material change in results and thus it is thought 
that this was unlikely to have significantly contributed to a results error. Cirrhosis and 
HCC were not screened for at the year 11 clinic follow-up so it is possible that some 
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participants may have developed asymptomatic incident disease during follow-up that 
was not identified. This is important as there is inherent selection bias in using records 
from routinely collected data (admissions and electronic patient records) as it will 
include only those who attended hospitals and only those who attended the hospitals 
sampled. It will also record incidental diagnoses but these would be recorded through 
study screening. Through collection of data from multiple sources (including the ISD 
data which is Scotland-wide) the study aimed to minimise this error. 
While all other biomarkers were measured at baseline, ELF and liver USS were 
undertaken at the year 1 clinic, so analyses using these markers have examined 
slightly different ‘baseline’ time points. However, no participant was diagnosed with 
incident disease during that year and given the time course of NAFLD progression it 
is likely that anyone with an abnormal result at year 1 would have had an abnormal 
result at the baseline clinic. 
Finally, this study examined a medium sized cohort, with a modest incidence of 
cirrhosis and HCC. The sample size was designed to be powered for cognitive 
outcomes, which are more frequent than liver outcomes in this population. The liver 
arm was introduced after the commencement of the study. Although the study was 
adequately powered to identify a large effect size, it is possible that a smaller effect 
may not have been identified. Therefore, a small absolute difference in the proportion 
of people developing cirrhosis or HCC between groups may have become statistically 
significant in a larger study. However, for example, USS examinations were 
performed to a ‘research standard’, with a formally validated process. In routine 
clinical practice, USS examinations may not be performed using such robust criteria. 
The present study has shown that USS failed to identify a significant proportion of 
individuals who develop cirrhosis/HCC (40%) and it is likely that USS may perform 
worse in a clinical setting. Statistical power alone would not explain the lack of an 
observed effect of ‘definite steatosis’ on mortality, as absolute mortality rates were 
higher in the group without ‘definite steatosis’. 
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6.6 Future Directions 
The data presented in this thesis has shown that the cirrhosis and HCC risk prediction 
tools developed thus far perform only modestly in in a community population with 
T2DM. The addition of hyaluronic acid to the FIB-4 tool does reduce the number of 
people identified incorrectly as being at high risk of developing cirrhosis or HCC but 
still leaves it well short of being a clinically reliable surveillance test. It is acknowledged 
that the cohort was of moderate size, in an older and predominantly Caucasian 
population. Thus, to examine generalisability, it would be necessary to validate results 
in more diverse populations. Validation in a larger population is also needed to 
address the possibility that effects and performance of a model can be over or 
underestimated in small populations. 280 
Furthermore, there are aspects of risk prediction that should be considered but were 
unable to be assessed due to the constraints of the size and characteristics of the 
cohort. Firstly, the number of outcomes among people in our cohort was too small to 
determine whether median time to diagnosis of cirrhosis or HCC was longer in those 
who had lower baseline risk scores. It is possible that, especially in the context of 
T2DM where it is thought that progression of NAFLD to fibrosis, cirrhosis and HCC 
can be accelerated, markers in the risk prediction tools for those who developed 
cirrhosis or HCC later in follow-up were not raised at baseline assessment. It would 
thus be interesting to assess this in a larger cohort and examine whether serial 
measurements show dynamic change in the pathway to cirrhosis/HCC. If this was the 
case, then serial measurement may result in fewer false negative results. 
Secondly, there is increasing interest in the subgroup of people who develop HCC in 
a non-cirrhotic liver. This is mechanistically intriguing, but also of clinical concern 
because cirrhosis is normally the clinical trigger for HCC surveillance monitoring. In 
this cohort, 29% of HCC instances were identified in people with a non-cirrhotic liver, 
but this represented just four individuals. This suggests that it may be valuable to 
investigate this subset of people in more depth in larger populations to identify factors 
that predispose to this rarer outcome. 
Thirdly, it is thought that genetic tendency plays a role in both the development of 
NAFLD and the aggressiveness of disease progression. 132 The study’s modestly 
sized population, in combination with the population prevalence of the alleles known 
to be consistently associated with NAFLD meant that it did not have enough power to 
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be able to investigate this association. However, it will likely be important to consider 
this in the development of future risk prediction strategies in larger cohorts. 
Fourthly, there is an expanding field of interest in pharmacological agents (including 
GLP-1 receptor agonists, SGLT-2 inhibitors, novel antifibrotic agents including 
Galectin 3 inhibitors and probiotics (section 1.9.2)) that may be able to treat NAFLD. 
A detailed understanding of how pharmacological agents affect disease progression 
needs to be studied. To have contributed any meaningful analysis based on drug 
exposure our study would have needed details on medication use not only for the 
duration of the study (which in terms of NAFLD pathogenesis is relatively short) but 
for the years prior to the study. Unfortunately the study did not have access to that 
data, nor were many of the agents of current research interest (such as GLP-1 
agonists) in common or indeed any use at recruitment. It would be very interesting to 
look prospectively at the outcomes of people now commenced on such medications, 
perhaps using pharmaco-epidemiological surveillance rather than a dedicated study, 
given the infrequency of the outcomes and length of their pathogenesis. 
Finally, it is important to acknowledge that there are existing and emerging risk 
prediction markers (and combinations) that were not examined within the context of 
this study; some of these novel markers may also have improved predictive ability. 
For example, recent publications discuss the potential for use of serum metabolite 
panels or the incorporation of PRO-C3 (a marker of type III collagen formation) into 
risk prediction tools for the identification of advanced hepatic fibrosis. 
{Harrison:2020cu, 283,284 Transient elastography is also increasingly been seen as a 
more reliable test for liver fibrosis than serum markers, and interest is growing in its 
use in combination with serum markers. 218,275,285 However whether the role that 
transient elastography could play a role in population screening as an imaging tool is 
uncertain. 
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6.7 Concluding Statement 
This study investigated the incidence of cirrhosis and HCC and factors that are 
associated with incident cirrhosis and HCC in a community population of older people 
with T2DM who were asymptomatic of liver disease at baseline. This study found an 
increased incidence of cirrhosis and HCC in our population compared to whole 
population data, confirming that people with T2DM do experience higher rates of 
cirrhosis and HCC than the general population. In addition, it was identified that 
existing fibrosis risk prediction tools performed only modestly and did not accurately 
identify those who developed incident disease. Further study identified that combining 
serum hyaluronic acid measurement with the FIB-4 risk prediction tool reduced the 
number of people who were identified as ‘high risk’ at baseline but did not develop 
incident cirrhosis or HCC. However, when several potential NAFLD screening tests 
were assessed for predictive value, inclusive of the fibrosis risk prediction tools, no 
‘good balance’ between false positive and negative rate was found. In an individual 
clinic setting, if clinicians wish to undertake any liver screening, they may want to 
choose a test with a low false positive rate (for example ‘raised liver enzymes PLUS 
FLI’ or ‘raised liver enzymes PLUS [FIB-4 with hyaluronic acid]’) as this would identify 
a proportion of cases but would minimise unnecessary investigation. But, most 
importantly, further investigation of this uncommon but increasing and clinically 
important accompaniment of T2DM is required in larger and more diverse cohorts. 
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Appendix 2- Formulae used in calculations for 
incidence and model predictive 
ability 
 
Formulae for Calculation of Incidence 
Total incidence over time was calculated as (total number of cases/ total number of 
participants). 
Incidence was calculated as ((number new cases) / (patient years in follow-up )) x 
1000 for cases per 1000 patient years. Patient follow up days were calculated for 
those who developed an event during follow up as (date of event – date of baseline 
clinic), for those who had no event but had died during follow up as (date of death – 
date of baseline clinic) and for those who had no event and were alive at end of follow 
up as (last date of data collection – date of baseline clinic). Years of follow up was 
calculated as total follow up days/365.25.  
Formulae for Calculation of Predictive Ability 
The performance of each tool in identifying incident cirrhosis or HCC was assessed 
using sensitivity, specificity, positive predictive value (PPV), negative predictive value 
(NPV), false positive rate and false negative rate. This was calculated from the 
standard 2x2 table: 
 Test positive Test negative 
Outcome present True positive (TP) False negative (FN) 
Outcome absent False positive (FP) True negative (TN) 
 
- Sensitivity is the proportion of participants with the outcome who test positive (TP 
/ (TP+FN)) 
- Specificity is the proportion of participants without the outcome who test negative 
(TN / (TN+FP)) 
- Positive Predictive Value is the probability that following a positive test result, an 
individual with truly have the outcome (TP / (TP+FP)) 
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- Negative Predictive Value is the probability that following a negative test result, an 
individual will truly not have the outcome (TN / (TN+FN)) 
- False Positive Rate is the proportion of people who do not have the outcome who 
test positive (FP / (FP+TN)) 
- False Negative Rate is the proportion of people who have the outcome who test 
negative (FN / (TP+FN)) 
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Appendix 3- Supplementary information for 
Chapter 3 
 
Identification of potential biomarkers 
To identify potential biomarkers that may improve predictive ability, reviews of the 
literature both considering what is understood about the pathogenesis of NAFLD 
(link) and which factors have been found to be significantly associated with disease 
progression in other human epidemiological studies (link) were undertaken. 
Following this, the study identified the following baseline biomarkers to investigate 
from those collected in the baseline clinic (Table 26). 
Additional detail on validation of model building 
The following validation checks were undertaken during model building. 
1. Co-correlation (to ensure there were no concerns about co-linearity) was checked 
using both Pearson and Spearman methodology (due to concern that all variables 
may not form a perfect normal distribution).  
2. The effect of extreme outliers on results for both the base models and the 
alternative biomarkers was assessed using Cook’s distance (>0.5 deemed 
significant) and regression re-run excluding any extreme outliers identified to look 
for influence. 
3. Final models were checked for co-linearity with the variance inflation factor (VIF), 
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Table 26. Baseline Factors to Consider During Data Analysis 
Baseline Factor Rationale 
Demographics Age Key population indicators. Population Deprivation 
Indices and Age have shown to be linked to 






BMI NAFLD is known to be associated with the 
metabolic syndrome and for metabolic syndrome 
to be associated with progressive NAFLD (section 
1.7). BMI has been shown to be associated with 
prognosis in previous analyses (section 1.7). 
Waist- Hip Ratio 
Smoking 
Alcohol Intake May be linked to overall outcome pathogenically 
(it is possible to have mixed NAFLD and ALD 
pathology) 
Cholesterol Although not identified in previous cohort studies 
to be implicated in disease progression, it would 
be thought pathophysiologically that lipid profile 




Duration T2DM T2DM is known to be associated with worse 
outcomes in NAFLD (section 1.4). Key markers of 
diabetes effect will be duration of T2DM and 
HbA1c as a marker of exposure to 
hyperglycaemia. 
HbA1c 




AST Enzymes released in liver injury. They have been 
associated with disease progression in cohort 









A glycosaminoglycan found in connective tissue 
that is almost exclusively cleared by liver 
metabolism. Raised levels have been found to be 
associated with cirrhosis and liver mortality 269,270 
Markers of 
inflammation 
CRP Implicated in the progression of NAFLD 
pathogenesis. Mixed results in previous cohort 
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